

Index

A

- ABCA1 ATP-dependent transporter
 - cholesterol and phospholipid translocation, 51–52
 - cholesterol synthesis, 31–32, 32f
- Acetylation, polyglutamine repeat diseases, 850
- Acetylcholine
 - acetylcholinesterase
 - acetylcholine removal, 262
 - active site, 264–265
 - catalysis, 263–264, 264f
 - gene encoding, 263
 - Gulf War syndrome, inhibition, 279–280, 280f
 - inhibitors, 265–266, 266f
 - molecular forms, 262–263, 263f, 265f
 - nonclassical functions, 266
 - in basal ganglia, 858
 - brain energy metabolism, acetyl coenzyme precursor, 218–219
 - chemical structure, 259–260, 259f
 - cholinergic pathways
 - choline acetyltransferase catalyst, 260
 - neuron distribution, central nervous system, 262, 262f
 - synaptic terminal, choline accumulation, 260–261, 261f
 - vesicular transporters, calcium-dependent neuronal release, 261–262, 262f
 - choline transporter termination in synapse, 54
 - enzymatic breakdown, 262–266
 - muscarinic cholinergic receptors, 274–280
 - G-protein-coupled receptor mediation, 274
 - molecular cloning, 275–276, 275f
 - muscarine mimicking, 274
 - neuropsychiatric disorders, central nervous system distribution, 277
 - peripheral tissue physiology, 274t
 - pharmacological therapies, cholinergic disorder, 278
 - subtype distribution, 277
 - subtype-G-protein coupling, 276, 276f
 - subtypes, pharmacological analysis, 274–275
 - synaptic terminal, choline accumulation, 260–261, 261f
 - transgenic studies, *in vivo* subtype assessment, 277–278
 - neuromuscular junction disorders, 789–790
 - neuromuscular junction mediation, release and postsynaptic effects, 238–239, 240–241f, 785
 - neuromuscular synapse, tyrosine phosphorylation, 509, 510
 - nicotinic acetylcholine receptors, 266–274
 - agonist binding, 268–269
 - agonist desensitization, 269, 270f
 - biochemical characterization, 266–267, 267f
 - brain function modulation, neuronal receptor, 271
 - cys-loop ligand-gated ion channel family, 268f, 269
 - disease and, 272–273
 - ion channel communication, 269
 - neuronal receptor family, 269–270, 270f
 - non-neuronal distribution, 272
 - pentameric ligand-gated ion channels, 267–268, 268f
 - subunit permutations and diversity, 270f, 271
 - therapeutic targeting, 273–274
 - transgenic research, physiology and clinical implications, 271–272
 - organophosphorus poisoning signs and symptoms, 279t
 - presynaptic release, botulinum toxin alteration, 795–796
 - receptor mutations, 789
 - myasthenia gravis, 793, 794f
 - sleep and wakefulness and, 987–988
 - depression, REM sleep and pain, 988
 - synthesis, storage and release, 260–262
- Acetylcholinesterase
 - acetylcholine breakdown, 262–266
 - acetylcholine removal, 262
 - active site, 264–265
 - catalysis, 263–264, 264f
 - gene encoding, 263
 - inhibitors, 265–266, 266f
 - molecular forms, 262–263, 263f, 265f
 - nonclassical functions, 266
 - deficiency, 790
 - Gulf War syndrome, inhibition, 279–280, 280f
 - protein active site, 264–265, 264f
- Acid maltase deficiency (AMD), 766–767, 770
- Acquired immune-mediated myelin disease, 692–699
 - axonal effects, 692
 - diagnosis, 692–693
 - multiple sclerosis, 692–696
- Actin microfilaments
 - hair cell molecules, 921–923
 - neuronal growth and secretion, 108–110
- Action potentials
 - depolarization propagation, 67
 - electrically excitable cells, 66–67
 - ion channels, 66
 - odorant recognition, 907–908, 908f
- Acute axonal motor neuropathy, 698–699, 698f
- Acute disseminated encephalomyelitis (ADEM), 697
- Acute post-infectious measles encephalomyelitis (APME), immune functions and, 607
- Adaptive immunity
 - evolutionarily novel molecules, 599
 - nervous system regulation, 602–603
 - neuroimmunology, 599–601
 - lymphoid tissue innervation, 602–603
 - neuropeptides, 603
- Addiction
 - barbiturates and benzodiazepines, 1050
 - basic principles, 1038, 1039f
 - cannabinoids, 1045–1048, 1047f
 - cyclic AMP second-messenger pathway, 1042–1043
 - dopamine transmission, 1038–1040, 1040f, 1042f
 - ethanol, 1049
 - hallucinogens and dissociative drugs, 1050–1051
 - neural circuitry, 1038–1041
 - neuronal plasticity, 1051–1052, 1052f
 - nicotine, 1048–1049
 - opiates, 1041–1043
 - psychomotor stimulants, 1043–1045, 1044f, 1046f
- Adenosine
 - extracellular sources, 379–380
 - metabolites, 380f
 - opioid-induced sleep disruption and pain, 993–994
 - receptor subtypes, 382, 382t
 - A₁ receptors, 383, 383f
 - A_{2A} receptors, 383, 383f
 - Parkinson's disease and antagonists of, 387–388
 - A_{2B} receptors, 384
 - A₃ receptors, 384
 - P₂ receptors, 384
 - sleep regulation, 993–994
 - transport, 379–380, 380f
 - wakefulness and, 993
- Adenosine epilepsy hypothesis, 387
- Adenosine kinase, nervous system disorders, 387

- Adenosine triphosphate (ATP)
 axonal release, 385
 brain energy metabolism
 electron transport chain production, 217
 glycolysis, 208–209
 phosphocreatine regulation, 218
 regulation, 217–218
 glial signaling, adenosine and, 384–385
 synaptic transmission, regulated secretory pathway, 245
- Adenylosuccinate lyase, Lesch-Nyhan syndrome, 381
- Adenylyl cyclases
 cAMP biochemistry, 423–425, 424f
 cAMP molecular targets, 429–430
 brain signaling functions, 430
 cyclic nucleotide-gated channels, 429
 dopamine signaling, striatum, 430
 drug abuse, 430
 Epac, 430
 neurodegeneration, 430
 olfaction, 430
 pain management, 430
 protein kinase A, 429
 synaptic plasticity, learning and memory, 430
 cellular regulation models, 427–429, 428f
 G protein stimulation and inhibition, 412
 isozyme expression and regulation, 425–427
 long-term regulation, 429
 phylogenetic tree, 425f
 serotonin receptor subtype stimulation, 319–320
 topographical structures, 425f
- Adipose triglyceride lipase (ATGL) defects, 768
- ADP-ribosylation, G protein modification, 419–420
- Adrenal gland, stress and brain function and, 946
- Adrenal medulla, norepinephrine
 metabolism to epinephrine, 288
- Adrenergic neurons, dopamine-
 norepinephrine conversion, 286
- Adrenergic receptors, 295–297, 295t, 296t
 G-protein-coupled receptors, 295–297
- Adrenocorticotrophic hormone (ACTH),
 neuronal synthesis, 393–394
- Adrenoleukodystrophy, myelination and, 578
- Afferent sensory neurons, taste, 912
- Age-related macular degeneration, 899
- Aging
 Alzheimer's disease epidemiology and, 815–823
 brain energy metabolism, cerebral
 metabolic rate declines, 205
 microglial dysfunction in, 613
 sodium-potassium-
 adenosinetriphosphatase and, 45
- Agonists
 catecholamines, downregulation, 297
 cholinergic
 chemical structure, 259–260, 259f
 nicotinic acetylcholine receptors
 binding, 268–269
 desensitization, 269, 270f
 glutamate receptors, 354, 355f
 nicotinic acetylcholine receptors, nicotine
 addiction, 1048
 Agrin receptor, neuromuscular synapse,
 tyrosine phosphorylation, 509
- Agrochemicals, acetylcholinesterase
 inhibitors, 265–266, 266f
- Alcohol addiction, 1049–1050
 novel treatments for, 1053
- Alcohol effects, extracellular adenosine, 387
- Allele-specific gene silencing, polyglutamine
 repeat diseases, 851–853
- Allodynia, pain management, 936–937
- Allostasis, stress and, 951
- Allostatic overload, stress and, 951
- Alsln mutation, amyotrophic lateral sclerosis,
 803
- Alzheimer's disease
 amyloid beta immunotherapy, 616
 APP mutations, 817
 aspartyl proteases, 819–820
 clinical syndrome, 816
 cytoskeleton alterations and, 114
 epidemiology, 815–823
 familial forms, 817
 gamma-secretase and presenilins, 824–825
 gene targeting therapy, 821–822
 genetics, 721–723, 721t
 early onset familial AD, 721
 late-onset AD
 apolipoprotein E in, 721–722
 genome-wide screening, 722–723
 laboratory measurements and diagnosis,
 816
 neuritic plaques, 818
 neurofibrillary tangles, 818–819
 neurotransmitter circuits and brain
 networks and, 817–818
 presenilin 1 and 2 mutations, 817
 protein phosphorylation and, 490–491
 transgenic mouse models, 820–823
- Amiloride, FMRF-amide-gated sodium ion
 channel, peptide expression, 402
- α -Amino-3-hydroxy-5-methyl-4-isoxazole
 propionic acid (AMPA) receptor
 flip/flop variants, 354–356, 355f
 identification, 347–356
 long-term potentiation induction, 967f
 quinoxalinedione blockage, 350
- Amino acid metabolism disorders
 aminoaciduria, 738–742, 739t, 741t
 brain edema, 742
 brain energy metabolism inhibition,
 738–740
 low-protein diet, 742
 neurotransmitter/neurotransmitter
 receptor deficits, 742
 organic acid conversion, 738
 blood amino acid imbalance, 740–742
 brain amino acids, lipid synthesis
 inhibition and demyelination, 742
 branched-chain amino acids, maple syrup
 urine disease, 742–743
 GABA disorders, 752–753
 glutathione metabolic disorders, 752, 753f
 homocystinuria, 745–749, 746f
 major metabolic pathways, 740f
 methionine synthase deficiency, 748
 N-acetylaspartate disorders, 753
 nonketotic hyperglycinemia, 744–745, 745f
 phenylketonuria, 743–744, 743f
 urea cycle defects, 749–752, 749f
 cognition and, 752
- Amino acid precursors, brain energy
 metabolism, glycolysis regulation,
 208–209
- Amino acids
 glutamate derivation, 343–344, 344f
 glycine receptor activation, 250
 L-tryptophan, serotonin precursor, 304–306
 sleep regulation and, 990–993
- Amino acid sequencing
 histamine receptors, 332f
 odorant receptors, 905–906, 906f
- Amino acid transmitters
 glutamate-glutamine metabolism, 220
 glutamate symporters, SLC1 proteins, 53
 SLC6 symporter subfamily, 52–53
- Aminoaciduria disorders, 738–742, 739t, 741t
 brain edema, 742
 brain energy metabolism inhibition,
 738–740
 low-protein diet, 742
 neurotransmitter/neurotransmitter
 receptor deficits, 742
 organic acid conversion, 738
- Ammonia detoxification, urea cycle and,
 749–750
 cognitive function and, 752
- Ammonia nitrogen excretion, urea cycle
 defects, 751
- Amnesia patients, memory function studies,
 964–965
- Amphetamine addiction, 1043–1044, 1044f
 neuronal adaptation, 1044
- Amphipathic molecules
 bilayered lamellar structures, 27–28, 28f
 multidrug resistance protein flipping, 52
- Amphiphilic molecules, membrane lipids
 as, 82
- Amygdala, stress and, 949–951
- Amyloid beta immunotherapy,
 neuroinflammation, 616
- Amyloid beta peptides
 Alzheimer's disease pathology and, 818
 transgenic mouse models, 820–821
 seeding and transmissibility, 883–884
- Amyloid precursor protein (APP)
 Alzheimer's disease
 aspartyl protease cleavage, 819–820
 secretase cleavages, 818
 familial Alzheimer's disease, mutations,
 817
- Amyotrophic lateral sclerosis (ALS)
 epidemiology, 801–806
 familial, 803–806
 genetics, 727–729, 728t
 familial ALS, 727–729

- models of, 806–809
- mutations, 803–806
- pathophysiology, 802
- SOD1 mice studies, 807
- Anaplerotic pathway, brain energy metabolism, pyruvate carboxylation, 218
- Andersen's disease, 767
- Anderson syndrome, potassium ion channel mutation, 791
- Angiogenic factors, amyotrophic lateral sclerosis, 803–804
- Animal models
 - Huntington's disease, 865
 - mechanoreceptors, 917–918, 917f
 - Parkinson's disease, 862, 863f
 - sleep disorders, 989–990
 - synucleinopathies, 833–834
 - tauopathies, 838–841, 838f, 839f
- Animal prion diseases, 873–874
- Anion antiporters, 56
 - intracellular pH in brain, 56
- Antagonists
 - catecholamines, repeated treatment, 297–298
 - cholinergic
 - chemical structure, 259–260, 259f
 - nicotinic acetylcholine receptors binding, 268–269
 - desensitization, 269, 270f
 - protein phosphorylation, kinase/phosphatase antagonism, 468–470
 - purinergic receptors, A_{2A} receptors and Parkinson's disease, 387–388
- Anterograde axonal transport
 - fast transport
 - membrane and secretory proteins, 150f, 151f, 152f
 - synaptic vesicles, axolemmal precursors and mitochondria, 153
 - kinesin, 157–158
 - membrane and secretory proteins, 151–152
- Antiapoptotic proteins, 671
- Antibody-mediated neuropathies, 684–687, 686t
- Antidepressants, cyclic nucleotide signaling and, 437–438
- Antigenic stem cells, 561–563
- Antigen-presenting cells (APCs)
 - innate immunity, 601, 601f
 - major histocompatibility complex, T-cell activation, neuroimmunology, 599–601, 600f
 - microglia and, 605–606
 - neuropeptide modulation, 603
 - PAMP and DAMP signals, 602
- Antioxidants
 - apoptosis inhibition, 671–672
 - ischemia-reperfusion injury, brain protection, 630–631
 - tripeptide glutathione, 752
- Antipsychotic drugs
 - addiction, 1050
 - schizophrenia, 1001–1002
- Antiseizure drugs, epilepsy and mechanisms of, 711–713
 - GABA-mediated synaptic inhibition, 711–712, 712f
 - voltage-gated calcium currents, 712, 712f
 - voltage-gated sodium channel targeting, 711, 711f
- Antisense oligonucleotides, polyglutamine repeat diseases, 850–851
- Anxiety disorders
 - cholecystokinin, 1032–1033
 - cortical-hypothalamic-pituitary-adrenal axis, 1032
 - epidemiology, 1030
 - future research and therapies, 1033–1034
 - GABAergic systems, 1031–1032
 - intracellular targeting, 1033
 - neurochemistry, 1030–1033
 - neuropeptides, 1032–1033
 - neuropeptide Y, 1032
 - noradrenergic systems, 1030–1031
 - serotonergic systems, 1031
 - substance P, 1033
- Apolipoprotein E (APOE), Alzheimer's disease, 721–722
- Apoprotein E (apoE), astrocyte secretion, 31–32, 32f
- Apoptosis
 - axon-based nervous system development, 542–543
 - basic features, 665f
 - cascade triggering, 672, 673f, 674f
 - caspase substrates, 664t
 - cell morphology and biochemistry, 664
 - embryonic and postnatal development, 663–664
 - ischemia-reperfusion injury, reactive oxygen species, 631
 - nervous system development, 664–665
 - neurodegenerative disorders, 667–668, 667f
 - neurological disease and, 665–667, 673–675
 - phosphoinositides, 452
 - phospholipases A₂, ischemia-reperfusion signaling, 654
 - synaptic plasticity, 675
 - triggers for, 668–669
 - trophic insufficiency, 668
- Appetite regulation, neuropeptides, 405
- Aquaporins
 - AQP4 regulation, serine phosphorylation, 58
 - in astrocyte membranes, 57–58, 58f
 - astrocytic perivascular endfeet membranes, 57
 - in brain, 57
 - brain edema
 - aquaporin-4 regulation, 59–60
 - ischemia and, 632
 - facilitated diffusion, 56–58
 - myelin disease, 693
- Arachidonic acid pathways
 - brain injury, lipid breakdown, 654–655
 - brain signaling mechanisms and, 658–660
 - cyclooxygenase conversion, prostaglandin H₂, 652
 - cyclooxygenase-derived metabolites, 652
 - cyclooxygenase/lipoxygenase conversion, 648–649, 648f, 649f
 - ischemia-reperfusion process, 656
 - lipoxygenase substrate, 649
 - 5-HpEtE formation, 653
 - molecular oxygen requirements, 649
 - neuroinflammation, 614–615, 615f
 - phospholipases A₂, ischemia and seizures, 647
- Arginase deficiency, 751
- Argininosuccinic aciduria, 751
- Aromatic amino acid decarboxylase (AAAD)
 - L-DOPA-dopamine conversion, 285–286
 - serotonin precursor, 306
- ARX gene mutation, epilepsy genetics, 714
- Aspartate, neurotransmission and, 346
- Aspartyl proteases, amyloid precursor protein cleavages, Alzheimer's disease, 819–820
- Astrocyte-lactate shuttle, brain energy metabolism, 215
- Astrocytes
 - adenosine-dependent heterosynaptic depression, 385
 - aquaporin4 in membranes of, 57–58, 58f
 - blood-brain barrier maintenance, 19
 - brain energy metabolism
 - citrate synthesis and release, 218
 - enzymes in, 207t
 - glutamate-glutamine cycle, 222
 - glycogen degradation, 209–210
 - pyruvate carboxylation, 218
 - subcellular compartmentation, 225–226
 - calcium signaling, local and global integration, 461–464, 463f
 - cerebral vasculature control, 463–464, 463f
 - tripartite synapse, gliotransmitter and modulation, 462–463
 - cholesterol synthesis, 31–33, 33f
 - glutamine transfer to neurons, 362
 - pH-dependent purine release, breathing control, 386
 - synaptic transmission, signaling events, 256
- Astrocytic interphase, 11, 11f, 12f
- Astrocytic perivascular endfeet membranes, aquaporins, 57
- Astroglia, neuronal extracellular clearance of potassium and water, 58
- Ataxin proteins, polyglutamine repeat diseases, 849
- SCA-7 transcription, 849
- ATP-binding cassette transporters (ABC)
 - blood-brain barrier luminal membranes, 22–23
 - gene superfamilies, 50
 - prokaryotic three-dimensional structures, 50–51, 51f
- Autism spectrum disorders (ASDs)
 - behavioral, neurobiological and genetic issues, 1013
 - clinical aspects, 1012–1014
 - current research issues, 1013–1014

- Autism spectrum disorders (ASDs) (*Continued*)
 dopaminergic functioning, 1015
 epistasis and emergence, 1014
 fragile X syndrome and, 1017–1018
 future research issues, 1016–1017
 genetic studies, 1014
 melatonin decrease, 1016
 neurochemistry, 1014–1016
 pharmacological treatment, 1014
 postmortem brain data, 1014
 serotonin system, 1015–1016
 stress response systems, 1015
 symptom clusters, 1012–1013
- Autocrine effects, neuropeptide receptors, 402
- Autoimmune disease
 nicotinic acetylcholine receptors, 272
 peripheral neuropathies, 684–687
- Autophagy
 endocytic pathway, macromolecular
 degradation and nutrient uptake,
 135–137
 polyglutamine protein turnover, 846–849
- Autosomal dominant Parkinson's disease,
 genetics, 723
- Autosomal recessive Parkinson's disease,
 genetics, 723–724
- Axolemma
 ion channels, voltage-dependent gating
 mechanisms, 66, 67f
 precursors, anterograde fast axonal
 transport, 153
- Axonal growth
 axotomy, structural and biochemical
 changes, 585
 cell adhesion molecules, 585
 glial scar and, 589–590
 neurofilamentous axonal pathology, IDPN
 administration, 806
 Nogo-A protein, neurite growth inhibition,
 586
 peripheral nervous system regeneration,
 583–585
 Schwann cells and basal lamina
 requirements, 584
 Wallerian degeneration, peripheral nervous
 system, 583
 Wallerian degeneration and myelin sheath
 disruption, 583, 584f, 584t
- Axonal transport
 fast and slow components, 148–150, 148t,
 149f
 molecular mechanisms, 156
 fast transport
 anterograde transport, 153
 biochemistry and pharmacology, 151
 Golgi apparatus passage, 152–153, 153f
 membrane and secretory proteins, 150f,
 151–152, 151f, 152f
 molecular sorting mechanisms, 154–155
 retrograde transport, 153–154
 hereditary spastic paraplegias, deficits and
 pathogenic mechanisms, 146
 molecular motors, 156–161
 biochemical properties, 157
 cytoplasmic dyneins, 159–160
 function matching, 160–161
 kinesins, 157–159
 membrane-bound organelles, 158
 myosins, 160
 myelination regulation, 574
 neural organelle motion, 147, 147f
 neuronal size and extent, 147–148
 neuropathology and, 161
 rate components, 148t, 149f
 slow transport
 cytoplasmic/cytoskeletal elements, 155
 growth and regeneration rates, 155–156
 molecular mechanisms, 156
- Axonal Transport, neuropathology and, 161
- Axons, 4–6, 5f
 adenosine triphosphate release, 385
 brain energy metabolism assays, 226
 compartmental elements, 9–10, 9f
 cytoskeleton and organization of, 102, 102f,
 104f
 early differentiation, 111–112
 glia influence on, 112–114, 113f
 epilepsy, sprouting, dentate granule
 circuits, 709
 growth and regeneration, slow axonal
 transport, 155–156
 myelin in, 185
 repair mechanisms, 702–703
 myelin sheath and function of, 578
 nervous system development, 542–543
 neurofilament disruption, neuropathology
 and, 115–116
 peripheral neuropathies, degeneration and
 protection, 687–688
- Axotomy, structural and biochemical changes
 and, 585
- ## B
- Bacterial toxins, G protein modification,
 ADP-ribosylation, 419–420
- Balance, mechanotransduction, 916–917
 vestibular organs, 923–926
- Barbiturate addiction, 1050
- Bardet-Biedl Syndrome, 23
- Bariatric surgery, peripheral neuropathies
 and, 687
- Basal ganglia
 A_{2A} receptors in, 383, 383f
 anatomy and physiology, 856–861
 disorders of, 861–868
 connectivity losses, 869–870
 drug actions, 868
 dystonia, 866–867
 Huntington's disease, 865–866, 866f
 neuropsychiatric disorders, 867–868
 Parkinson's disease, 861–865, 863f
 movement control and, 857
 neurotransmitter systems in, 857–860
 acetylcholine, 858
 dopamine, 859–860, 859f
 dopamine-acetylcholine balance, 860
 GABA, 857, 858f
 glutamate, 858
 multiple systems, 860
- Basal lamina
 axonal regeneration, 584
 blood-brain barrier and, 19–21
- Basement membrane (BM), blood-brain
 barrier and, 19–21
- Bcl-2 protein, mood disorders and, 1029
- Behavioral arousal/activity
 autism spectrum disorders, 1013
 immune-related changes in neuronal
 function and, 607–608
 olfaction and, 909–910
 serotonin, 311–312
 stress and, 950–951
- Benzodiazepine addiction, 1050
- Beta-enolase deficiency, 766
- Beta-sheet conformation, prion protein,
 879–880, 879f
- Bioactive lipid mediators, phospholipid
 reservoirs, 645
- Bioactive peptide products, tissue-specific
 processing, 394, 395f
- Biogenesis, peroxisomal diseases, 761, 762t
- Biogenic amines, SLC6 symporter subfamily,
 52–53
- Biological membranes, basic properties, 29–36
- Biopterin, phenylketonuria and deficiency
 in, 744
- Biosynthetic secretory pathway
 catecholamines, 284f
 intracellular membrane trafficking, 120,
 126–135
 compartments and transport sequence,
 128f
 constitutive secretory pathway, 133f, 134
 COPII-coated vesicles, Golgi complex
 delivery, 127–129
 endoplasmic reticulum classification,
 126–127
 glycosylation compartmentalization, 127t
 Golgi apparatus components, 129
 Golgi cisternae protein/lipid transport,
cis to *Trans* direction, 130–131, 131f
 lysosomal pathway convergence, 132
 neuroendocrine secretion pathways,
 132–133
 protein sorting and glycosylation, Golgi
 complex, 129–130
 secretory cells, regulated pathway
 specialization, 133f, 134
 secretory vesicle biogenesis, 134–135
trans-Golgi network, lysosomal protein
 sorting and targeting, 132
trans-Golgi network, plasma membrane
 protein sorting, 131–132
 neuropeptides, 394, 394f, 395f
- Biotin-dependent syndromes, 772
- Bipolar cells, photoreceptor downstream
 signaling, 897
- Blood-brain barrier (BBB)
 astrocytes and maintenance of, 19
 ATP-binding cassette transporters,
 molecular entry restriction, 22–23
 basal lamina and basement membrane,
 19–21
 brain energy metabolism
 endothelial cell transporters, glucose/
 monocarboxylic acid uptake,
 203–204, 204f
 energy-yielding substrates, 203–204

- neuropathology and alteration of, 204
- brain function and, 17–18, 18t
- central nervous system, 16–18, 17f
 - diseases and therapeutic efficacy, 23
- cholesterol transport and regulation, 31
- CNS immune activity and, 604
- evolution of concept, 18
- extracellular fluid control, 18
- facilitated glucose diffusion, 58–59
- glutamate transport, 343–344
- lipid solubility and substance permeability through, 21–22
- multiple transporters and transport processes, 21–23, 21t
- pathogenesis and dysfunction of, 23
- pericytes, 19
- protein, metabolite and toxin exchange, 18–21, 18t
- solute carriers, 22
- transport function, 19, 20f
- Blood-cerebral spinal fluid barrier
 - brain function and, 17–18, 18t
 - central nervous system, 16–18, 17f
- Blood composition, amino acid imbalance, neurotransmitters and protein synthesis effects, 740–742
- Blood oxygen level-dependent (BOLD) signal
 - brain energy metabolism, 223
 - brain function and, 206
- Botulinum toxin, muscle excitation alteration, 795–796
- Bovine spongiform encephalopathies, prion protein dysfunction, 873–874
- Brain chemistry, amino acid disorders, low-protein diet, 742
- Brain-derived neurotrophic factor (BDNF)
 - basic properties, 548–550
 - epileptogenesis, 710–711
 - mood disorders and, 1029
- Brain development
 - aquaporins in, 57
 - brain energy metabolism
 - cerebral metabolic rate, 205
 - glucose requirements, adult brain, 206–207
 - transporters and pathways, 204–205
 - docosahexaenoic acid (DHA) pathways and, 656
 - fatty acids, long-chain carboxylic structure, 82–83
 - immune-competent microglia, 23
 - second messenger-independent protein Ser/Thr kinases, 478–479
 - sodium-potassium-adenosinetriphosphatase and, 45
 - tau protein isoforms, 834–835
 - visual system, 891–892
- Brain edema
 - aminoacidurias and intracranial pressure, 742
 - aquaporin-4 regulation, 59–60
- Brain endothelial cells (BECs)
 - central nervous system homeostasis, 16–17
 - cerebral capillaries, 18
 - sodium-dependent D-glucose symporter, 52
 - transport function, 19, 20f
- Brain function
 - aminoaciduria disorders, 738–740
 - blood-brain barrier and blood-cerebral spinal fluid barrier and, 17–18
 - carbohydrate/lipid metabolic disorders, 770–772
 - cGMP signaling, guanylyl cyclase receptors, 433–434
 - cholesterol synthesis, adult astrocytes, 31–32
 - continuous cerebral circulation, 206
 - energy metabolism
 - aging and maturation declines, 205
 - basic requirements, 202t
 - blood-brain barrier transport, 204
 - brain imaging and spectroscopy, 222–226, 223f, 224f, 225f
 - cell and subcellular structures and functions, 203
 - compartmentalization, 207
 - compound concentrations, intact brain, 226
 - developmental metabolic rate, 205
 - developmental transporters and pathways, 204–205
 - glutamate-glutamine metabolism, 220–222, 221f
 - glycogen synthesis, astrocytic degradation, 209–210
 - glycolysis, 207–209, 208f
 - imaging applications, signaling mechanisms, 202–203
 - lactate metabolism, 211–215
 - malate-aspartate shuttle, 210–211, 214f
 - mitochondrial heterogeneity, 219–220
 - neuropathology, 226
 - pentosephosphate shunt, 210
 - signaling mechanisms, 201–202
 - SLC25A12* gene mutation,
 - N*-acetylaspargate formation and myelination, 212–213, 212f
 - sleep regulation, 983f
 - substrates, 203–204
 - supply-demand relationships, 205–207
 - tricarboxylic acid cycle, 215–219, 216f
 - epileptogenesis and, 709
 - histamine
 - enzyme synthesis and breakdown, 327–329, 327f
 - mast cells, 324
 - metabolism and methylation, 328
 - neuromodulation and neurotransmission, 335
 - storage and release, 324
 - lipids, 82–83, 85f
 - biosynthesis, 90–96, 90f
 - chromatography and mass spectrometry analysis, 89–90
 - normal adult, 91t
 - neuronal extracellular clearance of potassium and water, 58
 - neuronal nicotinic acetylcholine receptor family, 271
 - nonketotic hyperglycinemia and, 744–745
 - plasma and cerebrospinal fluid levels and, 18t
- SLC25A12* gene mutation,
 - N*-acetylaspargate formation and myelination, 212–213, 212f
- sleep regulation, 983–984, 984f
- stress and, 945–946, 947f
 - allostasis and allostatic overload, 951
 - behavioral effects, 950–951
 - future research issues, 953–954
 - hippocampus, 946–947
 - modern life factors, 951–953
 - neurogenesis and, 959–960
 - prefrontal cortex and amygdala, 949–951
 - research and definitions, 946–947
 - sleep and circadian rhythms and stress axis, 946
 - stress hormones, 946
- Brain growth factors, mood disorders, 1025
- Brain imaging
 - function-derived signals, 202–203
 - glycine receptor distribution, 252
 - schizophrenia, 1003–1004
- Brain injury. *See also* Ischemia
 - acute ischemic stroke, potential therapeutic strategies, 638–640
 - compensatory plasticity and functional recovery, Nogo-A blockade, 591–592, 591f
 - ischemic phase, 627–629
 - calcium overload, 627–628, 628f
 - excitotoxicity, 627
 - NMDA receptors
 - brain function and cell death, 628–629
 - downstream cell death signals, 629, 629f
 - membrane lipid breakdown, 654–655
 - neonatal brain damage, compensatory plasticity and, 590
 - neuroprotection signaling and inflammation resolution, 632–638
 - apoptotic signaling, 633–635, 634f, 635f
 - docosanoids and penumbra protection, 635–638, 636f, 637f
 - inflammatory mediators and anti-inflammatory regulation, 632–633
 - neurovascular breakdown and edema, 631–632, 632f
 - aquaporins, 632
 - metalloproteinases, 631–632
 - phospholipid targeting, synaptic membranes, 645
 - reperfusion phase, 629–631
 - antioxidants, ischemia-reperfusion injury protection, 630–631
 - excitotoxic enhancement, ROS, 631
 - ischemia-reperfusion, 630
 - polyunsaturated fatty acids, ROS generation, 630
 - reactive oxygen species, 629
 - spectrin-ankyrin network and, 37
- Brain metabolism, cardiolipin, 81, 86f, 87f
- Brain neoplasms, stem cells as, 562
- Brain slices, brain energy metabolism assays, 226
- Brainstem, pain management, 931–933
- Brain ventricles, ependymal cells in, 16, 16f

- Branched-chain amino acids
major pathways, 740f
maple syrup urine disease, 742–743
- Branching enzyme deficiency, 767, 770–771
- Brody disease, sarcoplasmic reticulum
calcium ATPase and, 793
- ## C
- CA3 pyramidal neurons, hippocampal
regulation, 708
- Cadherins, cell adhesion molecules, 169–170, 171f
extracellular cadherin, 169, 172f
homophilic type I cadherins, 169
integrin cross-talk, 177–178
nervous system processes, 169–170
- CAG-polyglutamine repeat diseases
epidemiology, 844–845
genetics, 845t
polyglutamine disease protein functions, 845, 847f
acetylation, 850
ataxin-1 complex, 849
ataxin-7 disruption, 849
autophagy pathway, 848f
gene silencing therapy, 850–853, 851f
misfolding and toxicity, 845–846
phosphorylation, 849–850
post-translational modification, 849
RNA toxicity, 850
transglutaminase inhibition therapy, 852–853
turnover pathways and pathogenesis, 846–849
- Calcium adenosine triphosphatases, basic
properties, 48, 49f
- Calcium/calmodulin-dependent kinases,
phosphorylation, 475–476
- Calcium/calmodulin-stimulated
phosphodiesterases, 434–435
- Calcium-dependent binding, proteins, 29, 31f
- Calcium ion channels
acetylcholine release, synaptic vesicles, 261–262
astrocyte integration, local and global
signaling, 461–464, 463f
cerebral vasculature control, 463–464, 463f
tripartite synapse, gliotransmitter and
modulation, 462–463
- cellular organelles and calcium pools, 458–461
- endoplasmic reticulum
intracellular calcium storage, 459
pumps, storage buffers, and release
channels, 459–460
signaling pathway activation, 459–460
store-operated calcium entry, 460
- epilepsy antiseizure drugs, voltage-gated
current regulation, 712, 712f
- future research issues, 464–465
- gene subfamilies, 75–76
- homeostasis, 49f, 457–458
- hypokalemic periodic paralysis, 791
- D-myo-Inositol 1,4,5-trisphosphate
liberation, endoplasmic reticulum, 448–449, 448f
- Lambert-Eaton syndrome, antibodies, 794
- malignant hyperthermia mutations, 793
- mood disorders and, 1029–1030
- muscle membrane excitation and
contraction, 787–789, 788f
- overloading
ischemia and toxicity, 464, 627–628, 628f
measurement, 456–457, 456f
indicator protein targeting, 457
monitoring optimization, fluorescence
indicators, 456–457
optical methods, 456–457
microdomain signaling, 461
mitochondria and, 460–461, 460f
neuropeptide release, 403
neurotransmitter receptors, G protein
coupling, 413–414
plasma membrane homeostasis, 457–458
efflux pathways, pumps and
transporters, 458
influx pathways, 458
primary plasma membrane calcium
transporter, 48
structure, 71, 72f
transport, store-operated, ligand-
operated, and voltage-operated
channels, 457f
photoexcited rhodopsin, 894–895
ryanodine receptor, malignant
hyperthermia, 792–793
in synaptic transmission, 239–241, 243f
presynaptic events, 241–245
- Calcium pumps, sodium-potassium-
adenosinetriphosphatase
subunits, 55, 56f
- Calcium-stabilizing proteins, apoptosis
inhibition, 671–672
- cAMP response element binding protein
(CREB), transcription factor
immunohistochemical localization, 525f
protein phosphorylation, 488f, 489
regulatory function, 524–527
transgenic modeling, 525–526
- Canavan's disease, 753
- Candidate-gene studies, Parkinson's disease, 724–725
- Cannabinoids
addiction, 1045–1048
pain management, 933–934
- Carbamates, acetylcholinesterase inhibitors, 266
- Carbamyl phosphate synthetase deficiency, 750
- Carbohydrates
brain energy metabolism, glycolysis
regulation, 208–209
metabolic disorders involving, 762–772
brain metabolism, 770–772
exercise-related signs and symptoms, 768–770
glucose metabolism, progressive
weakness, 766
glycogen or lipid disorders, 763, 764f
muscle disorders, 763–768
- Carbon-13 nuclear magnetic resonance
spectroscopy, brain energy
metabolism, 224–225, 224f, 225f
- Carbon monoxide, intercellular signaling, 256
- Carboxylic-acid transporters, bacterial
expression, 53
- Cardiolipin, brain metabolism, normal brain,
neurodegeneration and gliomas, 81, 86f, 87f
- Cardiotonic steroid signal receptors,
sodium-potassium-
adenosinetriphosphatase, 46–48, 47f
- Cardiovascular disease, homocystinuria and
risk of, 747
- Cargo components
biosynthetic secretory pathway, 127–129
intracellular membrane trafficking, 120, 121f
- Carnitine deficiency, 767–768
- Carnitine palmitoyltransferase II (CPTII)
deficiency, 766
- Casein kinase 1 (CK1), phosphorylation, 478–479
- Caspase substrates
apoptosis activation
postmitochondrial events, 670
synaptic plasticity, 675
apoptosis and necrosis, 664t
- Catabolism
catecholamine termination, 288–290, 289f
serotonin catabolic pathway, 310–311
- Catalytic subunits
nonreceptor protein tyrosine kinases, 494–498, 496f, 497t
sodium-potassium-
adenosinetriphosphatase pump
heterodimer formation, 43
isoform expression, 43
molecular structure, 43, 44f
monotopic glycoproteins, 43–44
sodium pump, 44–45
- Catecholamines
adrenergic receptors, 295–297, 295t, 296t
G-protein-coupled receptors, 295–297
agonist-induced downregulation, 297
amine transporters, 289, 289f, 289t
aromatic amino acid decarboxylase,
L-DOPA-dopamine conversion, 285–286
biosynthetic pathway, 284f
tyrosine hydroxylase regulation, 284–285, 285f
catechol-O-methyltransferase (COMT)
metabolism, 291–292
cell surface receptor binding, 293–295, 294f, 294t
diffusion and inactivation of, 290
dopamine metabolites, 292
familial dysautonomia and, 286–287
knockout mice studies, 285t
adrenergic receptors, 296t
monoamine oxidase metabolism, 290–291, 291f
as monoamine transmitters, 283
neuroanatomy, 292–295, 293f
noradrenergic/adrenergic neurons,
dopamine-norepinephrine
conversion, 286

- norepinephrine metabolism, 292
 phenylethanolamine-N-methyltransferase,
 norepinephrine-epinephrine
 metabolism, 288
 repeated antagonists, 297–298
 reuptake and termination, 288–290
 synaptic vesicle release, 288
 synaptic vesicle storage, 288
 Catechol-O-methyltransferase (COMT),
 catecholamine metabolism,
 291–292
 Cation antiporters, 55–56
 cytoplasmic calcium regulation
 mechanisms, 55
 sodium-calcium antiporters and calcium
 pumps, 55, 56f
 cytoplasmic calcium pulses, 55
 CB1 receptor, cannabinoid addiction,
 1045–1046
 CD9 protein, myelin sheath, 194–195
 cDNA cloning, sodium ion channel, 69–71,
 70f
 Cell adhesion molecules (CAMs)
 apoptosis, 670–671
 axonal regeneration, 585
 catalytic subunits, sodium-potassium-
 adenosinetriphosphatase pump,
 43–44
 cooperation and crosstalk, 175–178
 integrin-cadherin crosstalk, neurite
 growth, 177–178
 interneuronal synapses, 175–177
 superfamilies, 166
 cadherins, 169
 immunoglobulin superfamilies, 166, 167f
 integrins, 170–175
 multiple sclerosis, 174
 Cell culture studies, synucleinopathies,
 833–834
 Cell death
 axon-based nervous system development,
 542–543
 ischemia-reperfusion injury, reactive
 oxygen species, 631
 phosphoinositides, 452
 phospholipases A₂, ischemia-reperfusion
 signaling, 654
 Cell membrane constituents
 myelin, 184–185
 retrograde axonal transport, 153–154
 Cell-surface receptors
 axonal regeneration, neurite growth
 mediation, 589
 catecholamine binding, 293–295, 294f, 294t
 molecular signaling mechanisms, 246–249,
 246f, 247t
 first group, 246–248
 fourth group, 248–249
 second group, 248
 third group, 248
 Cellular neuroscience
 basic principles, 4
 schizophrenia, 1004–1009
 Cellular phenotyping, transcription factors,
 527–528, 527f
 transcriptome regulation, 528
 Cellular signaling mechanisms, 245–256
 adenylyl cyclase regulation, 328, 333f
 astrocyte function, 256
 G protein subunits, 415–416, 415f
 intracellular signaling pathways, crosstalk,
 249
 molecular mechanisms, cell-surface
 receptors, 246–249, 246f, 247t
 first group, 246–248
 fourth group, 248–249
 second group, 248
 third group, 248
 nitric oxide intercellular signaling
 molecule, 249–256
 protein phosphorylation pathways,
 483–484
 receptor-mediated signaling, 246
 signaling molecules, gene transcription
 activation, 249
 Central nervous system (CNS)
 blood-brain barriers and, 16–18, 17f
 cholesterol transport and regulation, 31, 32f
 cholinergic neuron distribution, 262
 development
 axon guidance, 542–543
 naturally occurring cell death, 542–543
 embryology, 534
 embryonic signaling, 538–539, 539f
 neurogenesis and gliogenesis, 539–541
 neuronal birthdate, 539
 proneural gene functions, 540–541
 reelin and notch signaling, cortical
 layer organization, 539, 539f
 diseases, blood-brain barrier dysfunction,
 23
 embryonic development, 534
 histamine actions in, 335–337
 histaminergic fibers, 325, 326f
 homeostasis, 16–18
 immunology activity in, 603–607
 blood-brain barrier and, 604
 injury and compensatory plasticity,
 590–592
 adult brain injury, Nogo-A blockade,
 591–592
 neonatal damage, 590
 major components, 4f
 mitochondrial distribution in, 219
 mitochondrial dysfunction in, 772–773
 muscarinic cholinergic receptor
 distribution, 277
 neuropsychiatric disorders, 277
 myelin
 in cell membrane, 184–185
 lipid enrichment, 186–187, 187f, 187t
 peripheral nervous system myelin
 comparisons, 187–188
 proteins in, 188–192, 190f
 nociceptive pathways, 932f
 oligodendrocytes, myelin production in, 13
 peroxisomal diseases, 760–761
 regeneration, 451f, 585–590
 axon growth, glial scar inhibition,
 589–590
 knockout studies, nogo gene
 development, 588
 myelin components, 588–589
 neurite growth inhibition, 589
 neurotrophic factors, 590
 Nogo-A inhibitor, 586, 587f, 588, 589
 reticulon superfamily, 587–588
 spinal cord injury, fiber growth and
 regeneration, 592
 stem cell repair, 563–567
 tyrosine phosphorylation in, 505–511
 Central sensitization, pain management,
 934–935, 935f
 descending facilitation, 937
 Centronuclear myopathy (CNM), mutant
 dynamin, 2, 123
 Cerebral blood flow (CBF)
 astrocytic control, calcium signaling,
 463–464, 463f
 brain function and, 206
 eicosanoids and, 656
 Cerebral circulation
 brain function and, 206
 cerebral capillaries, structure and function,
 18
 Cerebral energy production,
 sodium-potassium-
 adenosinetriphosphatase, 45
 Cerebral metabolic rate (CMR), 202t
 brain development and, 205
 brain function, continuous cerebral
 circulation, 206
 brain maturation, 205
 glucose, functional imaging, redox state
 and metabolic pathway analysis,
 222–223, 223f
 supply-demand relationships, 205–207
 Cerebral X-linked adrenoleukodystrophy,
 stem cell therapy, 565
 Cerebrovascular disease
 homocystinuria and risk of, 747
 phospholipase A₂ signaling, 654
 Chanarin Dorfman syndrome, 768
 Chaperone proteins
 endocytic pathway, autophagy mediation,
 136–137
 intracellular membrane trafficking, coat
 protein removal, 124–125
 tubulin-specific chaperone E mutations,
 transgenic mice studies, 808
 Charcot-Marie-Tooth (CMT) disease
 gene mutations, 701
 molecular motor and, 688
 mutant dynamin, 2, 123
 peripheral neuropathy, 680–684
 phosphoinositides and, 445
 Chemical transmission, nerve cells, 235–245,
 236f
 Chemokines, neuroinflammation and, 614
 Chemosensing system, vomeronasal organ,
 910, 911f
 Chemotherapy, microtubule disruption,
 114
 Chlorine ion channels
 congenital myotonia, 792
 ligand-gated strychnine-sensitive
 receptors, glycine inhibition,
 250–251

- Cholecystokinin (CCK)
 anxiety disorders, 1032–1033
 identification, 390–391, 392
 plurichemical coding, neuronal signals, 403
- Cholesterol
 adult brain synthesis in astrocytes, 31–33, 33f
 central nervous system transport and regulation, 31, 32f
- Choline, acetylcholine synthesis, storage and release, synaptic terminal accumulation, 260–261, 261f
- Choline acetyltransferase (ChAT)
 acetylcholine formation, 260
 deficiency, 789
- Cholinergic agonists and antagonists
 chemical structure, 259–260, 259f
 mood disorders, 1024
 nicotinic acetylcholine receptors
 binding, 268–269
 desensitization, 269, 270f
 schizophrenia, 1008
- Cholinergic disorders, muscarinic cholinergic receptor therapies, 278
- Cholinergic neurotransmission, REM sleep, 988
- Cholinergic pathways, acetylcholine
 synthesis, storage and release, 260–262
 choline acetyltransferase catalyst, 260
 neuron distribution, central nervous system, 262, 262f
 synaptic terminal, choline accumulation, 260–261, 261f
 vesicular transporters, calcium-dependent neuronal release, 261–262, 262f
- Choline transporter, neurotransmitter function, 54
- Choroid plexus, extracellular fluid control, 18
- Chromatin immunoprecipitation assay (ChIP), transcription analysis, 518–520, 521f
- Chromatin modulation
 apoptosis activation, 670
 transcription co-regulators, 516
- Chromatography, brain lipids, 89–90
- Chronic inflammatory demyelinating polyradiculopathy (CIDP), 699
- peripheral neuropathies, 684–687
- Chronic wasting disease (CWD), 874
- Circadian rhythms
 autism spectrum disorders, 1016
 serotonin modulation, 312
 stress and disruption of
- Cis-Golgi network, biosynthetic secretory pathway
 organelle polarization, 129
 protein and lipid transport, 130–131, 131f
- Citrate, brain energy metabolism, astrocyte synthesis and release, 218
- Citric acid cycle. *See* Tricarboxylic acid (TCA) cycle
- Citrullinemia, 750
- c-jun NH2-terminal kinases, phosphorylation, 477–478
- Clathrin-coated vesicles
 endocytic pathway, receptor-mediated endocytosis, 137–139, 138f
 intracellular membrane trafficking, 64f, 71–72
 coating removal, chaperone proteins, 124–125
 synaptic vesicle trafficking, 142
- Clathrin-mediated endocytosis, pinocytosis mediation, 136
- Claudins, myelin sheath, 194
- Clinical pain management, 928–929, 938–939
 genetic factors, 939
- Coat proteins, intracellular membrane trafficking, 124–125
- Cobalamin-C disease, homocystinuria and, 748–749
- Cobalamin-E disease, homocystinuria and, 748
- Cocaine
 addiction, 1043
 neuronal adaptation, 1044
- Cochlea
 hair cell mechanotransduction, 926
 mechanisms of, 923
- Coenzyme Q1₀ deficiency, respiratory chain abnormalities, 777
- Cognitive dysfunction
 cGMP signaling, guanylyl cyclase receptors, 434
 G proteins and, 420
 nicotinic acetylcholine receptor targeting, 273
 protein phosphorylation and enhancement strategies, 486–487
 serotonin effects, 301–304
 urea cycle defects, 752
- Collective co-spiking, neural cliques, memory function, 974, 979f
- Collybistin, glycine receptor structure and function, 251, 251f
 submembrane gephyrin aggregation, 252
- Compensatory plasticity, adult central nervous system, Nogo-A blockade, 591–592, 591f
- Concept cells, memory function, 975, 979f
- Conditional gene knockout technology, learning and memory research, 969, 969f
- Cone phototransduction
 bipolar cell signaling, 897
 visual function, 895–897
- Congenital fibrosis of extraocular muscles 1 (CFEOM1), molecular motor and, 688
- Congenital fibrosis of extraocular muscles 3 (CFEOM3), TUBB3 mutation, 115
- Congenital myasthenic syndromes, 789–790
- Constitutive secretory pathway, eukaryotic cells, 133f, 134
- Cooperation, cell adhesion molecules, 175–178
- Cooperativity, learning and synaptic plasticity, 966
- COPI (coatomer), intracellular membrane trafficking
 coating removal, chaperone proteins, 124
 monomeric and heterodimeric GTPases, 122
 transport vesicle coating, 72
- COPII-coated vesicles
 biosynthetic secretory pathway,
 endoplasmic reticulum coating,
 Golgi complex delivery, 127–129, 128f
 intracellular membrane trafficking
 coating removal, chaperone proteins, 124
 monomeric and heterodimeric GTPases, 122–123
 transport vesicle coating, 72–74
- Copper oxidative toxicity, motor neuron disease, 809
- Cori's disease, 767
- Cortical-hypothalamic-pituitary-adrenal axis, mood disorders, 1024
- Cortical layer organization, neurogenic development, reelin and notch signaling, 539
- Corticobasal degeneration, 836
- Corticolimbic abnormalities, schizophrenia, 1003–1004
- Corticosteroid receptors, transcription factors, regulatory mechanisms, 522, 522f
- Corticotropin-releasing hormone (CRH)
 anxiety disorders, 1032
 neuronal synthesis, 393–394
- Cranial nerves, taste bud, 912
- Creatine phosphatase, brain energy metabolism, 218
- Creutzfeld-Jakob disease
 etiology, 874
 genetics, 730–731
 prion proteins, 875
- Crosstalk
 cell adhesion molecules, 175–178
 cadherin-integrin cross-talk, 177–178
 molecular signaling mechanisms, cell surface receptors, intracellular signaling pathways, 249
- Cyclic adenosine monophosphate (cAMP)
 addiction and upregulation, 1042–1043
 adenylyl cyclase
 brain signaling function, 329–331
 molecular targeting, 329
 production biochemistry, 324, 326f
 histamine activity, histamine H₂ receptor, 331
 protein kinase A, phosphorylation, 473
 transcription regulation, 524–527, 524f, 525f, 526f
- Cyclic GMP-gated ion channels, guanylyl cyclase receptors, 433
- Cyclic guanosine monophosphate (cGMP)
 guanylyl cyclase molecular effectors, signaling mechanisms, 433–434
 brain function, 433–434
 cGMP-gated ion channels, 433
 cognition and mood, 434
 pain management, 434
 phosphodiesterases, 433

- protein kinase G, 433
synaptic plasticity, learning and memory, 434
molecular signaling mechanisms, cell surface receptors, 248
phosphodiesterase regulation, 435–436
phototransduction, 896f
protein kinase G phosphorylation, 473
2':3'-Cyclic nucleotide 3'-phosphodiesterase, central nervous system myelin, 190–191
- Cyclic nucleotide-gated (CNG) channels
adenylyl cyclase molecular targeting, 329–335
phototransduction, 896f
- Cyclic nucleotides. *See* Adenylyl cyclases
adenylyl cyclases, 423–430
antidepressant mechanisms, 437–438
future research issues, 439
guanylyl cyclases, 430–434
phosphodiesterases, 434–438
second messenger hypothesis, 423, 424f
spatiotemporal integration in neurons, 438–439
- Cyclin-dependent kinases 5 (CDK5), phosphorylation, 478
- Cyclooxygenases
arachidonic acid conversion, 648–649, 648f, 649f
arachidonic acid metabolites, 652
hippocampal kainic-acid-induced cyclooxygenase-2 expression, 654
ischemia-reperfusion process and accumulation of, 656
lipid mediator pathways, 652–653
neuroprotectin D1 inhibition, 657
platelet-activating factor transcriptional activator, 652
synaptic plasticity, 652–653
- Cys-loop ligand-gated ion channel family, nicotinic acetylcholine receptors, 268f, 269
- Cystathionine synthase, sulfur amino acid metabolism disorders, 747
- Cysteine residues, protein tyrosine phosphatases, active site, 503–504
- Cytokines
apoptosis, 670–671
depression and, 1034
microglia production, 614
neurotrophic, 555–556
- Cytoplasmic calcium pulses
regulation mechanisms, 55
sodium-calcium antiporters, 55
- Cytoplasmic elements
brain energy metabolism, malate dehydrogenase, 217
immunoglobulin cell adhesion molecules, 169
neuronal axonal transport, 159–160
receptor protein tyrosine kinase, 498–501
slow axonal transport, 155–156
- Cytoplasmic signaling enzymes, metabotropic glutamate receptors, 358
- Cytoskeleton
glycine receptor, pentamer assembly and interaction, 252
growth cone elements, 110f
intracellular membrane trafficking, coating removal, chaperone proteins, 124–125
lipid raft interaction, 35–36, 36f
membrane protein interaction, 34
neuronal
complementary distributions and functions, 112–116
molecular components, 102–110
actin microfilaments, neuronal growth and secretion, 108–110
eukaryotic cell definition, 102, 102f
microfilament proteins, 109t, 110f
microtubules, structure and organelle tracking, 102–106, 103f, 104f, 105t, 107f
neuronal and glial intermediate filaments, morphology support, 106–108, 107f
neuropathology and alterations, 114–116
 β -III tubulin mutations and, 115
ultrastructure and molecular organization, 110–112
protein expression
injury and regeneration, 114
phosphorylation and neuropathology, 116
slow axonal transport, 155–156
spectrin-ankyrin network, 34–35
- Cytosol compartment
brain energy metabolism, malate-aspartate shuttle, mitochondrial transfer, 210–211
glutamate symporter failure, 54
- Cytosolic phospholipases A₂, bioactive lipid formation, 647
- ## D
- Danger-associated molecular patterns (DAMPs)
APC function and T-cell differentiation, 602
neuroimmunology, 597
neuroinflammation, 616–617
- Deafness, genetics, 922
- Death receptor, apoptosis activation, 668, 669f
- Debrancher enzyme deficiency, 767, 770
- Declarative memory, 965
- Default mode network, Alzheimer's disease diagnosis, 816
- Dementia
Alzheimer's disease, 816
frontotemporal dementia, genetics, 726–727, 726t, 727t
Lewy bodies, genetics, 725–726, 833f
sodium-potassium-adenosinetriphosphatase and, 45
- Demyelination
consequences of, 580
repair, 702–703
- Dendrites, 4–6, 5f
as afferent components, 9, 9f
- cytoskeleton and organization of, early differentiation, 111–112
cytoskeleton composition and organization, 104f
epilepsy, sprouting, dentate granule circuits, 709
lipid mediation pathways, 658
motility and synaptic activity, 361
transport mechanisms, molecular sorting, 155
- Dentate granule cells, epilepsy
axonal/dendritic sprouting, excitatory synaptic transmission, 709
CA3 pyramidal neuron regulation, 708
inhibitory/excitatory synaptic input abnormalities, 709
- Depolarization, action potential propagation, 67
- Depression
inflammation, cytokines, and glutamate, 1034
sleep disorders and, 987
acetylcholine and pain and, 988
glutamate modulation, 992–993
- Diabetes insipidus, vasopressin production, 404
- Diabetic neuropathy, 684, 685f
- Diacylglycerol kinases
brain injury, lipid breakdown, 654–655
lipid mediation, 654
- Diet and nutrition
amino acid disorders
low-protein diet, 742
maple syrup urine disease, 743
myelin formation and stability, 701–702
peripheral neuropathies and, 687
sulfur amino acid metabolism disorders, 747
urea cycle defects, 751
- Diffusion mechanisms, catecholamine inactivation, 290
- Diffusion tensor imaging, white matter pathology, 196–197
- Disinhibition, pain management, 937–938
- Disulfide bridging, secretory phospholipases A₂, 647
- DNA damage, apoptosis activation, 668
- DNA methylation
histone and, 517–518
S-adenosylmethionine transfer, neurodegenerative disease epigenetics, 731–733
- DNM2* gene, neuromuscular disorders, 123
- Docosahexaenoic acid (DHA) pathways
brain injury, lipid breakdown, 654–655
lipid mediation, 656–657
lipid peroxidation, 657
neuroinflammation, 614–616, 615f
neuroprotectin D1 derivation, 657
phospholipases A₂, ischemia and seizures, 647
retinal identification, 657
sequential oxygenation, resolvin/protectin mediation, 657
stroke penumbra protection, 635–638, 636f, 637f

- Docosanoids, lipid mediation, 657
- Dominant optic atrophy (DOA), dynamin proteins and, 124
- Doogie* mice, learning and memory research, 969–971
- NR2B targeting, 972–973
- Dopa decarboxylase. *See* Aromatic amino acid decarboxylase (AADC)
- Dopamine
- addiction and neurotransmission mechanisms, 1038–1040, 1040f, 1042f
 - adenylyl cyclase targeting, striatal signaling, 430
 - aromatic amino acid decarboxylase L-DOPA conversion to autism spectrum disorders, 1015
 - in basal ganglia, 859–860, 859f
 - cell-surface receptor binding, 293–295, 294f, 294t
 - metabolites, 292
 - norepinephrine conversion, adrenergic/noradrenergic neurons, 286
 - sleep regulation, 988–989
- Dopamine-acetylcholine balance, in basal ganglia, 860
- Dopamine- β -hydroxylase, dopamine-norepinephrine conversion, adrenergic/noradrenergic neurons, 286
- Dopamine depleting agents, basal ganglia disorders, 868
- Dopamine hypothesis, schizophrenia, 1004–1005
- Dopamine receptor blocking agents, basal ganglia disorders, 868
- Dopamine receptors, psychomotor stimulant addiction, 1045, 1046f
- Dopaminergic system, mood disorders, 1024
- Dopamine transporters (DAT)
- catecholamine termination, 289
 - psychomotor stimulant addiction, 1043–1044
- Dorsal horn, nociceptive pain, 930, 931f
- Dorsal root ganglion, pain management, 929
- Dorsoventral pattern, embryonic nervous system development, 534–535, 536f
- Drug abuse
- adenylyl cyclase targeting, 430
 - barbiturates and benzodiazepines, 1050
 - basic principles, 1038, 1039f
 - cannabinoids, 1045–1048, 1047f
 - cyclic AMP second-messenger pathway, 1042–1043
 - dopamine transmission, 1038–1040, 1040f, 1042f
 - ethanol, 1049
 - hallucinogens and dissociative drugs, 1050–1051
 - neural circuitry, 1038–1041
 - neuronal plasticity, 1051–1052, 1052f
 - nicotine, 1048–1049
 - opiates, 1041–1043
 - psychomotor stimulants, 1043–1045, 1044f, 1046f
- Drug therapy
- alcohol addiction, 1049–1050
 - antiseizure drugs, epilepsy and mechanisms of, 711–713
 - GABA-mediated synaptic inhibition, 711–712, 712f
 - voltage-gated calcium currents, 712, 712f
 - voltage-gated sodium channel targeting, 711, 711f
 - autism spectrum disorders, 1014
 - basal ganglia disorders, 868
 - brain histamine and, 337–339
 - GABA_A receptors, 372–374
 - G proteins and, 420
 - neuropeptide receptors, 402
 - Parkinson's disease, 863–864
 - phosphodiesterase targeting, 438
 - tardive syndromes and, 868
 - transcription targeting, 528–529
- Dual-specificity phosphatases (DUSPs)
- phosphorylation, 481
 - protein tyrosine phosphatases, 505, 506f
- Dual-transport model, biosynthetic secretory pathway, protein and lipid transport, 131
- Dynactin p150^{Glued}, familial amyotrophic lateral sclerosis, 804
- transgenic mice studies, 808
- Dynamin proteins
- intracellular membrane trafficking, vesicle and organelle targeting, 123–124
 - mutant dynamin 2 and neuromuscular disorders, 123
- Dyneins
- axonal transport
 - biochemical properties, 157
 - molecular motor attachment, 158
 - neuronal cytoplasm, 159–160
 - molecular motor, peripheral neuropathies, 688
- Dysferopathies, axonal transport and neurodegeneration, 161
- Dysmyelinating diseases, stem cell therapy, 565
- Dystonia, basal ganglia involvement, 866–867
- Dystrophin protein complex, aquaporins, 57

E

- Ectoenzymes, extracellular nucleotide regulation, 379
- Edema, brain injury, 631–632, 632f
- aquaporins, 632
 - metalloproteinases, 631–632
- Efflux pathways, calcium pumps and transporters, 458
- Eicosanoids
- cerebrovasculature source for, 656
 - lipid mediator pathways, 648–649, 648f, 649f, 650f
- Electrical signals, excitable cells, 65–66
- Electrolyte imbalance, muscle ion channel alteration, 798
- Electron transport chain, brain energy metabolism, ATP production, 217
- Embryology, nervous system development, 534
- cortical neuron layers, 538–539, 539f
 - Embryonic stem cells, derivation, 559
- Emergence, autism spectrum disorders, 1014
- Endocannabinoids
- CB1 receptor ligands, 1046
 - retrograde messengers, synaptic plasticity, 1046–1047, 1047f
- End-binding proteins, microtubule organization, 106
- Endocytic-exocytic cycling
- sodium-potassium-adenosinetriphosphatase plasmalemma regulation, 45, 46f
 - synaptic transmission, presynaptic events, 244
- Endocytic pathway, intracellular membrane trafficking, 120, 135–139
- macromolecular degradation and nutrient uptake, 135–137
 - receptor-mediated endocytosis, 137–139, 138f
- Endocytosis
- GABA receptors, refractory status epilepticus, 373
 - synaptic transmission, presynaptic events, 244
- Endoplasmic reticulum (ER)
- biosynthetic secretory pathway
 - COPII-coated vesicles, Golgi complex delivery, 127–129, 128f
 - rough *vs.* smooth classification, 122f, 126–127
 - calcium ion channels
 - intracellular calcium storage, 459
 - pumps, storage buffers, and release channels, 459–460
 - signaling pathway activation, 459–460
 - store-operated calcium entry, 460
 - cholesterol synthesis, 32–33
 - D-myo-Inositol 1,4,5-trisphosphate, calcium liberation in, 448–449, 448f
 - lipid composition, 31
- Endoproteases, peptide biogenesis, 395–397, 396f
- Endothelial cells, brain energy metabolism, transporters, glucose/monocarboxylic acid uptake, 203–204, 204f
- Energy crises, phosphorylase deficiency, 763
- Energy metabolism
- brain function
 - aging and maturation declines, 205
 - aminoaciduria disorders, 738–740
 - basic requirements, 202t
 - blood-brain barrier transport, 204
 - brain imaging and spectroscopy, 222–226, 223f, 224f, 225f
 - cell and subcellular structures and functions, 203
 - compartmentalization, 207
 - developmental metabolic rate, 205
 - developmental transporters and pathways, 204–205
 - glutamate-glutamine metabolism, 220–222, 221f

- glycogen synthesis, astrocytic degradation, 209–210
- glycolysis, 207–209, 208f
- imaging applications, signaling mechanisms, 202–203
- lactate metabolism, 211–215
- malate-aspartate shuttle, 210–211, 214f
- mitochondrial heterogeneity, 219–220
- neuropathology, 226
- pentose phosphate shunt, 210
- signaling mechanisms, 201–202
- SLC25A12* gene mutation, N-acetylaspartate formation and myelination, 212–213, 212f
- substrates, 203–204
- supply-demand relationships, 205–207
- tricarboxylic acid cycle, 215–219, 216f
- carbohydrate/lipid metabolic disorders, 768–770
- Enkephalin knockout mice, neuropeptide studies, 405–406
- Environmental toxins, myelination and, 578
- Enzymes
- acetylcholine breakdown, 262–266
 - brain energy metabolism, 207, 207t
 - glycogen regulation, 210
 - histamine synthesis and breakdown, 327, 327f
 - myelin, 195–197
 - peptide biogenesis, 394–399, 394t, 396f
- Ependymal cells, in brain ventricles and spinal cord canal, 16, 16f
- Epigenetic modifications, neurodegenerative diseases, 731–733
- Epilepsy
- antiseizure drug mechanisms, 711–713
 - GABA-mediated synaptic inhibition, 711–712, 712f
 - voltage-gated calcium currents, 712, 712f
 - voltage-gated sodium channel targeting, 711, 711f
 - axonal and dendritic sprouting, dentate granule circuits, 709
 - CA3 pyramidal neuron, hippocampal regulation, 708
 - cellular hyperexcitability, hippocampal electrophysiology, 708
 - dentate granule cells, animal models, inhibitory/excitatory synaptic input abnormalities, 709
 - epidemiology, 705
 - epileptogenesis, 709
 - molecular mechanisms, 710–711
 - prevention, 710
 - genetics, 713–717, 713t, 714t
 - spontaneous and engineered mutations, mouse studies, 715–717, 715–716t
 - inhibitory/excitatory synaptic transmission disruption, 706–708, 707f
 - terminology and classification, 705–711, 706t
- Epileptogenesis
- molecular mechanisms, 710–711
 - prevention, 710
 - cyclooxygenase-2 and synaptic plasticity, 652–653
- Episodic cell assemblies, memory function, 975–977
- Episodic memory, 965
- Epistasis, autism spectrum disorders, 1014
- Equilibrative transporters (ENT)
- adenosine transport, 379–380, 380f
 - alcohol effects, 387
- Equilibrium potentials, excitable cells, 65
- ErbB family, neuromuscular synapse, 509
- ER-Golgi intermediate compartments (ERGICs), biosynthetic secretory pathway, 127, 128f
- Ethanol addiction, 1049–1050
- Eukaryotic cells
- cytoskeletal definition, 102, 102f
 - intracellular membrane trafficking, 120–121
 - neurotransmitter release, 237–238
- Evoked endplate potential (EPP), synaptic transmission exocytosis, 239, 242f
- Exchange proteins (Epac), adenylyl cyclase molecular targeting, 329
- Excitable cells
- action potentials, 66–67
 - electrical signals, 65–66
 - membrane phospholipids, transmembrane ion gradients, 644
 - negative membrane potential, 64–65, 64f
 - nonequilibrium in, 65
- Excitatory neuronal signals
- brain energy metabolism, 205–206
 - epilepsy
 - axonal and dendritic sprouting, 709
 - dentate granule cells, input abnormalities, 709
 - disruption, 706–708, 707f
 - glutamate-glutamine cycle, 221–222
- Excitatory neurotransmitters, glutamate, 343
- Excitatory postsynaptic potential, glutamate receptor production, 356–358, 357f
- Excitotoxicity
- brain injury, ischemic phase, 627
 - glutamate receptors, 363
 - ischemia, 627
 - ischemia-reperfusion injury, reactive oxygen species, 631
 - necrosis and, 673
- Exercise-related pathologies, carbohydrate/lipid metabolic disorders, 768–770
- Exocytosis
- neurotransmission, synaptic vesicle trafficking, 139–142
 - serotonin vesicle storage, 306–308, 307f, 308f
 - synaptic transmission, 237f, 238
 - calcium ion channels, 239–241, 243f
 - quantal analysis, 239, 242f
- Exogenous material, retrograde axonal transport, 153–154
- Exome sequencing, amyotrophic lateral sclerosis genetics, 806
- Exonic mutations, MAPT gene, 836–837
- Exoproteases, peptide biogenesis, 395–397, 396f
- Experimental allergic encephalomyelitis (EAE)
- multiple sclerosis modeling, 697
 - myelin basic protein and, 189
- Extracellular cadherin (EC), cell adhesion molecules, 169, 172f
- Extracellular domain
- receptor protein tyrosine kinase, 498–501
 - receptor protein tyrosine phosphatases, 505
- Extracellular fluid (ECF)
- blood-brain barrier and choroid plexus control of, 18
 - glutamate symporter failure, 54
 - hair cells, 919–920
- Extracellular matrix (ECM) proteins, integrin receptors, cell adhesion, 170–172
- Extracellular nucleotides, purine regulation, 379
- Extracellular signaling, G protein activity, 412, 414f
- Extracellular signaling-regulated protein kinases (ERKs), phosphorylation, 477
- Extrasynaptic mechanisms, protein phosphorylation, 489

F

- Fabry disease, 759
- Facilitated diffusion
- aquaporins, 56–58
 - glucose and myoinositol, 58–60
- Familial Alzheimer's disease, 817
- Familial amyotrophic lateral sclerosis (FALS)
- dynactin p150^{Glued} mutation, 804
 - epidemiology, 803–806
 - genetics, 727–729
 - wild-type SOD1 misfolding, 809–811
 - SOD1 mice studies, 807
- Familial dysautonomia, catecholamines and, 286–287
- Farber disease, 757
- Fast channel syndrome, 790
- Fatty acids
- brain energy metabolism, 219–220
 - glycerolipid composition, 83–85, 84f
 - hydrophobic lipids, 82
 - ischemia and release of, signaling cascades, 655–656
 - long-chain carboxylic structure, 82–83, 83f
 - metabolic disorders involving, 762–772
 - brain metabolism, 770–772
 - exercise-related signs and symptoms, 768–770
 - glucose metabolism, progressive weakness, 766
 - glycogen or lipid disorders, 763, 764f
 - muscle disorders, 763–768
 - oxidation, 765f, 772
 - production rate and ischemia resistance, 656
- Fear, neurochemistry, 1030–1033
- Feature-encoding pyramid, memory function, neural cliques, 974–975, 978f
- Feeding behavior and food intake, serotonin modulation, 312–313
- Fenfluramine, serotonin transporter and, 307
- Fibrous astrocytes, 12, 12f
- Fimbrin, neuronal and glial morphologies, 109–110
- Fish venom, muscle excitation alteration, 796–798

- Five-carbon branched chain, isoprenoids, 82
- Fluorescence indicators, calcium signal monitoring, 456–457, 456f
- FM1-43 fluorescent probe, synaptic transmission, endocytosis, 244, 244f
- FMRF-amide-gated sodium ion channel, peptide expression, 402
- Focal cerebral ischemia, 622–623, 622f, 623f
- Folic acid, homocystinuria and remethylation deficit, 748
- Forbe disease, 767
- Fragile X syndrome, autism spectrum disorders, 1017–1018
- Free inositol, inositol phosphate metabolism, 449, 449f
- Free radical peroxidation, apoptosis and, 665–667, 666f
- Frontotemporal dementia
genetics, 726–727, 726t, 727t
MAPT mutation, 836, 837f
- Fructose-1,6-bisphosphatase deficiency, 771
- FTDP-17 neurological disorders, cytoskeleton alterations and, 114
- Functional magnetic resonance imaging (fMRI)
brain energy metabolism, 223
mood disorders, 1025–1026
- FUS gene, amyotrophic lateral sclerosis, 804–805
- ## G
- GABAergic neurons. *See also* γ -Aminobutyric acid
anxiety disorders, 1031
basal ganglia and movement control, 857
glutamate-glutamine cycle, 222
glycine receptors and, 251, 253
mood disorders, 1024
schizophrenia and, 1007–1008
sleep and wakefulness, 991
- GABA shunt, 368, 369f
- γ -Aminobutyric acid (GABA)
in basal ganglia, 858f, 859–860
epileptic anti-seizure drugs, synaptic inhibition, 711–712, 712f
- GABA shunt, 368, 369f
- GABA transaminase deficiency, 753
- inhibitory neurotransmitter function, 375
- metabolic disorders, 752–753
congenital defects, 752–753
sleep regulation, 990–991
synthesis, uptake and release, 368
tyrosine phosphorylation, 511
- γ -Aminobutyric acid (GABA) receptors
GABA_A receptors
drug targeting, 372–374
ligand-gated ion channel family, 370, 370f, 371f, 372t
mouse genetics, 375
neurosteroids, 374
three-dimensional ligand-gated ion channel structures, 374–375
- GABA_B receptors
G protein coupling, 369
heterodimers, 369–370
- physiology and pharmacology, 368–369
brain distribution and utilization, 368–369
refractory status epilepticus, endocytosis, 373
structure and function, 369–375
- Ganglion cells
optic nerve axons, 890–891
pain management, 929
- Gasotransmitters, intercellular signaling, 256
- Gastrin, identification, 391–392, 391f
- Gaucher disease, 757–758
- Gene encoding
acetylcholinesterase, 263
nociceptive response, 939
Parkinson's disease mutations, 832–833
prion proteins, 874–875
- Gene expression, addiction and, 1051
- General-to-specific feature-encoding neural clique assemblies, 974–975
- Gene silencing therapy, polyglutamine repeat diseases, 850–853, 851f
- Gene splicing
acetylcholinesterase, 263, 263f
histamine H₃ receptor, 333
peptide diversity, 399–400, 401f
- Gene-targeted therapy, Alzheimer's disease, 821–822
- Genetically encoded calcium indicators (GECIs), calcium signal monitoring, 457
- Genetic disease
autism spectrum disorders, 1013, 1014
ion channel mutations, 77
myelination, 576–577
myelin disorders, 699–701, 700t
neurodegenerative disease
Alzheimer's disease, 721–723, 721t
amyotrophic lateral sclerosis, 727–729, 728t
Creutzfeldt-Jakob and other prion diseases, 730–731
epidemiology, 719–721
epigenetic modifications, 731–733
frontotemporal dementia, 726–727, 726t, 727t
Huntington's disease, 729–730
Lewy body dementia, 725–726
mutation and polymorphism identification, 721t
Parkinson's disease, 722t, 723–725, 723t, 724t
triplet repeat disorders, 729–730
neuromuscular junction disorders, 789–790
peripheral neuropathies, 680–684, 681–682t
schizophrenia as, 1009–1010
- Gene transcription, molecular signaling mechanisms, cell surface receptors, 249
- Genome screening
Alzheimer's disease, 722–723
Parkinson's disease, 724–725, 832–833
- Gephyrin, glycine receptor structure and function, 251, 251f
submembrane aggregation, 252
- GFL receptors, 554–555
- Glc-6-P substrate, brain energy metabolism, 210
- Glial cell line-derived neurotrophic factor (GDNF), 553–554, 554f
GFL receptors, 554–555
- Glial cells
ATP-adenosine signaling, 384–385
respiration and sleep, 385–386
development, neural stem cells, 559–561, 560f
intracellular membrane trafficking, 120–121
mitochondrial heterogeneity in, 219–220
prostaglandin release, 648–649, 650f
schizophrenia, 1008–1009
- Glial fibrillary acidic protein (GFAP)
cytoskeletal expression, injury and regeneration, 114
neuronal and glial morphologies, 108
- Glial filaments
axonal cytoskeleton organization and, 112–114, 113f
neuronal and glial morphologies, 106–108, 107f
- Glial scar, axonal growth and, 589–590
- Gliogenesis, nervous system development, 539–541
neuronal birthdate, 539
proneural gene functions, 540–541
reelin and notch signaling, cortical layer organization, 539, 539f
- Gliomas, cardiolipin, 81, 86f, 87f
- Global brain assays, brain energy metabolism, 222
- Global cerebral ischemia, 623, 626f
- Globoid cell leukodystrophy. *See* Krabbe disease
- Glucocorticoid receptors, transcription factors, 521–524, 523f
- Glucocorticoid response element (GRE), transcription factors, 523
- Glucocorticoids
hippocampal stress effects and, 949–953
mood disorders and, 1026
- Glucose
brain development, cerebral metabolic rate, 205
brain energy metabolism, 206–207
acetyl coenzyme formation, 218–219
functional imaging, redox state and metabolic pathway analysis, 222–223, 223f
lactate as fuel, 214–215
metabolic fates, 207, 208f
oxidation, pyruvate dehydrogenase, 217
pyruvate conversion (glycolysis), 207–209
brain function and, 201–202
facilitated diffusion, 58–60
glutamate derivation, 343–344
- Glucose-6-phosphatase deficiency, 771
- Glucose transporters (GLUT 1,2,3)
blood-brain barrier, transport defects, 770
brain energy metabolism
endothelial cell uptake, 203–204, 204f
neuropathology, BBB alteration, 204
facilitated glucose diffusion, blood-brain barrier, 58–59
motor neuron disease, 808

- Glutamate
 agonist-binding site, 354
 in basal ganglia, 858
 blood-borne glucose derivation, 343–344, 344f
 brain energy metabolism, 219–220
 glutamate-glutamine
 compartmentalization, 220–222, 221f
 cocaine and amphetamine addiction, 1044
 dendritic motility, 361
 excitatory neurotransmission, 343
 excitatory postsynaptic potentials, 356–358
 genetic regulation, 354–356, 355f
 glutamatergic synapse potentiation/
 depression, learning and, 346–347
 glutamine cycle, 344–346, 345f
 ketoglutarate loss, tricarboxylic acid
 cycle, 345–346
 neuronal autoimmune encephalitis, 353
 neurotoxicity and excitotoxicity, glutamate
 analogs, 363
 postsynaptic diffusion, 359–360
 presynaptic terminal release, 645–646, 646f
 protein intracellular mediation, receptor
 activation, 360–361
 PSD95 scaffolding protein, 360–361
 small GTP-binding proteins, 361
 Q/R site, 354–356, 356f
 rod and cone release, photoreceptor
 downstream signaling, 897
 sleep and wakefulness regulation, 991–992
 sodium-dependent transporters, astrocyte-
 neuron glutamine transfer, 362
 symporters
 pathologic failure, synaptic, extracellular
 and cytosol compartments, 54
 SLC1A1-4 and SLC1A6 genes, 53–54
 SLC1 proteins, 53
 sodium-dependent, extracellular
 clearance, 361–362
 synaptic vesicle accumulation, 346
 transmembrane topology, 354, 355f
 Glutamate-glutamine metabolism, brain
 energy metabolism, 220–222
 amino acid transporters, mitochondrial
 membrane, 220
 GABAergic neurons and astrocytes, 222
 glutamate-glutamine cycle, 221–222
 metabolic pathways and
 compartmentalization, 220–222, 221f
 nitrogen shuttles, 222
 tricarboxylic acid cycle activity, 220
 Glutamate receptors
 AMPA receptors, 350, 351f
 central nervous system disorders, 363–364
 dietary neurotoxins, activation and cell
 death, 363
 excessive receptor activation, neurological
 disorders, 363–365
 ionotropic receptors
 classification, 347–356, 349f
 genetic knockout studies, 358
 permeation pathways, 48, 357f
 structural homologies, 348–350
 subunits, 348–350, 350f
 kainate receptors, 350, 351f
 metabotropic receptors, 347, 349f
 classification, 358
 cytoplasmic signaling enzymes, 358
 genetic knockout studies, 359
 ion channel modulation, 358–359
 presynaptic activation and inhibition, 359
 synaptic transmission, 358–359
 NMDA receptors, 350–354, 351f, 352f
 splice variants and RNA editing, 354–356
 transmembrane topology, 354
 Glutamatergic system, mood disorders, 1024
 Glutamine
 glutamate precursor, 344–346, 345f
 sodium-dependent glutamine transporters,
 astrocyte to neuron glutamine
 transfer, 362
 urea cycle defects, cognitive function and,
 752
 Glutamine cycle, glutamate precursor,
 344–346, 345f
 Glutamine lactate, brain energy metabolism,
 219–220
 γ -Glutamylcysteine synthetase deficiency,
 752, 753f
 γ -Glutamyltranspeptidase deficiency,
 752–753, 753f
 Glutathione metabolism, disorders of, 752, 753f
 Glutathione synthetase deficiency,
 5-oxoprolinuria, 752
 Glutmaesamate, depression and, 1034
 Glycerol
 glycerolipid composition, 83–85, 84f
 phospholipid esterification, 645–646
 Glycerolipids
 composition, 83–85, 84f
 distribution profile, 88t
 Glycine
 biochemistry and transport, 250
 metabolic disorders, 744–745
 receptor distribution, 252–253
 brain and spinal cord imaging, 252
 GABA-glycine neurotransmitter
 co-utilization, 253
 immunocytochemical mapping, 252
 receptor structure and function, 251–252
 cys-loop superfamily, 251
 gephyrin and collybistin accessory
 proteins, 251, 251f
 site-directed mutagenesis studies, 252
 Glycinergic neurotransmission, neurologic
 disease, 250–255
 glycine biochemistry and transport, 250
 glycine receptor distribution, 252–253
 glycine receptor structure and function,
 251–252
 H⁺-dependent vesicular transporter, 250
 ligand-gated chloride channel, glycine
 inhibition, 250–251
 postsynaptic effects and pharmacology,
 250–251
 postsynaptic gene mutations, 253–254
 presynaptic glycine transporter 2 mutation,
 254
 startle disease molecular genetics, 253
 Glycine transporter 2 (GlyT2), glycinergic
 neurotransmission and mutation
 in, 254
 Glycogen
 brain energy metabolism
 astrocyte degradation, 209–210
 enzyme-regulated steady-state
 concentration, 210
 muscular metabolic disorders, 763, 764f
 Glycogenesis type IV, 763
 Glycogen phosphorylase, brain energy
 metabolism, 210
 Glycogen synthase kinase (GSK3)
 brain energy metabolism, 210
 mood disorders and, 1027, 1029
 Glycogen-synthase kinase-3 (GSK3),
 phosphorylation, 478
 Glycogen synthetase deficiency, 772
 Glycolysis
 brain energy metabolism, 207–209, 209f
 ATP, pyruvate and amino acid/
 carbohydrate precursor production,
 208–209
 hexokinase regulation, 207–208
 phosphofructokinase regulator, 208
 brain metabolic disorders, 771
 enzymatic glycolytic defects, 764–767
 muscular metabolic disorders, 764f
 Glycoproteins
 central nervous system myelin, 191–192
 hormones, 391–392, 391f
 peripheral nervous system myelin, 192–193
 Glycosylation, biosynthetic secretory
 pathway, 126, 127t
 membrane and secretory proteins, 129–130
 G_{M2} gangliosidosis, lysosomal mutations,
 759–760
 Golgi complex, 8, 8f
 axonal transport of proteins, 152–153, 153f
 biosynthetic secretory pathway
 cisternae-based protein/lipid transport,
 130–131, 131f
 COPII-coated vesicles, endoplasmic
 reticulum delivery, 127–129, 128f
 membrane and secretory protein sorting
 and glycosylation, 129–130
 organelle polarization, 129
 cholesterol synthesis, 32–33
 Golgi-derived organelles, V₀V₁ proton
 pumps, 50, 50f
 Golgi membranes, lipid composition, 31
 GoLoco protein, G protein subunit
 regulation, 416
 GPI-anchored proteins (GPI-APs),
 lipid rafts and, 34
 G-protein-coupled receptors
 adrenergic receptors, 295–297
 catecholamine receptors, 293
 histamine activity, 329–335, 330t
 histamine H₁ receptor, 329–331
 histamine H₂ receptor, 331
 histamine H₃ receptor, 331–334
 muscarinic cholinergic receptor mediation, 274
 neuropeptide receptors, 400–401
 taste receptors, 912–913, 913f
 signaling cascade, 913–914

- G protein inward-rectifying potassium channel (GIRK), neurotransmitter receptor coupling, 412–414
- G-protein-receptor kinases (GRKs), structure and function, 415, 415f
- G proteins
- bacterial toxins, ADP-ribosylation catalysis, 419–420
 - diacylglycerol kinases, 654
 - GABA_B receptor coupling, 369
 - heterotrimeric structure, 411–418
 - cell membrane trafficking, 415
 - extracellular signaling, dissociation and reassociation, 412
 - functional cycle, 414f
 - intracellular second messenger regulation, 414–415
 - long-chain fatty acids, covalent modification, 418
 - multiple nervous system structures, 412
 - neurotransmitter ion channel coupling, 412–414
 - phosphorylation, 418
 - protein modulation, 416–418, 416f, 417f
 - subunits, 412, 413t, 415–416, 415f
 - transmembrane signaling, 411–412
 - intracellular membrane transport, 122–123
 - metarhodopsin II activation, 895f
 - molecular signaling mechanisms, cell surface receptors, 248–249
 - muscarinic cholinergic receptors, 276, 276f
 - neuropathology and disease, 420, 421
 - phosphodiesterase activation, retinal phototransduction, 436–437
 - small G proteins, 418–419, 418t
 - Rab family, 419, 419f
 - Ras proteins, 418–419
- G-protein-subunit/cyclic adenosine monophosphate (CAMP)-generating signaling pathway, mood disorders and, 1027
- Growth cone motility
- cytoskeleton, 110f
 - microfilament and microtubule dynamics, 112
- Growth factors
- basic properties, 546
 - glial cell line-derived neurotrophic factor, 553–554, 554f
 - GFL receptors, 554–555
 - mood disorders, 1025
 - in nervous system, 557t
 - neuregulins, 555
 - neurotrophic cytokines, 555–556
 - neurotrophin receptors, 551–553
 - p75 neurotrophin receptor, 552–553, 553f
 - Trk receptors, 552, 552f
 - neurotrophins, 547–551, 547f, 548f
 - brain-derived neurotrophic factor, 548–550
 - nerve growth factor, 547–548
 - neurotrophin, 3, 550
 - neurotrophin, 4, 550–551
 - proneurotrophins, 551, 551f
 - regulation, 551
 - stem cell sources, 565–566
- GTPase-activating proteins (GAPs), heterotrimeric G protein modulation, 416, 416f
- GTPases
- G protein extracellular signaling, 412, 414f
 - intracellular membrane transport, 122–123
 - dynamain protein structure and function, 123–124
 - Rab proteins, 125
 - NMDA receptor activation, postsynaptic density, 361
- Guanine nucleotide exchange factors (GEFs), Ras small G protein, 418–419
- Guanine nucleotides, phototransduction, 892–894
- Guanosine diphosphate (GDP), G protein extracellular signaling, 412, 414f
- Guanosine triphosphate (GTP), G protein extracellular signaling, 412, 414f
- Guanylyl cyclases
- cGMP signaling, molecular effectors, 433–434
 - brain function, 433–434
 - cGMP-gated ion channels, 433
 - cognition and mood, 434
 - pain management, 434
 - phosphodiesterases, 433
 - protein kinase G, 433
 - synaptic plasticity, learning and memory, 434
- GC-A, -B, and -C receptors, natriuretic peptides, 432
- GC-D and GC-G, olfaction, 432
- GC-E and GC-F, photoreceptor signal transduction, 432
- membrane-bound structure, 431–432, 431f
- soluble compounds, 432–433
- nitric oxide regulation, 433
- Guillain-Barré syndrome
- demyelination and, 698–699
 - peripheral neuropathies, 684–687, 686f
- Gulf War syndrome, acetylcholinesterase inhibition, 279–280, 280f
- ## H
- Hair cells
- mechanotransduction, 918–923, 919f, 920f
 - cochlear cells, 926
 - inner ear, 923
 - stereocilia actin, 921–923
 - transduction and adaptation, 920f
- Halle Berry cells, memory function, 975
- Hallucinogen addiction, 1050
- H⁺-dependent vesicular transporter, glycine transport, 250
- Head rotation, vestibular organs, 923–925
- Hearing
- cochlea, 923
 - cochlear hair cells, 926
 - deafness genes, 922
 - hair cells, 918–923
 - high-frequency sound detection, 925–926
 - inner ear anatomy, 924f
 - prestin electromotility, 925f
- Heat shock proteins, transcription factors, 523
- Hebb's rule, learning mechanisms
- Doogie* mice, 969–971
- synaptic plasticity and, 965–966
- Helicase gene mutation, amyotrophic lateral sclerosis, 803
- Hematopoietic stem cells (HSC)
- derivation, 559, 559f
 - dysmyelinating disease therapies, 565
- Heme oxygenase-2 (HO-2), intercellular signaling, 256
- Hereditary canine spinal muscular atrophy (HCSMA), motor neuron disease, 806–807
- Hereditary folate malabsorption, 749
- Hereditary motor and sensory neuropathies (HMSN), peripheral neuropathy, 680–684
- Hereditary muscle membrane diseases, 790–793
- Hereditary neuronal disorders, protein kinase/phosphatase mutations, 489–491, 490t
- Hereditary neuropathy with liability to pressure palsies (HNPP), 682
- Hereditary sensory-motor neuropathy, Rab protein and, 421
- Hereditary spastic paraplegias, axonal transport deficits and pathogenic mechanisms, 146
- Heterodimeric GTPases, intracellular membrane transport, 122–123
- Heterodimeric structures, GABA_B receptors, 369–370
- Heterosynaptic depression, astrocyte-mediated, adenosine-dependent action, 385
- Heterotrimeric G proteins, 411–418
- cell membrane trafficking, 415
 - extracellular signaling, dissociation and reassociation, 412
 - functional cycle, 414f
 - intracellular second messenger regulation, 414–415
 - long-chain fatty acids, covalent modification, 418
 - multiple nervous system structures, 412
 - neurotransmitter ion channel coupling, 412–414
 - phosphorylation, 418
 - protein modulation, 416–418, 416f, 417f
 - subunits, 412, 415–416, 415f, 413t
 - transmembrane signaling, 411–412
- Hexokinase, brain energy metabolism and regulation of, 207–208
- High-affinity transporters
- choline accumulation, synaptic terminals, 260–261, 261f
 - secretory phospholipases A₂, 647–648
- High-frequency sound detection, cochlear anatomy, 925–926
- Hippocampus
- epileptic electrophysiology
 - CA3 pyramidal neuron regulation, 708
 - cellular hyperexcitability, 708
 - kainic-acid-induced cyclooxygenase-2 expression, 654
 - memory function

- concept cells, 975
 generalization function, 977–978
 imagination and, 978–979
 real-time memory visualization, 976f
 retrograde and post-learning consolidation, 971
 neuronal pathways, memory formation and, 347, 348f
 stress effects on, 947–949
 structure and function, 947–949
 synaptic plasticity, pathways and, 966f
- Histamine**
 brain dynamics, 327–329, 327f
 l-histidine and HDC activity, 328
 brain storage and release, 324
 cell anatomy and morphology, 324–327
 chemical structure, 324, 325f
 daytime sleepiness and narcolepsy, 338
 drug action, 337–339
 central nervous system disease, 337–339
 pain perception, 337
 sleep-wake cycles and appetite, 337
 enzyme synthesis and breakdown, 327
 fiber distribution, central nervous system, 325, 326f
 ionotropic transmission modification, 335
 methylating enzyme
 distribution outside nerve terminals, 328–329
 metabolism and, 328
 polymorphism (Thr105Ile), 329
 molecular action sites, 329–335
 cyclic AMP synthesis, 331
 G-protein-coupled receptors, 329
 intronless H₁ receptors, 329–331
 nervous system actions, 335–337
 diseases and disorders, 337
 neuromodulation and
 neurotransmission, 335
 neurotransmitter connections, 335–336, 336f
 physiological functions, 336–337
 neuron morphological and membrane properties, 325
 neuron storage and release, 328
 physiological and pathological functions, 324
 receptors, 330t
 gene splicing, 332f
 H₁ receptors, 329–331
 H₂ receptors, 331
 H₃ autoreceptors, neuron regulation, 329
 H₃ receptors, 331–334, 333f, 337–339
 H₄ receptors, 334–335
 intracellular messengers, 330–331, 333–334, 335
 signaling pathways, 334f
 sleep and wakefulness, 987
 tuberomammillary fibers, hypothalamic origin, 324, 326f
- Histamine decarboxylase, genetic sources, 328**
- Histamine-methyl transferase (HMT)**
 brain metabolism, 328
 non-histaminergic nerve terminals, 328–329
 polymorphisms and neurologic disorders, 329
- Histidine decarboxylase (HDC)**
 brain histamine synthesis, 328
 genetic derivation, 328
- L-Histidine, brain histamine synthesis, 328**
- Histone**
 nucleosome modification,
 neurodegenerative disease epigenetics, 731–733
 transcription, DNA methylation and, 517–518
- Histone acetylation**
 neurodegenerative disease epigenetics, 731–733
 transcription, 516, 517f
- Histone deacetylase inhibitors,**
 neurodegenerative disease epigenetics, 731–733
- H/KDEL receptor, biosynthetic secretory pathway, COPII-coated vesicles, endoplasmic reticulum delivery, 129**
- HMIT symporter, 59**
- Homeobox genes, central nervous system development, rostrocaudal axis, 535–538, 537f**
- Homeostasis**
 calcium ion channels, 49f, 457–458
 central nervous system, 16–18
 tight junctions, 16–17
 microglial sensors for disruption of, 618
 sleep regulation, adenosine and, 993
- Homocitrullinuria, 751**
- Homocysteine, homocystinuria and methionine formation, 748**
- Homocystinuria, 745–749, 746f**
- Homosynaptic facilitation, pain management, 935–936**
- Hormesis-based mechanisms, apoptosis inhibition, 671**
- H-Ras protein, lipid rafts and, 34**
- Human kinome, 471f**
- Huntington's disease**
 animal models, 865
 basal ganglia involvement, 865–866
 connectivity losses in, 869–870
 genetics, 729–730, 865, 866f
 polyQ-htt enzymatic aberration, 731–733
 molecular aspects, 865, 866f
 transcription factors, 519
 treatment, 865–866
- Hydroperoxides (HpETEs), lipoxygenase formation, 653**
- Hydrophobic lipid bilayers**
 isoprenoids or fatty acids in, 82
 polar water molecule diffusion, 56–57
- 5-Hydroxytryptamine (5-HT). See Serotonin**
- Hyperammonemia, 751**
- Hyperkplexia**
 glycine transporter 2 mutation, 254
 molecular genetics and pathophysiology, 253
 GlyR α 1 mutations, 253
- Hyperexcitability, hippocampal electrophysiology, epilepsy, 708**
- Hyperkalemic periodic paralysis, 790–791**
- Hyperornithinemia, 751**
- Hyperphosphorylation, tau protein, 835–836**
 animal models, 838–841
- Hypocretins, sleep regulation, 989–990**
- Hypoglycemia, brain energy metabolism blood-brain barrier alteration, 204**
 partial TCA cycles and, 219
- Hypokalemic periodic paralysis, 791**
- Hypothalamic pituitary adrenal (HPA) axis**
 anxiety disorders, 1032
 autism spectrum disorders, response systems, 1015
 stress and brain function and, 946
- Hypothalamus, tuberomammillary region, histaminergic fibers, 324, 326f**
- Hypoxia-inducible factor (HIF), brain function and, 206**
- Hypoxia response element (HRE), brain function and, 206**
- Hypoxic conditions, brain energy metabolism, lactate formation, 211–214**

I

- IDPN, neurofilamentous axonal pathology, 806**
- Immune-mediated neurodegenerative disorders, 598**
- Immune response, nerve injury, 938–939**
- Immune tolerance, neuroimmunology, 601–602**
- Immunocytochemical mapping, glycine receptor distribution, 252**
- Immunoglobulin superfamily, cell adhesion molecules**
 diversity and structure, 166–168, 168f
 protein immunoglobulin-like domain, 166, 167f
- Immunomodulation, stem cell sources, 566**
- Impulse conduction, myelin facilitation, 180–181, 181f**
- Indicator proteins, calcium signal monitoring, 457**
- Indolealkylamine 5-hydroxytryptamine, identification as serotonin, 301**
- Infantile acid maltase deficiency, 770**
- Infection**
 myelin diseases and, 692–699
 peripheral neuropathies, 687
- Inflammasome, neuroinflammation, 616–617**
- Inflammatory processes**
 microglia and, 15–16, 15f
 pain management, 929f, 934–936
- Influx pathways, calcium entry, 458**
- Inherited diseases, purine metabolism, 381**
- Inhibitory neuronal signals**
 brain energy metabolism, 205–206
 epilepsy
 dentate granule cells, input abnormalities, 709
 disruption, 706–708, 707f
- Injury, cytoskeletal protein expression, 114**
- Innate immunity**
 alarm signals, 599
 major histocompatibility complex, T-cell activation, 601
 nervous system regulation, 602–603
 neuroimmunology, 599–601
 lymphoid tissue innervation, 602–603
 neuropeptides, 603

- Inner ear
 anatomy, 924f
 hair cells, 923
- Inositol lipids, 443–448, 444f
 D-myo-Inositol 1,4,5-trisphosphate,
 calcium liberation, endoplasmic
 reticulum, 448–449, 448f
 cell regulation, 451–453, 451f
 Charco-Marie-Tooth disease, 445
 ligand-activated hydrolysis, neural tissue,
 446t
 phosphatase dephosphorylation, 445–446
 phosphatidylinositol 3-kinase synthesis,
 3'-phosphoinositides, 444
 phospholipase C isozyme cleavage, 446–
 448, 446f, 447f
 structure and metabolic function, 443–444,
 443f, 444f
- Inositol phosphates, 448–449
 D-myo-inositol 1,4,5-trisphosphate,
 calcium liberation, 448–449, 448f
 metabolism and free inositol regeneration,
 449, 449f
 myo-inositol cell presence, 449
- Insect venom, muscle excitation alteration,
 796–798
- Inside-out signaling, integrins, cell adhesion
 molecules, 172–173, 175f
- Insomnia, 995–996
- Integrins, cell adhesion molecules, 170–175
 anti-integrin antibodies, multiple sclerosis
 therapy, 174
 cadherin cross-talk, 177–178
 extracellular matrix proteins, 170–172, 173f
 inside-out and outside-in signals, 172–173
 myelination regulation, 173–175
- Intercellular signaling
 molecular signaling mechanisms, cell
 surface receptors, nitric oxide,
 249–256
 peptides, 392
- Interleukin-10, neuroinflammation and, 614
- Intermediate filaments (IFs), neuronal and
 glial morphologies, 106–108, 107f,
 108t
- Interneuronal synapses, cell adhesion
 molecules, cooperative regulation,
 175–177, 176f, 177f
- Intracellular catalytic domains, receptor
 protein tyrosine phosphatases, 505
- Intracellular membrane trafficking
 biosynthetic secretory pathway, 126–135
 compartments and transport sequence,
 128f
 constitutive secretory pathway, 133f, 134
 COPII-coated vesicles, Golgi complex
 delivery, 127–129
 endoplasmic reticulum classification,
 126–127
 glycosylation compartmentalization, 127f
 Golgi apparatus components, 129
 Golgi cisternae protein/lipid transport,
cis to *Trans* direction, 130–131, 131f
 lysosomal pathway convergence, 132
 neuroendocrine secretion pathways,
 132–133
 protein sorting and glycosylation, Golgi
 complex, 129–130
 secretory cells, regulated pathway
 specialization, 133f, 134
 secretory vesicle biogenesis, 134–135
trans-Golgi network, lysosomal protein
 sorting and targeting, 132
trans-Golgi network, plasma membrane
 protein sorting, 131–132
 coat protein removal, 124–125
 dynamin proteins, vesicle and organelle
 targeting, 123–124
 endocytic pathway, 120, 135–139
 macromolecular degradation and
 nutrient uptake, 135–137
 receptor-mediated endocytosis, 137–139,
 138f
 G proteins, 415
 GTP-binding proteins, transport function,
 122–123
 inositol lipids, 451–452
 mammalian cell mechanisms, 120–121, 121f
 molecular events, 121–126
 SNARE and Rab proteins, target membrane
 recognition, 125
 synaptic vesicles, 139–144
 future research issues, 142, 143f
 neurotransmission exocytosis, 139–142
 presynaptic terminal organization,
 secretion/recycling optimization,
 139, 140–141t
 transport vesicles
 budding, 65
 cargo unloading, membrane fusion, 125
- Intracellular messengers
 glutamate ionotropic/metabotropic
 receptors, postsynaptic density,
 360–361
 histamine H₁ receptor, 330–331
 histamine H₂ receptor, 331
 histamine H₃ receptor, 333–334
 histamine H₄ receptor, 335
- Intracellular pH, anion antiporters, 56
- Intracellular signaling
 anxiety disorders, 1033
 axonal regeneration, neurite growth
 mediation, 589
 G protein second messenger regulation,
 414–415
 molecular signaling mechanisms, cell
 surface receptors, cross-talk, 249
 mood disorders and, 1026–1030, 1028f
 neuropeptides, 393f
 schizophrenia, 1008
 transmembrane domains, 29, 30f
- Intracranial pressure, aminoacidurias and
 brain edema, 742
- Intronic mutations, MAPT gene, 836–837
- Ion channelopathies, 77–78
- Ion channels
 action potentials, electrically excitable cells,
 66
 backbone structure and topology, 77
 cyclic GMP-gated ion channels, guanylyl
 cyclase receptors, 433
 diversity, 75–77
 electrolyte imbalance and alteration of, 798
 gating mechanisms, 66, 67f
 macromolecular complexes, voltage-
 dependent gating mechanisms,
 67–68
 mechanical transduction activation,
 920–921
 membrane phospholipids, 644
 metabotropic glutamate receptor
 modulation, 358–359
 molecular basis, 71–75
 fast inactivation gate, 74–75, 75f
 selectivity filter and pore, 71–74, 73f
 molecular signaling mechanisms, cell
 surface receptors, 246–248
 mutations and genetic disease, 77
 neurotransmitter receptor coupling, G
 proteins, 412–414
 nicotinic acetylcholine receptors, 269
 pharmacological agents in, 68–69
 phosphoinositide regulation, 452–453
 taste receptor interaction, 914
 voltage-dependent gating mechanisms
 moving charges, 73f, 74
 protein component conformation, 68, 69f
- Ionotropic glutamate receptors
 classification, 347–356, 349f
 genetic knockout studies, 358
 permeation pathways, 48, 357f
 subunits, 348–350, 350f
- Ionotropic purinergic receptors, classification,
 384
- Ionotropic transmission, histamine
 modification, 335
- Ion potentials, mammalian skeletal muscle,
 65t
- Ion selectivity filter, 71–74, 73f
- Isaac syndrome, potassium ion channel
 antibodies, 794–795
- Ischemia
 acute ischemic stroke, therapeutic
 protection, 638–640
 brain responses to, 621–623
 calcium signaling and, 464
 excitotoxic glutamate neurotransmitter, 627
 focal cerebral, 622–623, 622f, 623f
 free fatty acid release, 655–656
 global cerebral, 623, 626f
 lipid mediator pathways, platelet-
 activating factor, 651f, 652
 membrane lipid breakdown, 654–655
 necrosis and, 672–673
 neuroinflammation, reperfusion damage
 and, 616
 neuroprotectin D1 inhibition, 657, 658f
 phospholipase A₂ signaling, reperfusion
 and, 654, 655f
 phospholipases A₂, arachidonic/
 docosahexaenoic acid release, 647
 phospholipid targeting, synaptic
 membranes, 645
 potential therapeutic strategies, 638–640
 stroke penumbra, 622–623, 624f, 625f, 626f
- Isoprenoids
 five-carbon branched chain, 82
 hydrophobic lipids, 82

Isozymes, adenylyl cyclase, expression and regulation, 324

J

Juxtacrine effects, neuropeptide receptors, 402
Juxtaparanodal proteins, myelin sheath, 195

K

Kainate (KA) receptor
 flip/flop variants, 354–356, 355f
 identification, 347–356
 quinoxalinedione blockage, 350
Katanin, microtubule organization, 106
 α -Ketoglutarate, glutamate derivation, 343–346, 344f
Ketone bodies, brain energy metabolism, 219–220
 brain development and, 204–205
Kinesin-related proteins (KRPs)
 axonal transport, 156–161
 anterograde fast axonal transport, 157–158
 biochemical properties, 157
 axonal transport and neurodegeneration, 161
KKXX retrieval signals, biosynthetic secretory pathway, COPII-coated vesicles, endoplasmic reticulum delivery, 129
Knock-down therapies, polyglutamine repeat diseases, 850–851
Knockout mice
 axonal regeneration, *nogo* gene development, 588
 catecholamine studies, 285t
 glutamate receptor genetics, 358
 learning research, 969–971, 970f
 metabotropic glutamate receptor studies, 359
 neuropeptide studies
 enkephalin function, 405–406
 peptide-processing enzyme genes, 404–405, 405f
 prion protein analysis, 878–879
Krabbe disease, 699–701
 lysosomal mutations, 758, 758f
 stem cell therapy, 565
K-Ras protein, lipid rafts and, 34
Krebs cycle, defects in, 776
Kuru, prion proteins, 875

L

Lactate, brain energy metabolism, 211–215
 astrocyte-neuron lactate shuttle, 215
 complex compartmentation, 214
 conditions, 214–215
 formation conditions, 211–214
 lactate-pyruvate interconversion, 211
Lactate dehydrogenase (LDH)
 brain energy metabolism, lactate-pyruvate interconversion, 211
 glycolytic defects, 764–766
Lafora disease, 771
Lambert-Eaton syndrome, calcium channel antibodies, 794
Large dense-core vesicle (LDCV), peptide release, 393
 neuronal expression, 393–394

Large dense-core vesicles (LDCVs), neuropeptide packing, 399, 400f
Lateral geniculate nucleus, nervous system development, 543
L-DOPA
 aromatic amino acid decarboxylase conversion to dopamine, 285–286
 tyrosine hydroxylase regulation, 284–285, 285f
Learning
 adenylyl cyclase cAMP targeting, 430
 cGMP signaling, guanylyl cyclase receptors, 434
 Doogie mice studies, 969–971, 969f, 970f
 glutamatergic synapse potentiation/depression, 346–347
 molecular mechanisms of, 965–971
 late-phase LTP expression, 967–968
 NMDA receptor and LTP induction, 966–967, 967f
 synaptic plasticity
 Hebb's rule, 965–966
 hippocampus and, 966f
 long-term depression and receptor-independent LTP, 968
Lesch-Nyhan syndrome, 381
Leucine-rich repeat kinase-2 (LRRK2), Parkinson's disease mutations, 832–833
Leukocytes, CNS immune activity
 influx and efflux mechanisms, 604
 parenchyma migration, 604–605
Leukodystrophies
 genetics, 699–701
 myelination and, 578
 stem cell treatment, 564
Leukotriene pathways
 lipoxygenases, 653
 neuroinflammation, 614–615
Lewy body dementia, 833f
 genetics, 725–726
 host-to-graft spreading pathology, 832f
 α -synuclein and, 831–832, 831f
Lifestyle factors, stress and, 951–953
Ligand-activated phosphoinositide hydrolysis, 446t
Ligand-gated ion channels
 alcohol addiction and, 1049
 GABA_A receptors, 370, 370f, 371f, 372t
 three-dimensional structure, 374–375
 nicotinic acetylcholine receptors, 269
 cys-loop channels, 268f
 pentameric channels, 267–268, 268f
 serotonin receptor subtypes, 318–319
 strychnine-sensitive chloride channel receptors, glycine inhibition, 250–251
 tyrosine phosphorylation, transmembrane topology, 510f
Ligand-operated channels (LOC), calcium ions, 457f
Light microscopy, myelin ultrastructure, 181–184, 182f
Linear acceleration, vestibular organs, 923–925
Lipid mediator pathways

 neural membrane phospholipids, 644–647
 cyclooxygenases, 652–653
 diacylglycerol kinases, 654
 docosahexaenoic acid, 656–657
 docosanoids, 657
 eicosanoids, 648–649, 648f, 649f, 650f
 lipid peroxidation and oxidative stress, 657
 lipoxygenases, 653–654
 messenger function, 645
 neuroinflammation, 654–656, 655f
 neurolipidomic signaling, 657–660
 neuroprotectin D1, 657, 658f
 phospholipase cleavage, 645
 phospholipases A₂, 647–648
 platelet-activating factor, 649–652, 651f
 polyunsaturated fatty acyl chains, 645–646, 646f
 synaptic membrane targets, 645
 translational neurosciences, 659
 transmembrane ion gradients, 644
 neuroinflammation, 614–616, 615f
 lipoxin, resolvin, and neuroprotectin pathways, 616
Lipid peroxidation, oxidative stress and, 657
Lipid rafts
 cell membrane function, 33–34
 cytoskeleton interaction, 35–36, 36f
 metabolopathies and, 778–779
Lipids
 amino acid disorders, myelin formation, 742
 biosynthetic secretory pathway, Golgi cisternae transport, 130–131, 131f
 brain lipids, 82–83, 85f
 biosynthesis, 90–96, 90f
 chromatography and mass spectrometry analysis, 89–90
 normal adult, 91t
 complex lipids, 83–89
 inositol lipids, 443–448, 444f
 cell regulation, 451–453, 451f
 Charco-Marie-Tooth disease, 445
 ligand-activated hydrolysis, neural tissue, 446t
 phosphatase dephosphorylation, 445–446
 phosphatidylinositol 3-kinase synthesis, 3'-phosphoinositides, 444
 phospholipase C isozyme cleavage, 446–448, 446f, 447f
 structure and metabolic function, 443–444, 443f, 444f
 muscular metabolic disorders, 763
 myelin, central nervous system
 enrichment, 186–187, 187t
 sorting and transport, 575–576
 peroxisomal diseases, 760–761
 in plasma membranes, endoplasmic reticulum and Golgi membranes, 31
 synuclein lipid-binding proteins, 830
Lipid solubility, blood-brain barrier permeability and, 21–22
Lipoxin pathway
 lipoxygenases, 653
 neuroinflammation, 616

- Lipoxygenases
 arachidonic acid conversion, 648–649, 648f, 649f
 arachidonic acid substrate, 649
 ischemia-reperfusion process and accumulation of, 656
 lipid mediator pathways, 653–654
- Long-chain aminodiol sphingosine backbone, sphingolipids, 85–89, 89f
- Long-chain carboxylic structure, fatty acids, 82–83, 83f
- Long-chain fatty acids, G protein modification, 418
- Long-term depression (LTD), synaptic plasticity and, 968
- Long-term memory, 965
- Long-term potentiation (LTP)
 glutamatergic synapses, learning and, 346–347
 induction mechanism, 966
 molecular mechanisms, 967–968
 NMDA receptor and, 966–967
 tyrosine phosphorylation, 509–511
- Low-threshold calcium current, epilepsy antiseizure drugs, 712, 712f
- Lymphoid tissue innervation, innate and adaptive immunity, 602–603
- Lymphoreticular system, prion disease pathology, 876
- Lysinuric protein intolerance, 751
- Lysosomal proteins, biosynthetic secretory pathway
 intracellular trafficking, pathway convergence, 132
trans-Golgi network sorting, 132
- Lysosomal storage diseases, 699–701, 756–757t
 Fabry disease, 759
 Farber disease, 757
 Gaucher disease, 757–758
 GM₂ gangliosidosis, 759–760
 Krabbe disease, 758, 758f
 lysosomal enzyme deficiency, 756–757
 metachromatic leukodystrophy, 758–759
 mucopolysaccharidoses, 760
 neuronal ceroid lipofuscinoses, 760
 Niemann-Pick disease A/B, 760
 Niemann-Pick disease C, 760
 organelle function, 755–756
 pleiotropic mutations, 757–760
 prognosis, 757
- ## M
- Macromolecular degradation, endocytic pathway, 135–137
- Macrophages, CNS immune activity, 605–606
- Magnetic resonance spectroscopy, brain energy metabolism, 222–223, 224f, 225f
- Major histocompatibility complex
 neuroinflammation, microglia activation, 612
 T-cell activation, neuroimmunology, 599–601
- Malate-aspartate shuttle, brain energy metabolism, 210–211, 214f
 cytosol-mitochondrial transfer, 210–211
 metabolic pathway linkage, 211
- Malate dehydrogenase, brain energy metabolism, tricarboxylic acid cycle, 217
- Malignant hyperthermia
 calcium ion channel mutations, 793
 ryanodine receptor mutation, calcium release channel, 792–793
- Maple syrup urine disease, 742–743
- MAPT gene
 tauopathies and mutations of, 836–837
 tau protein isoforms, 834–835, 835f
- Mass spectrometry, brain lipids, 89–90
- Mast cells
 functions, 324
 histamine function, 324
 histamine storage and release, 324
- McArdle disease, 763
- MDMA (Ecstasy), serotonin transporter and, 307
- Mechanoreceptors, organisms and cell types, 916–917
- Mechanotransduction
 balance, 916–917
 vesicular organs, 923–926
 deafness genes, 922
 hair cells, 918–923, 919f, 920f
 cochlear cells, 926
 inner ear, 923
 stereocilia actin, 921–923
 hearing, 916–917
 cochlea, 923
 cochlear hair cells, 926
 high-frequency sound detection, 925–926
 inner ear anatomy, 924f
 prestin electromotility, 925f
 ion channel activation, 920–921
 molecular mechanisms, 921
 non-vertebrate model system, 917–918, 917f
- Medial temporal lobe epilepsy (MTLE), 709
- Megaloblastic anemia, hereditary folate malabsorption, 749
- Melatonin, autism spectrum disorders, 1016
- Membrane-associated polysomes,
 biosynthetic secretory pathway,
 endoplasmic reticulum
 membrane, 126–127
- Membrane-bound organelles (MBOs)
 axonal transport, molecular motors, 158
 fast axonal transport
 molecular sorting, protein distribution to membrane components, 154–155
 pharmacological studies, 152f, 153
 retrograde transport, 153–154
 video images, 151
- Membrane cytoskeleton, neuronal and glial morphologies, 108–110
- Membrane fusion, intracellular membrane trafficking, transport vesicle cargo unloading, 125
- Membrane lipids, amphiphilic molecules, 82
- Membrane potential
 excitable cells, negative potential, 64–65, 64f
 transport system production, 65
- Membrane proteins, 28–29
 axonal transport, fast transport, 150f, 151–152, 151f, 152f
 cytoskeleton interaction, 34
 Golgi complex sorting and glycosylation, biosynthetic secretory pathway, 129–130
 lipid bilayer fluidity, 29–31
 primary active transport (P-type) pumps, 41–42, 41f
 protein-lipid binding, 29
 transmembrane domains, 28–29, 29f
- Membrane signaling. *See also* Intracellular membrane trafficking
 lipid rafts and, 33–34
- Membrane vesicle trafficking, Rab proteins, 419, 419f
- Memory consolidation, 965
 episodic cell assemblies, 975–977
 molecular mechanisms, 971
- Memory function
 adenylyl cyclase cAMP targeting, 430
 cGMP signaling, guanylyl cyclase receptors, 434
 declarative *vs.* procedural memory, 965
 differential reactivations, episodic cell assemblies, 975–977
 fear memory recall
 hippocampal concept cells, 976f
 multiple-discriminant analysis, 977f
 hippocampal concept cells, nest cells and Halle Berry cells, 975, 979f
 hippocampal function, 977–978
 imagination, 978–979
 hippocampal neuronal pathways, 347, 348f
 molecular mechanisms, consolidation and storage, 971
 network-level real-time memory traces, 974
 neural cliques
 categorical/hierarchical organization, 978f
 general-to-specific feature-encoding, 974–975
 real-time memory coding, 974
 neural coding, 971–974
 neural population-level memory traces, 971–979
 NR2B targeting, 972–973
 Penfield studies, 964
 protein phosphorylation, 479t, 484–489
 research background, 963–965
 short-term *vs.* long-term memory, 965
 temporal lobe system, 964–965, 964f
- Mental retardation, G proteins and, 420
- Mesocorticolimbic system, addiction and dopamine transmission, 1040f, 1042f
- Metabolic crisis, neonatal, urea cycle defects, 750–751
- Metabolic stress, apoptosis activation, 668
- Metabolism
 blood-brain barrier solute carriers and, 22
 myelin metabolic turnover, 577
- Metabotropic glutamate receptors
 classification, 347, 349f, 358
 cytoplasmic signaling enzymes, 358

- diacylglycerol kinases, 654
 genetic knockout studies, 359
 ion channel modulation, 358–359
 presynaptic activation and inhibition, 359
 synaptic transmission, 358–359
- Metachromatic leukodystrophy, 699–701
 lysosomal mutations, 758–759
 stem cell therapy, 565
- Metalloproteinases, neurovascular unit
 disruption, 631–632
- Methionine, homocystinuria and
 homocysteine remethylation, 748
- Methionine synthase, homocystinuria and
 deficiency of, 748
- Microautophagy, endocytic pathway, 136
- Microdomain signaling, calcium ion
 channels, 461
- Microfilaments (MFs)
 associated proteins, 109t
 eukaryotic cytoskeleton, 102, 102f, 103f
 growth cone motility and, 112
- Microglia
 CNS immune activity, 605–606
 phenotype, 606–607
 components of, 11–15
 immune-competent microglia, brain
 development and, 23
 injury response, 386, 386f
 neuroinflammation and, 611–612, 611f
 aging and, 613
 cytokine production, 614
 homeostasis disruption, 618
 neurodegenerative disease, 613
 phagocytosis, 612
 protein aggregation and, 614
 receptors, 612–613
 phagocytosis and inflammatory process
 and, 15–16, 15f
- Microinjection techniques, learning research,
 mouse models, 970f
- Microinterfering RNA, neurodegenerative
 disease epigenetics, 731–733
- Microtubule-associated proteins (MAPs),
 105–106
- Microtubule organizing center (MTOC), 103
- Microtubule plus-end tracking proteins
 (+ TIIPs), microtubule
 organization, 106
- Microtubules (MT)
 cytoskeletal proteins, 105t
 eukaryotic cytoskeleton, 102, 102f
 growth and regeneration, slow axonal
 transport, 155–156
 growth cone motility, 112
 structure and organelle tracking, 102–106,
 103f, 104f, 105t, 107f
 tau protein association, 834–835
- Mild cognitive impairment, Alzheimer's
 disease diagnosis, 816
- Mineralocorticoid receptors, transcription
 factors, 521–524, 523f
- Miniature endplate potentials (MEPPs),
 synaptic transmission exocytosis,
 239, 242f
- Mitochondria
 anterograde fast axonal transport, 153
 apoptosis activation and changes in, 670,
 671f
 brain energy metabolism
 assays, 226
 glutamate-glutamine metabolism, amino
 acid transport, 220
 glycolysis regulation, 208–209
 heterogeneity, neural and glial
 mitochondria, 219–220
 malate-aspartate shuttle, cytosol transfer,
 210–211
 malate dehydrogenase, 217
 partial TCA, 219
 substrates, 219–220
 tricarboxylic acid cycle, astrocytes and
 neurons, 219
 and calcium ion channels, 460–461, 460f
 central nervous system distribution, 219
 diseases
 substrate utilization defects, 775–776
 transport defects, 775
 DNA, maternal inheritance, 773
 ischemia-reperfusion injury, 631
 metabolism cycle, 769f
 genetic mitochondrial diseases, 774–775
 nDNA-mtDNA communication
 defects, 775
 metabolic dysfunction, 772–779, 774t
 mitochondrial DNA and, 775–779
 mtDNA biochemistry, 775–779
 neuroinflammation and, 617
 neuron morphology, 8–9
- Mitochondrial DNA (mtDNA)
 biochemical classification, 775–779
 genetic translation defects, 775
 maternal inheritance, 773
 mutations and disease, 774t
 nuclear DNA, communication defects, 775
- Mitogen-activated protein kinase (MAPK)
 pathway
 G protein subunit regulation, 415–416
 protein Ser/Thr kinase signaling, 476–478,
 476f
- Molecular biology
 neuropeptide receptors, drug targeting,
 402
 schizophrenia, 1004–1009
 serotonin receptor subtypes, 314
- Molecular cloning, muscarinic cholinergic
 receptors, 275–276, 275f
- Molecular geometry, bilayered lamellar
 structures, amphipathic
 molecules, 27–28
- Molecular mechanisms
 learning, 965–971
 pain management, 934
 slow axonal transport, 156
- Molecular mimicry, Guillain-Barré syndrome,
 686f
- Molecular motors
 axonal transport, 156–161
 biochemical properties, 157
 cytoplasmic dyneins, 159–160
 function matching, 160–161
 kinesins, 157–159
 membrane-bound organelles, 158
 myosins, 160
 peripheral neuropathies and, 688
- Molecular signaling mechanisms
 cell-surface receptors, 246–249, 246f,
 247t
 first group, 246–248
 fourth group, 248–249
 second group, 248
 third group, 248
 tau protein scaffolds, 840
- Molecular sorting mechanisms, fast axonal
 transport, 154–155
- Monoamine oxidase (MAO)
 catecholamine metabolism, 290–291, 291f
 serotonin catabolic pathway, 310–311
- Monoamines
 catecholamines, 283
 cocaine and amphetamine addiction, 1044
 sleep regulation, 986–987
 depression and, 987
- Monocarboxylic acid transporter (MCT),
 brain energy metabolism,
 transporters, glucose/
 monocarboxylic acid uptake,
 203–204, 204f
- Monogenic disorders, nicotinic acetylcholine
 receptors, 272
- Monomeric GTPases, intracellular membrane
 transport, 122–123
- Monomer structures, polyglutamine protein
 misfolding, 846
- Mood disorders
 cGMP signaling, guanylyl cyclase
 receptors, 434
 epidemiology, 1021, 1022
 future research and therapies, 1033–1034
 intracellular signaling pathways,
 1026–1030, 1028f
 neuroanatomical and neuropathological
 correlates, 1025–1026
 neurotransmitters and neuropeptide
 systems, 1022–1025
 brain growth factors, 1025
 cholinergic system, 1024
 cortical-hypothalamic-pituitary-adrenal
 axis, 1024
 dopaminergic system, 1024
 GABAergic system, 1024
 glutamatergic system, 1024
 neuropeptides, 1025
 noradrenergic system, 1023
 serotonergic system, 1022–1023
 substance P, 1025
 thyroid axis, 1024–1025
- Motility, cytoskeleton growth cone, 110f
- Motor neurons
 diseases. *See also* specific diseases
 amyotrophic lateral sclerosis, 801–806
 axon communication disruption, 806
 genetic models, 806–809
 mouse models, 809–811
 superoxide dismutase and redox
 signaling, 810
 nerve injury models, 806
 neuromuscular junction, muscle cells,
 543

- Mouse genetics
 amyotrophic lateral sclerosis, phenotype development, 807–808
 epilepsy genetics and, 713–717, 713t, 714t
 spontaneous and engineered mutations, mouse studies, 715–717, 715–716t
 GABA_A receptor subtypes, 375
 learning and memory research, 969–971
 motor neuron disease therapies, 809–811
 synucleinopathies, 833–834
 Movement control, basal ganglia and, 857
 MsbA ATP-binding cassette transporter, three-dimensional structure, 50–51, 51f
 Mucopolysaccharidoses (MPS), 760
 Multidrug resistance (MDR) proteins, amphipathic molecule flipping, 52
 Multiphoton confocal analysis, neurolipidomic signaling, 660
 Multiple-discriminant analysis, real-time memory coding, 977f
 Multiple sclerosis
 animal models, 696–697
 anti-integrin antibodies, 174
 axonal and neuronal pathology, 694
 biochemistry, 694–695, 695f
 demyelination, 692–696
 diagnosis, 692–693
 environmental factors, 695–696
 epidemiology and natural history, 695
 etiology, 695
 future research, 696
 genetics, 696
 gray matter lesions, 693–694, 694f
 immunology, 696
 pathology, 693
 remyelination, 702
 stem cell immunomodulation, 566
 therapy, 695
 viral models, 696
 Multiple system atrophy (MSA), 833, 833f
 Multipotent stem cells, 558–559
 Multivesicular bodies (MVBs), endocytic pathway, clathrin-coat-dependent process, 139
 Muscarinic cholinergic receptors, 274–280
 G-protein-coupled receptor mediation, 274
 molecular cloning, 275–276, 275f
 muscarine mimicking, 274
 neuropsychiatric disorders, central nervous system distribution, 277
 peripheral tissue physiology, 274t
 pharmacological therapies, cholinergic disorder, 278
 subtype distribution, 277
 subtype-G-protein coupling, 276, 276f
 subtypes, pharmacological analysis, 274–275
 synaptic terminal, choline accumulation, 260–261, 261f
 transgenic studies, *in vivo* subtype assessment, 277–278
 Muscle cells
 fiber excitation and contraction, 788f
 calcium coupling, 787–789, 788f
 neuromuscular junction
 motor neurons, 543
 organization, 783–786, 784f
 Muscle diseases
 carbohydrate and fatty acid metabolic dysfunction, 763–768
 excitability disorders, 789t
 acetylcholine synthesis, 785
 electrolyte imbalances, 798
 immune diseases, 793–795
 neuromuscular junction, 783–786, 784f
 toxins and metabolites, 795–799
 hereditary diseases, 790–793
 Brody disease, 793
 calcium channel mutations, 791, 792–793
 chloride channel mutations, 792
 potassium channel mutations, 791
 ribonuclear inclusions, 791–792
 ryanodine receptor calcium release channels, 792–793
 sodium channel mutations, 790–791
 mitochondrial dysfunction in, 772–773
 Muscle relaxants, nicotinic acetylcholine receptor targeting, 273
 Muscle-specific kinase (MuSK)
 myasthenia gravis mimicking, 793–794
 neuromuscular junction development, 798–799
 tyrosine phosphorylation, 509
 Myalgia, phosphorylase deficiency, 763
 Myasthenia gravis, 793, 794f
 Myelin
 amino acid disorders, reduction of, 742
 assembly, lipid/protein sorting and transport, 575–576
 axonal cytoskeleton organization and loss of, 113–114
 axonal regeneration, growth inhibition activity, 588–589
 axonal structure, 185
 Canavan's disease and, 753
 cell membrane extension, 184–185
 central nervous system, neurite growth inhibition, 585–586
 composition, 185–197
 central nervous system proteins in, 188–192, 188f
 2':3'-cyclic nucleotide
 3'-phosphodiesterase, 190–191
 developmental changes, 576
 lipid enrichment, 186–187, 187t
 myelin-associated glycoprotein, 191–194
 myelin basic proteins, 189–190, 190f, 193
 P₀ glycoprotein, 192
 P₂ protein, 193
 peripheral and central nervous system myelin, 187–188
 peripheral myelin protein-22, 192–193
 peripheral nervous system proteins, 192–193
 proteolipid protein, 188–189
 subcellular fractionation yield and purity, 185–186, 187f
 conduction functions, 180–181, 181f
 diseases
 acquired immune-mediated and/or infectious disease, 692–699
 animal models, 696–697
 biochemical changes, 692
 classification, 692
 developmental insults, nutritional deficiency, and toxins, 701–702
 genetically-determined disorders, 699–701, 700t
 neurochemistry, 693
 neuronal disorders, 703
 peripheral neuropathies, 697–699
 repair mechanisms, 702–703
 integrin regulation, 173–175
 maintenance, 577–579
 nervous system development and function, 570
 oligodendrocytes, central nervous system, 13, 570, 573f
 periventricular leukomalacia, 579
 Schwann cells, peripheral nervous system, 13–15, 14f, 570, 571f, 572f
 spinal cord injury, fiber growth and regeneration, 592
 stem cell replacement therapy, 564–565
 synthesis and deposition, 575
 ultrastructure, 181–184, 182f, 183f
 nodes of Ranvier, 182–183, 184f, 186f
 Schmidt-Lanterman clefts, 185
 Myelin-associated glycoprotein (MAG)
 central nervous system myelin, 191–192
 CNS/PNS myelin, 193–194
 immunoglobulin-cellular adhesion molecules, 167
 Myelin-associated oligodendrocytic basic protein, myelin composition, 197
 Myelination
 genetic disorders, 576–577
 rodent mutants, 576–577, 577t
 nervous system development and function, 570
 regulation, 574–575, 575f
 remyelination, 579–580
 SLC25A12 gene mutation, *N*-acetylaspertate formation and brain function, 212–213, 212f
 Myelin basic protein (MBP)
 central nervous system myelin, 188, 189–190, 190f
 CNS/PNS myelin, 193
 Myelin/oligodendrocyte-specific protein (MOSP), myelin composition, 197
 Myelin protein zero, peripheral neuropathies, 682
 Myelin sheath
 axon function and, 578
 protein content, 194–197
 enzymes, 195–197
 miscellaneous proteins, 197
 neurotransmitter receptors, 197
 nodal, paranodal, and juxtaparanodal proteins, 195
 tetraspan proteins, 194–195
 signal transduction, 577–578
 structure and properties, 180–185
 Wallerian degeneration, peripheral nervous system, 583
 Myoadenylate deaminase (MADA), Lesch-Nyhan syndrome, 381

- Myocytes, structure and function, 786–787, 787f
- Myofibrils, structure and function, 786–787, 787f, 788f
- Myoglobinuria
clinical manifestations, 766
phosphorylase deficiency, 763
- Myoinositol
facilitated diffusion, 58–60
urea cycle defects, cognitive function and, 752
- Myo-inositol, phosphorylated forms, 449
- Myosin, axonal transport
biochemical properties, 157
neuronal function, 160
- Myotonia, congenital, 792
- Myotonic dystrophy, ribonuclear inclusions, 791–792
- N**
- N-acetylaspartate (NAA), *SLC25A12* gene mutation, formation of, 212–213, 212f
- N-acetyl aspartate metabolic disorders, 753
- N-acetylglutamate synthetase deficiency, 750
- Narcolepsy
GABAergic neurotransmission, 991
histamine and, 338
hypocretins and, 990
- Natriuretic peptides, guanylyl cyclase receptors, 432
- Necrosis
basic features, 665f
caspase substrates, 664t
cell disintegration, 672
cell morphology and biochemistry, 664
embryonic and postnatal development, 663–664
energy failure/ischemia, 672–673
neurological disease and, 673–675
trauma, 672
- Negative feedback, olfactory transduction, 908–909
- Neonatal brain damage
compensatory plasticity and, 590
metabolic crisis, urea cycle defects, 750–751
- Nernst equation, membrane potential, 65
- Nerve growth factor (NGF)
axon-based nervous system development, 542–543
basic properties, 547–548
identification, 547–551, 547f, 548f
pain management, 549
- Nerve injury
immune response, 938–939
motor neuron disease model, 806
pain management, 936–939, 937f
- Nervous system development
axon guidance, 542–543
naturally occurring cell death, 542–543
embryology, 534
embryonic signaling, 538–539, 539f
myelination and, 570
neurogenesis and gliogenesis, 539–541
neuronal birthdate, 539
proneural gene functions, 540–541
reelin and notch signaling, cortical layer organization, 539, 539f
peripheral nervous system, target interaction, 541–542, 542f
sensory experience and motor activity, 543–544
spatial regionalization, 534–539
dorsoventral pattern, 534–535, 536f
rostrocaudal axis, 535–538, 537f
synapse formation, 543, 544f
tuberous sclerosis, 540
- Nest cells, memory function, 975
- Network-level real-time memory research, 974
- Neural cell adhesion molecules (NCAM)
intracellular signaling, 29
structure and properties, 167–168, 168f, 170f
- Neural cliques
general-to-specific feature-encoding assemblies, 974–975, 978f
real-time memory coding, 974, 976f, 977f, 978f
- Neural crest, peripheral nervous system development, 541–542, 542f
stem cells, 560–561, 561f
- Neural function, P-type copper transporters, 50
- Neural markers, 562t
- Neural population-level memory traces, 971–979
- Neural stem cells, neuron and glial development, 559–561
- Neural tube, central nervous system development, 534–539, 535f
cortical neuron layers, 538–539, 538f
- Neuregulins, basic properties, 555
- Neurexin-neuroligin interactions, cell adhesion molecules, synapse regulation, 176, 177f
- Neurites
Alzheimer's disease pathology and, 818
antibody-mediated neutralization, spinal cord injury, 592
axon regeneration
Nogo-A neuronal expression, 589
Nogo-A protein inhibition, 586
surface receptors and intracellular signaling molecules, 589
cadherin-integrin cross-talk, 177–178
- Neuritic plaques, Alzheimer's disease, 818
- Neurochemicals
anxiety disorders, 1030–1033
autism spectrum disorders, 1013, 1014–1016
stem cell replacement, Parkinson's disease, 563–564
- Neurodegenerative disease. *See also*
Neurological disease. specific diseases
adenylyl cyclase targeting, 430
apoptosis, 667–668, 667f
cardiolipin, 81, 86f, 87f
genetics
Alzheimer's disease, 721–723, 721t
amyotrophic lateral sclerosis, 727–729, 728t
Creutzfeldt-Jakob and other prion diseases, 730–731
epidemiology, 719–721
epigenetic modifications, 731–733
frontotemporal dementia, 726–727, 726t, 727t
Huntington's disease, 729–730
Lewy body dementia, 725–726
mutation and polymorphism identification, 721t
Parkinson's disease, 722t, 723–725, 723t, 724t
triplet repeat disorders, 729–730
hereditary folate malabsorption, 749
immune-mediated disorders, 598
microglia, 611–612, 611f, 613
disease sensors, 618
mitochondria, neuroinflammation and, 617
phospholipid targeting, synaptic membranes, 645
prion-mediated mechanisms, 883
retina, 899–900
molecule-directed therapies, 900
- Neurodevelopmental disorders, myelin formation and stability, 701–702
- Neuroendocrine secretion
biosynthetic secretion pathway, 132–133
serotonin modulation, 312
synaptic transmission, regulated secretory pathway, 245
- Neuroepithelium, olfactory system, 905, 905f
- Neurofibrillary tangles, Alzheimer's disease, 818–819
- Neurofibromatosis type 1 (NF1), G proteins and, 420
- Neurofilaments (NFs)
disruption, neuropathology and, 115–116
eukaryotic cytoskeleton, 102, 102f
growth and regeneration, slow axonal transport, 155–156
motor neuron disease models, 807
neuronal and glial morphologies, 108
- Neurogenesis
brain function and stress and, 959–960
hippocampal stress and, 949
nervous system development, 539–541
neuronal birthdate, 539
proneural gene functions, 540–541
reelin and notch signaling, cortical layer organization, 539, 539f
- Neuroimmunology
central nervous system, 603–607
blood-brain barrier and leukocyte influx/efflux, 604
leukocyte migration, 604–605
microglia function, 605–606
microglia phenotyping, 606–607
defined, 597
immune-mediated neurodegenerative disorders, 598
immune responses and neurologic outcomes, 607
immune tolerance and inflammation, 601–602
innate vs. adaptive immunity, 599–601
lymphoid tissue innervation, 602–603
neuropeptides, 603
manipulation, 608
neuronal function and mammalian behavior, 607–608
Toxoplasma gondii, 598–599

- Neuroinflammation
 CNS immune system and, 616–617
 cytokines/chemokines, 613–614
 defined, 610–612
 depression and, 1034
 ischemia-reperfusion damage, 616
 lipid mediator pathways, 614–616, 615f
 lipoxin, resolvin, and neuroprotectin pathways, 616
 lipid signaling, 654–656
 lipoxygenases, 654
 microglia and, 611–612, 611f
 aging and, 613
 cytokine production, 614
 homeostasis disruption, 618
 neurodegenerative disease, 613
 phagocytosis, 612
 protein aggregation and, 614
 receptors, 612–613
 mitochondria, neurodegeneration and, 617
 neuroprotection pathway, apoptotic signaling, 633–635, 634f, 635f
 neuroprotective signaling circuits, 617–618
 protein aggregation and, 613–614
 Neurolipodomic signaling
 future research, 657–660
 translation neuroscience, 659, 659f
 Neurological disease. *See also*
 Neurodegenerative disease
 apoptosis and necrosis, 673–675
 glutamate receptor activation, 363–365
 glycinergic neurotransmission, 250–255
 glycine biochemistry and transport, 250
 glycine receptor distribution, 252–253
 glycine receptor structure and function, 251–252
 H⁺-dependent vesicular transporter, 250
 ligand-gated chloride channel, glycine inhibition, 250–251
 postsynaptic effects and pharmacology, 250–251
 postsynaptic gene mutations, 253–254
 presynaptic glycine transporter 2 mutation, 254
 startle disease molecular genetics, 253
 G proteins and, 420, 421
 histamine functions and, 337
 H₃ receptors, 337–339
 histamine-methyl transferase polymorphisms, 329
 immune functions and, 607
 nicotinic acetylcholine receptors, 272–273
 peptides in, 404–406
 purinergic receptors, 387–388
 tubulation mutations, 115
 Neuromuscular disorders
 carbohydrate and fatty acid metabolic dysfunction, 763–768
 mutant dynamin 2, 123
 Neuromuscular junction
 acetylcholine synthesis, 785
 development, muscle-specific kinase and, 798–799
 genetic disorders, 789–790
 congenital myasthenic syndromes, 789–790
 organization, 783–786, 784f
 signal transmission, 785–786, 785f
 synapse formation, 543, 544f
 synaptic transmission, 238–239, 240–241f
 calcium ion channels, 239–241, 243f
 toxin and metabolite targeting of, 796–798
 Neuromuscular synapse, tyrosine phosphorylation, 509
 Neuromyotonia, Isaac syndrome, 794–795
 Neuronal autoimmune encephalitis, glutamate and, 353
 Neuronal β -tubulin isoforms
 microtubule organization, 105
 β -III tubulin mutations, 115
 Neuronal ceroid lipofuscinoses (NCLs), 760
 Neuronal development
 astrocytic cholesterol synthesis, 32–33, 33f
 cytoskeleton molecular components, 102–110
 actin microfilaments, neuronal growth and secretion, 108–110
 eukaryotic cell definition, 102, 102f
 microfilament proteins, 109t, 110f
 microtubules, structure and organelle tracking, 102–106, 103f, 104f, 105t
 neuronal and glial intermediate filaments, morphology support, 106–108, 107f
 sodium-dependent D-glucose symporter, 52
 tyrosine phosphorylation, 505–508, 508f
 Neuronal disorders, myelin involvement, 703
 Neuronal inhibition, opioid receptor mediation, 1041
 Neuronal primary cilium, Bardet-Biedl Syndrome, 23
 Neuronal signals
 addiction and, 1038–1041
 excitatory/inhibitory, brain energy metabolism, 205–206
 peptide-based plurichemical coding, 403
 Neuronal specific enolase (NSE), brain energy metabolism, 207
 Neurons
 acetyl coenzyme formation, 218–219
 alcohol addiction and, 1049
 basic components, 4–11, 5f
 brain energy metabolism, subcellular compartmentation, 225–226
 cholinergic neurons, central nervous system distribution, 262
 cyclic nucleotide spatiotemporal integration, 438–439
 development, neural stem cells, 559–561
 disordered synchronous firings, epilepsy, 706t
 enzymes in, 207t
 epilepsy, firing regulation, anti-seizure drugs, 711, 711f
 excitation mechanisms, 64f
 glutamine transfer from astrocytes, 362
 histaminergic
 histamine storage and release, 328
 morphological and membrane properties, 325
 neurotransmitter connections, 335–336, 336f
 immune-related changes, 607–608
 intracellular membrane trafficking, 120
 mitochondrial heterogeneity in, 219–220
 neurogenic development, 539
 proneural and neurogenic gene junctions, 540–541
 neuropeptides in, 393–394, 393f
 nicotinic acetylcholine receptor family, 269–270, 270f
 brain function and, 271
 norepinephrine metabolism to epinephrine, 288
 pain management, 936
 phosphoprotein function, phosphorylation, 482–483
 phosphoprotein regulation, 483, 483f
 prostaglandin release, 648–649, 650f
 protein kinase/phosphatase function, 481–482
 retinal sublayers, 890, 891f
 secretory cells, regulated secretory pathway, 133f, 134
 secretory vesicle biogenesis, 134
 serotonergic neurons, 301–304
 structural morphology, 6–9, 6f, 7f
 schizophrenia, 1008
 ultrastructure and molecular organization, 110–112
 axonal and dendritic cytoskeletons, 111–112
 cytoskeleton functions, 110–111
 Neuropathology
 brain energy metabolism
 blood-brain barrier alteration, 204
 imaging studies, 226
 cytoskeletons
 alterations as hallmarks of, 114–116
 protein phosphorylation, 116
 mood disorders, 1025–1026
 axonal transport and, 161
 pain management, 936–939
 phospholipid targeting, synaptic membranes, 645
 protein phosphorylation and, 490–491
 tau protein, 836
 Neuropeptide receptors
 amiloride-sensitive FMRF-amide-gated sodium ion channel, 402
 distribution, 401–402
 molecular drug targeting, 402
 peptide correspondence and, 402
 seven-transmembrane-domain, G-protein coupling, 400–401, 401f
 Neuropeptides. *See also* Peptides
 antigen-presenting cell modulation, 603
 anxiety disorders, 1032–1033
 appetite regulation and obesity, 405
 basic properties, 392–393, 392f
 biosynthesis, 394, 394f, 395f
 classification, 390–391
 dense-core vesicles, 399, 400f
 enkephalin knockout mice studies, 405–406
 mood disorders, 1022–1025
 brain growth factors, 1025
 cholinergic system, 1024
 cortical-hypothalamic-pituitary-adrenal axis, 1024
 dopaminergic system, 1024
 GABAergic system, 1024

- glutamatergic system, 1024
- neuropeptides, 1025
- noradrenergic system, 1023
- serotonergic system, 1022–1023
- substance P, 1025
- thyroid axis, 1024–1025
- in neurons, 393–394, 393f
- pain perception, 406
- peptidergic neurons, 402–403
- plurichemical neuronal signal coding, 403
- regulation, 403–404, 404f
- signaling function, 403
- Neuropeptides, novel compounds, 391f
- Neuropeptide Y
 - anxiety disorders, 1032
 - derivation, 392f, 392–393
 - identification, 392
 - plurichemical coding, neuronal signals, 403
 - structure and properties, 396–397, 396f
- Neuroplasticity, mood disorders and, 1026
- Neuroprotectin D1,
 - ischemia-reperfusion inhibitor, 657
 - lipid mediation, 657
- Neuroprotection pathway
 - neuroinflammation, 616
 - apoptotic signaling, 633–635, 634f, 635f
 - inflammatory mediators and anti-inflammatory regulation, 632–633
 - Parkinson's disease treatment, 864–865
 - phospholipases A₂, ischemia-reperfusion signaling, 654
- Neuroprotective signaling circuits
 - mood disorders and, 1029
 - neuroinflammation and, 617–618
- Neuropsychiatric disorders
 - basal ganglia involvement, 867–868
 - cGMP signaling, guanylyl cyclase receptors, 434
 - muscarinic cholinergic receptors, 277
 - schizophrenia
 - brain imaging, 1003–1004
 - cellular and molecular studies, 1004–1009, 1006f
 - clinical aspects, 1000–1003
 - genetics, 1009–1010
 - serotonin effects, 301–304
- Neuroscience, cellular neuroscience, 4
- Neurosphere functional assay, 561, 562f
- Neurosteroids, GABA_A receptor function, 374
- Neurotensin, neuropeptide receptors, 400–401
- Neurotoxicity
 - glutamate receptors, 363
 - dietary neurotoxin activation and cell death, 363
 - polyglutamine protein misfolding, 845–846
- Neurotoxin labeling, sodium ion channel, 69–71, 70f
- Neurotransmission
 - exocytosis, synaptic vesicle trafficking, 139–142
 - neuropeptide receptors, 401–402
- Neurotransmitter receptors
 - aminoacidurias and deficits in, 742
 - G protein ion channel coupling, 412–414
 - myelin composition, 197
- Neurotransmitters
 - Alzheimer's disease damage to, 817–818
 - aminoacidurias and deficits in, 742
 - aspartate, 346
 - in basal ganglia, 857–860
 - acetylcholine, 858
 - dopamine, 859–860, 859f
 - dopamine-acetylcholine balance, 860
 - GABA, 857, 858f
 - glutamate, 858
 - multiple systems, 860
 - GABA, 375
 - glutamate, 343
 - histamine, 335
 - mood disorders, 1022–1025
 - brain growth factors, 1025
 - cholinergic system, 1024
 - cortical-hypothalamic-pituitary-adrenal axis, 1024
 - dopaminergic system, 1024
 - GABAergic system, 1024
 - glutamatergic system, 1024
 - neuropeptides, 1025
 - noradrenergic system, 1023
 - serotonergic system, 1022–1023
 - substance P, 1025
 - thyroid axis, 1024–1025
 - neuropeptides *vs.*, 392, 392f, 394f
 - Rab protein release, 419, 419f
 - serotonin
 - amino acid L-tryptophan precursor, 304–306, 305f
 - behavioral arousal/activity, 311–312
 - chemical structure, 301f
 - circadian rhythm modulation, 312
 - feeding behavior and food intake, 312–313
 - indolealkylamine 5-hydroxytryptamine identification, 301
 - monoamine oxidase oxidative deamination, catabolic pathway regulation, 310–311
 - neuroanatomical organization, 301–304, 302f, 302t, 303f, 304f
 - neuroendocrine function, 312
 - receptors, 313–321
 - 5-HT_{1P} receptor, 320–321
 - 5-HT₁ subfamily, 314–317, 315t
 - 5-HT₂ subfamily, 317–318
 - 5-HT₃ receptor, as ligand-gated ion channel, 318–319
 - 5-HT₄ receptor, 319–320
 - 5-HT₅ receptor, 320–321
 - 5-HT₆ receptor, 320
 - 5-HT₇ receptor, 320
 - mental illness and 5-HT_{1A}, 316
 - subtype definition, 313–314
 - subtype research, 314
 - serotonin transporter, acute and chronic regulation, 309–310
 - synapse termination, 308–309, 310f
 - synthesis conditions, 306
 - vesicle storage and exocytotic release, 306–308, 307f, 308f
 - volume and paracrine neurotransmission, 311
- sleep regulation and wakefulness, 984, 985f, 986–987
- synaptic transmission
 - replenishment, fast transmission, 245
 - secretory release, eukaryotic cells, 237–238
 - synaptic vesicle trafficking, 142, 143f
 - uptake and storage physiology, 55
- Neurotransmitter sodium symporters (NSS) subfamilies, 52
- synaptic clefts, neurotransmitter recovery, 52, 53f
- Neurotrophic cytokines, 555–556
- Neurotrophic factor hypothesis, 547–551, 547f
- Neurotrophic factors
 - apoptosis, 668, 670–671
 - axonal growth, 590
- Neurotrophin 3, basic properties, 550
- Neurotrophin 4, basic properties, 550–551
- Neurotrophin receptors, 548f, 551–553
 - p75 neurotrophin receptor, 552–553, 553f
 - Trk receptors, 552, 552f
- Neurotrophins, 547–551, 547f, 548f
 - brain-derived neurotrophic factor, 548–550
 - epileptogenesis, 710–711
 - nerve growth factor, 547–548
 - neurotrophin 3, 550
 - neurotrophin 4, 550–551
 - proneurotrophins, 551, 551f
 - regulation, 551
- Neurovascular unit
 - brain injury and breakdown of, 631–632, 632f
 - aquaporins, 632
 - metalloproteinases, 631–632
 - cerebral capillaries, 18
 - components, 19, 19f
- Neutral lipid storage disease, 768
- NextGen sequencing, transcription factors, 520–521
- NF gene mutations, transgenic mice studies, 808
- NFκB, neuroprotectin D1 inhibition, 657
- Nicotine addiction, 1048–1049
 - nicotinic acetylcholine receptor targeting, 273
- Nicotinic acetylcholine receptor agonist, nicotine addiction, 1048
- Nicotinic acetylcholine receptor polymorphisms, 272
- Nicotinic acetylcholine receptors (nAChRs), 266–274
 - agonist binding, 268–269
 - agonist desensitization, 269, 270f
 - biochemical characterization, 266–267, 267f
 - brain function modulation, neuronal receptor, 271
 - cys-loop ligand-gated ion channel family, 268f, 269
 - disease and, 272–273
 - ion channel communication, 269
 - neuronal receptor family, 269–270, 270f
 - non-neuronal distribution, 272
 - pentameric ligand-gated ion channels, 267–268, 268f
 - subunit permutations and diversity, 270f, 271

- Nicotinic acetylcholine receptors (nAChRs), (*Continued*)
 therapeutic targeting, 273–274
 transgenic research, physiology and clinical implications, 271–272
- Niemann-Pick diseases
 type C, 760
 types A and B, 760
- Nissl substance, 6–7
- Nitric oxide
 molecular signaling mechanisms, cell surface receptors, intercellular signaling, 249–256
 soluble guanylyl cyclase regulation, 433
- Nitric oxide synthase, ischemia-reperfusion injury, 631
- Nitrogen shuttles, brain energy metabolism, 222
- N-methyl-D-aspartate (NMDA) receptors
 aminoacidurias and deficits in, 742
 glycine activation, 250–251
 GTPase activation, 361
 identification, 347–356
 ischemic injury
 brain function and cell death, 628–629, 629f
 downstream death signals, 629
 learning and memory research, NR2B targeting, 972–973
 long-term potentiation induction, 966–967, 967f
 multiple regulatory sites, 350–354, 352f
 phospholipid esterification, 645–646, 646f
 schizophrenia and hypofunction of, 1005–1007
 tyrosine phosphorylation, 510–511
- Noiceptive pain, 928–929
 dorsal horn, 930
 genetic factors, 939
- Noiceptors
 pain management, 929–930
 receptor profiles, 929–930
- Nodal proteins, myelin sheath, 195
- Nodes of Ranvier, 14, 15f
 myelin ultrastructure, 182–183, 184f, 186f
 sodium channel concentration, 67
- Nogo-A protein
 axonal regeneration
 antibodies and peptides, 588
 neurite growth inhibition, 586, 586f, 587f
 neuronal expression, neurite growth regulation, 589
 compensatory plasticity, adult brain injury, 591–592, 591f
 spinal cord injury, fiber growth and regeneration, 592
- Nogo gene, axonal regeneration, 587–588
 knockout mouse studies, 588
- Non-declarative memory, 965
- Nonketotic hyperglycinemia, 744–745, 745f
- Non-neuronal nicotinic acetylcholine receptors, 272
- Non-rapid eye movement (NREM) sleep, neurochemical substrates, 983
- Nonreceptor protein tyrosine kinases (NRPTKs)
 families, 496f
 phosphorylation, catalytic domains, 494–498
- Nonreceptor protein tyrosine phosphatases (NRPTs), schematic structure, 504f
- Noradrenergic neurons, dopamine-norepinephrine conversion, 286
- Noradrenergic system
 anxiety disorders, 1030–1031
 mood disorders, 1023
- Norepinephrine
 cell-surface receptor binding, 293–295, 294f, 294t
 dopamine conversion, adrenergic/noradrenergic neurons, 286
 epinephrine metabolism, neurons and adrenal medulla, 288
 metabolism, 292
 sleep regulation and wakefulness, 986
- Norepinephrine transporters (NET)
 catecholamine termination, 289
 psychomotor stimulant addiction, 1043–1044
- Notch signaling, neurogenic development, 539
- NRG1/ErbB receptor signaling, myelination regulation, 574, 575f
- Nuclear DNA (nDNA)
 defects of, 774–775
 mitochondrial DNA communication defects, 775
- Nuclear envelope, 7f
- Nucleosome, histone modification, neurodegenerative disease epigenetics, 731–733
- Nutrient exchange. *See also* Diet and nutrition
 blood-brain barrier, 18–19
 endocytic pathway, 135–137
- ## O
- Obesity
 neuropeptides, 405
 peripheral neuropathies and, 687
- Odorant receptors, smell
 gene encoding, 905–906, 906f
 odor discrimination, 906
 zonal expression, 907
- Odor discrimination, odorant receptors, 906
- Olfaction
 adenylyl cyclase targeting, 430
 epithelium, 905, 905f
 guanylyl cyclase receptors, 432
 mammalian processes, 904
 negative feedback, olfactory transduction, 908–909
 odorant receptors
 gene encoding, 905–906, 906f
 odor discrimination, 906
 zonal expression, 907
 olfactory sensory neurons
 action potentials, 907–908
 convergence, olfactory bulb, 907
 subpopulations, 909–910
 second-messenger cascade, odorant recognition, 907–908, 908f
 social communication and, 909–910
 taste, 911–914, 912f
 cranial nerves, 912
 G-protein-coupled receptors, 912–913
- G-protein-coupled signaling cascade, 913–914
- ion channel interaction, salts and acids, 914
- receptor cells, 912
- vomeroneasal organ
 semiochemical detection, 910
 sensory transduction, 911, 911f
- Olfactory bulb, olfactory sensory neuron convergence, 907
- Olfactory sensory neurons (OSNs)
 action potentials, 907–908
 convergence, olfactory bulb, 907
 subpopulations, 909–910
- Oligodendrocytes
 integrin myelin regulation and, 173–175
 myelin production, central nervous system, 13, 13f, 570–574, 573f
 transcriptional and epigenetic regulators, 572–574
- Oligomeric structures, polyglutamine protein misfolding, 846
- Oligosaccharide formation, biosynthetic secretory pathway, Golgi complex sorting and glycosylation, 129
- O-linked glycosylation, biosynthetic secretory pathway, membrane and secretory proteins, 130
- Opiate peptides, identification, 391–392, 391f
- Opiates
 addiction to, 1041–1043
 cannabinoid similarities, 1048
 tolerance, adenylyl cyclase regulation, 328–329
- Opiate withdrawal syndrome, 1043
- Opioid analgesia
 pain management, 933
 sleep disruption, 993–994
- Opioid receptors, addiction and, 1041
- Optic atrophy 1 (OPA1), dynamin proteins and, 124
- Optic nerve, ganglion cell axons, 890–891
- OPTN gene mutation, amyotrophic lateral sclerosis, 805–806
- Orexins, sleep regulation, 989–990
- Organ dysfunction, peroxisomal diseases, 760–761
- Organelle traffic
 biosynthetic secretory pathway, Golgi apparatus polarization, 129
 calcium pools and, 458–461
 intracellular membrane trafficking, dynamin protein targeting, 123–124
 lysosomal storage diseases, 755–756
 microtubule tracking, 102–106, 103f, 104f, 105t, 107f
 peroxisomal diseases, 760–761
- Organic acids, aminoaciduria disorders, 738, 741t
- Ornithine transcarbamylase deficiency, 750
- Orphan receptors
 neuropeptide identification, 392
 serotonin receptor subtypes as, 320–321
- Outside-in signaling, integrins, cell adhesion molecules, 172–173, 175f

- Oxidation-phosphorylation coupling defects, 776
- Oxidative deamination, serotonin catabolic pathway, 310–311
- Oxidative phosphorylation, mitochondrial heterogeneity, 219–220
- Oxidative stress
apoptosis activation, 668
lipid peroxidation, 657
- 5-Oxoprolinase deficiency, 752, 753f
- 5-Oxoprolinuria, glutathione synthetase deficiency, 752
- Oxygen peroxide metabolism, peroxisomal diseases, 760–761
- Oxytocin, identification, 391–392, 391f
- P**
- P₀ glycoprotein, peripheral nervous system myelin, 192
- P₂ protein, peripheral nervous system myelin, 180
- p38 MAPKs, phosphorylation, 477
- p75 neurotrophin receptor, 552–553, 553f
- Pain management
adenylyl cyclase cAMP targeting, 430
brainstem, thalamus and cortex, 931–933, 932f
cannabinoids, 933–934
cGMP signaling, guanylyl cyclase receptors, 434
clinical challenges in, 938–939
dorsal horn signal transmission, 930, 931f
genetic factors, 939
histamine and, 337
inflammatory pain, 934–936, 935f
neuropathic pain, 936–939
nicotinic acetylcholine receptor targeting, 273
nociceptive *vs.* clinical pain, 928–929, 929f
nociceptor function, 929–930
opioid analgesia, 933
purinergic receptors, 387
sleep disorders and
acetylcholine, depression, and REM sleep, 988
glutamate modulation, 992–993
opioid-induced sleep disruption, adenosine and, 993–994
spinal cord transmission, 930–931
voltage-gated sodium channels, 930
- Paired helical filaments (PHF)
neurofibrillary tangles, Alzheimer's disease, 818–819
tau protein, 835
- Paracrine neurotransmission
neuropeptide receptors, 402
serotonin, 311
- Paramyotonia, congenital, 790–791
- Paranodal proteins, myelin sheath, 195
- Paraproteinemic polyneuropathy, 698
- Parenchyma, leukocyte migration, CNS immune activity, 604–605
- Parkinson's disease
animal models 863f, 862
basal ganglia involvement, 861–865
connectivity losses in, 869–870
etiology, 861–862
familial PD, SNCA gene mutations, 831, 831f
genetics, 722t, 723–725, 723t, 724t
autosomal dominant, 723
autosomal recessive, 723–724
candidate-gene studies and genome-wide screening, 724–725
mutations, 832–833
host-to-graft Lewy body spreading, 832f
neuroprotective treatment, 864–865
nicotinic acetylcholine receptor targeting, 273
pathology, 861
pathophysiology, 862–863
purinergic A_{2A} receptors, 387–388
sleep regulation and, 989
stem cell repair, 563–564
surgical therapy, 864
symptomatic drug treatment, 863–864
- Pathogen-associated molecular patterns (PAMPs)
APC function and T-cell differentiation, 602
neuroimmunology, 597
neuroinflammation, 616–617
- Pattern recognition receptors (PRRs),
neuroinflammation, 616–617
- Pelizaeus-Merzbacher disease, myelination and, 578
- Penfield studies, learning and memory, 964
- Pentameric ligand-gated ion channels
GABA_A receptors, 370–372, 372t
nicotinic acetylcholine receptors, 267–268, 268f
- Pentose phosphate shunt (PPS), brain energy metabolism, 210
- Peptides. *See also* Neuropeptides
disease mechanisms, 404–406
enzyme-based biogenesis, 394–399, 394t, 396f, 398f
as first messengers, 392
identification techniques, 392
neurotransmitter release, eukaryotic cells, 237–238
propeptide families, 399–400, 401f
receptor-mediated transcytosis, 22
structure and function, 391–392, 391f
toxins, muscle excitation alteration, 796–798
- Pericytes, blood-brain barrier, 19
- Perikaryon, 4–6, 5f
structural morphology, 6–7
- Peripheral anionic site (PAS),
acetylcholinesterase, 265, 265f
- Peripheral myelin protein-22
genetic peripheral neuropathies, 682
peripheral nervous system myelin, 192–193
- Peripheral nervous system
autoimmune neuropathies, 684–687, 686f, 686t
axon degeneration and protection, 687–688
demyelinating neuropathies, 697–699
development and target interactions, 541–542
diabetic neuropathy, 684, 685f
genetically determined neuropathies, 680–684, 681–682t
- Charcot-Marie-Tooth and hereditary
motor and sensory neuropathies, 680–684
infection-related disorders, 687
molecular motors and peripheral neuropathies, 688
muscarinic cholinergic receptor mediation, 274t
myelin
in cell membrane, 183, 187f
central nervous system myelin
comparisons, 187–188
deficiencies of, 701
peripheral neuropathies and loss of, 578
proteins in, 192–193
regeneration and remyelination, 579–580
neural crest stem cells, 560–561
neuroanatomy, 680
pain management, 934
Schwann cell myelin production, 13–15, 570, 571f, 572f
- Periventricular leukomalacia (PVL),
myelination and, 579
- Permeation pathways, ionotropic glutamate receptors, 356
- Peroxisomal diseases
biogenesis defects, 761
classification, 761–762
epidemiology and pathology, 760–761
single enzyme defects, 761–762, 762t
therapy, 762
- Peripheral neuropathies, myelin loss and, 578
- Phagocytosis
endocytic pathway, macromolecular degradation and nutrient uptake, 135–137
microglia activation, 612
microglia and, 15f, 15–16
- Pharmacological agents
ion channel function, 68–69
phosphodiesterase targeting, 438
- Phencyclidine addiction, 1050
- Phenylalanine hydroxylase, phenylketonuria and deficiency in, 743–744
- Phenylalanine metabolism, phenylketonuria and, 743–744
- Phenylethanolamine-N-methyltransferase (PNMT), norepinephrine metabolism to epinephrine, 288
- Phenylketonuria, 743–744, 743f
phenylalanine hydroxylase deficiency, 743–744
- Phosducin, G protein subunit regulation, 416
- Phosphatases
phosphoinositide dephosphorylation, 445–446
protein Ser/Thr phosphatases,
phosphorylation, 479–482, 479t
dual-specificity phosphatases, 481
protein phosphatase-1, 479–480
protein phosphatase-2A, 480
protein phosphatase-2B, 480–481
protein phosphatase-2C, 481
protein tyrosine phosphatases, 501–505, 504f
cysteine residue, 503–504
dual-specificity phosphatases, 505, 506f
RPTs 505, 504f

- Phosphatidylinositol 3-kinase, phosphoinositide synthesis, 444
- Phosphatidyl serine, protein-lipid binding, 29, 31f
- Phosphocreatine, brain energy metabolism, ATP levels, 218
- Phosphodiesterases (PDEs)
cGMP signaling, guanylyl cyclase receptors, 433
drug targeting, 438
families, 434, 435t, 436f
calcium/calmodulin-stimulated PDEs, 434–435
cGMP-regulated PDEs, 435–436
G protein-activated PDEs, retinal phototransduction, 436–437
PDEs 7, 8, and 9, 438
phosphorylation regulation, 437
transducin activation, 896f
- Phosphoenolpyruvate carboxykinase (PEPCK) deficiency, 771
- Phosphofructokinase, brain glycolysis regulation, 208
- Phosphofructokinase (PFK), glycolytic defects, 764–766
- Phosphoglycerate kinase (PGK), 771
glycolytic defects, 764–766
- Phosphoglycerate mutase (PGAM), glycolytic defects, 764–766
- Phosphoinositides
cell growth and survival, 452
cell regulation, 451–453
diacylglycerol, 449–451
protein kinase C as second messenger, 449–451, 450f
inositol lipids, 443–448, 444f
cell regulation, 451–453, 451f
Charcot-Marie-Tooth disease, 445
D-myo-inositol 1,4,5-trisphosphate, calcium liberation, 448–449, 448f
ligand-activated hydrolysis, neural tissue, 446t
phosphatase dephosphorylation, 445–446
phosphatidylinositol 3-kinase synthesis, 3'-phosphoinositides, 444
phospholipase C isozyme cleavage, 446–448, 446f, 447f
structure and metabolic function, 443–444, 443f
inositol phosphates, 448–449
metabolism and free inositol regeneration, 449, 449f
myo-inositol cell presence, 449
membrane trafficking, 451–452
- Phospholipase C (PLC) isozymes, phosphoinositide cleavage, 446–448, 446f, 446t, 447f
- Phospholipases
lipid messengers, cleavage from phospholipids, 645
phospholipases A₂
cytosolic lipid formation, 647
fatty acyl chain cleavage, phospholipids, 647
high-affinity receptors, 647–648
ischemia and seizures, arachidonic/docosahexaenoic acid release, 647
ischemia-reperfusion signaling, 654, 655f
secretory properties, 647
- Phospholipids
amphipathic molecules, 27–28, 28f
basic properties, 26–28
biological membranes, 29–36
lipid mediator pathways, 644–647
cyclooxygenases, 652–653
diacylglycerol kinases, 654
docosahexaenoic acid, 656–657
docosanoids, 657
eicosanoids, 648–649, 648f, 649f, 650f
lipid peroxidation and oxidative stress, 657
lipoxygenases, 653–654
messenger function, 645
neuroinflammation, 654–656, 655f
neurolipidomic signaling, 657–660
neuroprotectin D1, 657, 658f
phospholipase cleavage, 645
phospholipases A₂, 647–648
platelet-activating factor, 649–652, 651f
polyunsaturated fatty acyl chains, 645–646, 646f
synaptic membrane targets, 645
translational neurosciences, 659
transmembrane ion gradients, 644
membrane protein interactions, 29–31
protein arrays, 26–27
protein-lipid binding, 29, 30f
transmembrane domains, 28–29, 29f
- Phosphoprotein, tau protein as, 835
- Phosphorylase b kinase (PHK), genetic defects, 763
- Phosphorylase deficiency, 763
- Phosphorylation
cell regulation, 467–470, 468f
G protein function and, 418
human kinome, 471f
myo-inositol in cells, 449
neuronal phosphoproteins, 482–484, 483f
oxidation-phosphorylation coupling defects, 776
phosphodiesterase regulation, 437
polyglutamine repeat diseases, 849–850
protein kinases/phosphatases
antagonistic actions, 468–470, 471f
cognitive enhancement, 486–487
CREB transcription factor, 488f, 489
extrasynaptic mechanisms, 489
hereditary neuronal disorders, 474t, 489–491
neuronal functions, 481–482
postsynaptic mechanism regulation, 487–489
presynaptic mechanism regulation, 485–487, 485f
synaptic plasticity and memory functions, 484–489, 484t
protein Ser/Thr kinases, 470–479
distribution, substrate specificity and regulation, 470–473, 472f
MAPK cascade, 476–478, 476f
second messenger-dependent proteins, 473–476, 474t
second messenger-independent proteins, 476, 478–479
protein Ser/Thr phosphatases, 479–482, 479t
dual-specificity phosphatases, 481
protein phosphatase-1, 479–480
protein phosphatase-2A, 480
protein phosphatase-2B, 480–481
protein phosphatase-2C, 481
tyrosine, 493, 494f
acetylcholine receptors, 510, 510f
GABA receptors, 511
neuromuscular synapse, 509
neuronal development, 505–508, 508f
NMDA receptors, 510–511
protein tyrosine kinases, 494–501, 495f
enzyme domains, 494–498, 496f, 498f, 499f, 497t
pleiotropic receptor mutations, 507
receptor domains, 498–501, 500f
RPTK activation, 500, 500f
RPTK inactivation, 500–501, 501f
RPTK phosphorylation, 501, 502–503f
protein tyrosine phosphatases, 501–505, 504f
cysteine residue, 503–504
dual-specificity phosphatases, 505, 506f
RPTPs 505, 504f
synapse formation, 509–511
voltage-gated ion channels, 511
Phosphotyrosine binding (PTB) domain-containing signaling proteins, 498f
- Photoreceptors
downstream signaling, 897–898
organization, 892, 892f, 893f
retinal neurodegeneration, 899
rhodopsin and docosahexaenoic acid (DHA) phospholipids, 656–657
rhodopsin regeneration, 898–899
- Phototransduction
cone phototransduction, 895–897
G protein-activated phosphodiesterase, 436–437
guanylyl cyclase receptors, 432
molecular recycling, 898–899
organization, 892–894
- Pick's disease, 836
- Pilocarpin model, epilepsy, dentate granule cells, synaptic input abnormalities, 709
- Pinocytosis, endocytic pathway, macromolecular degradation and nutrient uptake, 135–137
- Plasmalemma
axonal regeneration, 585
primary plasma membrane calcium transporter, 48
sodium-potassium-adenosinetriphosphatase regulation, 45, 46f
- Plasma membrane
biosynthetic secretory pathway, *trans*-Golgi network sorting, plasma membrane proteins, 131–132
calcium homeostasis, 457–458
efflux pathways, pumps and transporters, 458
influx pathways, 458

- cholesterol and phospholipid translocation, ABCA1, 51–52
lipid composition, 31
structure, 27f
- Plasma membrane calcium transporter (PMCA), basic properties, 48
- Plasma membrane integral proteins (PMIPs), cholesterol synthesis and, 32–33
- Platelet-activating factor (PAF)
cyclooxygenase-2 transcriptional activator, 652
hippocampal kainic-acid-induced cyclooxygenase-2 expression, 654
lipid mediator pathways, 649–652, 651f
- Platelet hyperserotonemia, autism spectrum disorders, 1015–1016
- Pleckstrin-homology (PH) domain, protein-lipid binding, 29, 30f
- Pleiotropic mutations
lysosomal storage diseases, 757–760
protein tyrosine kinase phosphorylation, 507
- Plurichemical coding, peptide-based neuronal signals, 403
- Pluripotent stem cells, reprogramming and directed differentiation, 562–563
- Polar water molecules, hydrophobic lipid bilayers, 56–57
- Polygenetics, autism spectrum disorders, 1014
- Polyglutamine disease protein, 845, 847f
acetylation, 850
ataxin-1 complex, 849
ataxin-7 disruption, 849
autophagy pathway, 848f
gene silencing therapy, 850–853, 851f
misfolding and toxicity, 845–846
phosphorylation, 849–850
post-translational modification, 849
RNA toxicity, 850
transglutaminase inhibition therapy, 852–853
turnover pathways and pathogenesis, 846–849
- PolyQ-htt enzymatic aberration. *See also* Polyglutamine disease protein
Huntington disease epigenetics, 731–733
- Polyunsaturated fatty acids
ischemia-reperfusion injury, 631
phospholipid esterification, 645–646
- Pontine cholinergic neurotransmission, REM sleep and, 988
- Pontine reticular formation, GABAergic neurotransmission, sleep and wakefulness, 991
- Positron emission tomography (PET), brain energy metabolism, 223
- Postmitochondrial events, apoptosis activation, 670
- Postmortem brain studies, autism spectrum disorders, 1014
- Postsynaptic density (PSD), glutamate ionotropic/metabotropic receptors, 347, 349f
distribution, 359–360
protein activity, 360–361
- Postsynaptic mechanisms
glycinergic neurotransmission, 250–251
accessory protein mutations, receptor localization, 253–254
GlyR α 1 mutations, 253
protein phosphorylation, 487–489
- Post-translational modification
peptide diversity, 399–400
polyglutamine repeat diseases, 849
- Potassium
membrane potential, 64–65, 64f
neuronal extracellular clearance, 58
- Potassium ion channels
Andersen syndrome, 791
genetic identification, 71
G protein inward-rectifying potassium channel (GIRK), neurotransmitter receptor coupling, 412–414
inwardly rectifying channels, 71
Isaac syndrome and neuromyotonia, 794–795
multiple gene families, 76
- Prefrontal cortex
pain management, 931–933
stress and, 949–951
- Premitochondrial events, apoptosis activation, 669–670
- Presenilin 1 and 2 genes, familial Alzheimer's disease, 817
- Prestin, electromotility, 925f
- Presynaptic events
botulinum toxin alteration, 795–796
metabotropic glutamate receptor modulation, 359
protein phosphorylation, 485–487
synaptic transmission, 241–245
- Presynaptic terminal
cell adhesion molecules, synapse regulation, 176–177
synaptic vesicle trafficking, 139
- Presynaptic vesicles
glycinergic neurotransmission, glycine transporter 2 mutations, 254
neurotransmitter packaging, proton-coupled antiporters, 54
neurotransmitter uptake and storage physiology, 55
- Primary active transport (P-type) pumps
ATP-binding cassettes, 50–52
basic properties, 41–42, 41f
calcium adenosinetriphosphatases, 48
plasma membrane calcium transporter, 48
P-type copper transporters, 50
smooth endoplasmic reticulum calcium pumps, 48–50
sodium-calcium antiporters, 48
sodium-potassium-adenosinetriphosphatase, 42–48, 42f
V₀V₁ proton pumps, 50
- Prion diseases
animal diseases, 873–874
scrapie and BSE, 873–874
central nervous system pathology, 876
clinical heterogeneity, 875–876
epidemiology, 873
future research issues, 883
genetics, 730–731
host encoding, 873
human diseases, 874–876, 874f
metabolic dysfunction, 873
pathology and pathogenesis, 876–877, 876f
peripheral pathogenesis, lymphoreticular system, 876
prion strain diversity, 880–882, 881f
protein identification, 873
protein-only propagation hypothesis, 877, 877f
PrP^c
alpha-helical conformation, 877–878, 878f
knockout mice studies, 878–879
reverse genetics, 878
unknown function, 878
PrP^{Sc} characterization, 879–880, 879f
alternative conformation and infectivity, 880
beta-sheet conformation, 879
tau, amyloid-beta and synuclein aggregates, 883–884
transmission barriers, 882–883
- Prion protein
beta-sheet conformation, 879–880, 879f
gene mutations, 874–875, 874f
isoform conversions, 877
alpha-helical conformation, 877–878, 878f
polymorphism, 875
strain diversity, 880–882, 881f
transmission barriers, 882
in vitro generation and infectivity, 880
- PRNP mutations, prion disease genetics, 730
- Procedural memory, 965
- Programmed cell death, cell morphology and biochemistry, 672
- Progressive motor neuropathy (PMN), tubulin-specific chaperone mutations, 808
- Progressive multifocal leukoencephalopathy, 697
- Progressive supranuclear palsy, 836
- Progressive weakness, glucose and fatty acid metabolic disorders, 766
- Proneurotrophins, 551, 551f
- Pro-opiomelanocortin (POMC) precursor
bioactive peptide production, 394, 395f, 398f
neuropeptide derivation, 392–393, 392f
- Propeptide families, peptide diversity, 399–400
- Prostaglandin pathways
cyclooxygenase arachidonic acid conversion, prostaglandin H₂, 652
neuroinflammation, 614–615
neuron and glial cell release, 648–649, 650f
- Protectins
docosanoids, 657
lipoxygenases and, 653
- Protein, aggregation, neuroinflammation and, 613–614
- Protein kinase A (PKA)
adenylyl cyclase molecular targeting, 329
cAMP-dependent phosphorylation, 473

- Protein kinase C (PKC)
 diacylglycerol activation, 449–451, 450f
 mood disorders and, 1027
 phosphorylation, 473–475
- Protein kinase G (PKG)
 cGMP signaling, guanylyl cyclase
 receptors, 433
 phosphorylation, 473
- Protein kinases, phosphorylation
 antagonistic actions, 468–470, 471f
 calcium/calmodulin-dependent kinases,
 475–476
 casein kinase, 1, 478–479
 c-jun NH2-terminal kinases, 477–478
 CREB transcription factor, 488, 489f
 cyclin-dependent kinases, 5, 478
 extracellular signaling-regulated protein
 kinases, 477
 extrasynaptic mechanisms, 489
 genetic neuronal disorders, 489–490
 glycogen-synthase kinase-3, 478
 hereditary neuronal disorders, 474t, 489–491
 neuronal functions, 481–482
 p38 MAPKs, 477
 postsynaptic mechanism regulation, 487–489
 presynaptic mechanism regulation,
 485–487, 485f
 synaptic plasticity and memory functions,
 484–489, 484t
- Protein-only hypothesis, prion propagation,
 877, 877f
- Protein phosphatases, phosphorylation,
 genetic neuronal disorders, 489–490
- Protein-protein interactions,
 acetylcholinesterase, 266
- Proteins. *See also* Membrane proteins;
 Secretory proteins. specific
 proteins
 biosynthetic secretory pathway
 Golgi cisternae transport, 130–131, 131f
 lysosomal proteins, *trans*-Golgi network
 sorting, 132
 plasma membrane proteins, *trans*-Golgi
 network sorting, 131–132
 cytoskeleton expression
 injury and regeneration, 114
 phosphorylation, in neuropathology, 116
 fast axonal transport, molecular sorting,
 154–155
 glutamate receptor activation, 360–361
 heterotrimeric G protein modulation, 416–418
 immunoglobulin-like domain, cell
 adhesion molecules, 166, 167f
 ion channel conformation, voltage-
 dependent gating mechanisms,
 68, 69f
 lipid bilayers, 26–27
 myelin composition
 myelin-associated glycoprotein, 191–194
 myelin basic proteins, 189–190, 190f, 193
 P₀ glycoprotein, 192
 P₂ protein, 193
 peripheral and central nervous system
 myelin, 187–188
 peripheral myelin protein-22, 192–193
 peripheral nervous system proteins, 192–193
- proteolipid protein, 188–189
 sorting and transport, 575–576
 myelin sheath, 194–197
 enzymes, 195–197
 miscellaneous proteins, 197
 neurotransmitter receptors, 197
 nodal, paranodal, and juxtaparanodal
 proteins, 195
 tetraspan proteins, 194–195
 neuronal structure and function,
 schizophrenia, 1008
 neurotransmitter release, eukaryotic cells,
 237–238
 phosphorylation. *See* Phosphorylation
 protein-lipid binding, 29
 synaptic vesicle trafficking, 140–141t
- Protein Ser/Thr kinases, phosphorylation,
 470–479
 distribution, substrate specificity and
 regulation, 470–473, 472f
 MAPK cascade, 476–478, 476f
 second messenger-dependent proteins,
 473–476, 474t
 second messenger-independent proteins,
 476, 478–479
- Protein Ser/Thr phosphatases,
 phosphorylation, 479–482, 479t
 dual-specificity phosphatases, 481
 protein phosphatase-1, 479–480
 protein phosphatase-2A, 480
 protein phosphatase-2B, 480–481
 protein phosphatase-2C, 481
- Protein tyrosine kinases, phosphorylation,
 494–501, 495f
 enzyme domains, 494–498, 496f, 497t, 498f,
 499f
 nonreceptor protein tyrosine kinases, 494–498
 pleiotropic receptor mutations, 507
 receptor domains, 498–501, 500f
 RPTK activation, 500, 500f
 RPTK inactivation, 500–501, 501f
 RPTK phosphorylation, 501, 502–503f
- Protein tyrosine phosphatases,
 phosphorylation, 501–505, 504f
 cysteine residue, 503–504
 dual-specificity phosphatases, 505, 506f
 RPTPs, 504f, 505
- Proteolipid protein (PLP), central nervous
 system myelin, 188–189
- Proteolytic processing, peptide diversity,
 399–400
- Protofibrils, polyglutamine protein
 misfolding, 846
- Proton-coupled antiporters, presynaptic
 vesicles, neurotransmitter
 packaging, 54
- Proto-oncogenes, G proteins and, 420
- PSD95 scaffolding protein, glutamate
 ionotropic/metabotropic
 receptors, postsynaptic density,
 360–361
- Psychomotor stimulants, addiction,
 1043–1045, 1044f, 1046f
- Psychosine, 778–779
- Psychostimulant, sleep regulation,
 norepinephrine, 986
- P-type copper transporters, neural function
 and, 50
- Purinergic receptors, 382–384, 382f
 adenosine subtypes, 382, 382t
 A₁ receptors, 383, 383f
 A_{2A} receptors, 383, 383f
 Parkinson's disease and antagonists of,
 387–388
 A_{2B} receptors, 384
 A₃ receptors, 384
 P₂ receptors, 384
 ionotropic receptors, 384
 nervous system disorders, 387–388
 pain management, 387
- Purines
 alcohol effects, 387
 astrocyte-mediated, adenosine-dependent
 heterosynaptic depression, 385
 ATP-adenosine, 384–385
 glial-derived ATP and adenosine,
 respiration and sleep, 385–386
 microglial injury response, 386, 386f
 myelination and axonal ATP release, 385
 nervous system effects, 384–387
 neurological disease and, 387
 nomenclature, 377, 378f
 pain management, 387
 pH-dependent astrocyte release, breathing
 control, 386
 release, 377–382
 release and metabolism, 378f
 extracellular adenosine sources, 379–380,
 380f
 extracellular nucleotide regulation, 379
 inherited diseases, 381
- Pyridoxine
 dependency disorder, 753
 sulfur amino acid metabolism disorders,
 747
- Pyrimidines, nomenclature, 377, 378f
- Pyruvate, brain energy metabolism
 astrocytic carboxylation, 218
 glucose conversion to (glycolysis), 207–209
 glycolysis production, 208–209
 lactate-pyruvate interconversion, 211
 pyruvate-lactate compartmentation, 214
- Pyruvate carboxylase deficiency, 771–772
- Pyruvate dehydrogenase complex,
 tricarboxylic acid cycle, 217
- ## Q
- Q/R site, glutamate receptors, 354–356, 356f
- Quantal analysis, synaptic transmission
 exocytosis, 239, 242f
- Quinoxalinediones, AMPA/kainate receptor
 blockade, 350
- ## R
- Rab proteins
 hereditary sensory-motor neuropathy and,
 421
 intracellular membrane trafficking, target
 membrane recognition, 125
 membrane vesicle trafficking, 419, 419f
- Radial glia stem cells, 560, 560f
- Rapid eye movement (REM) sleep

- acetylcholine and, 987–988
 depression, and pain and, 988
 cholinergic neurotransmission, 988
 dopamine and, 988–989
 neurochemical substrates, 983
 Rapsyn deficiency, 790
 Ras protein family, small G protein
 characterization, 418–419
 Reactive oxygen species (ROS), ischemia-
 reperfusion injury, 629
 excitotoxic and apoptotic consequences, 631
 sources of, 631
 Readily releasable pool (RRP), synaptic
 transmission, presynaptic events,
 244
 Real-time memory visualization, 974, 976f
 Receptor-mediated endocytosis (RME),
 endocytic pathway, clathrin-coat-
 dependent process, 137–139, 138f
 Receptor-mediated signaling, cell signaling
 mechanisms, 246
 Receptor-mediated transcytosis (RMT),
 peptide and signaling molecule
 transport, 22
 Receptor protein tyrosine kinase (RPTK)
 activation, 500, 500f
 ErbB family, neuromuscular synapse, 509
 extracellular, single transmission and
 cytoplasmic domains, 498–501
 GFL receptors, 554–555
 inactivation, 500–501
 pleiotropic mutations, 507
 structure, 495f
 Trk receptors, 552
 tyrosine phosphorylation, 501, 501f,
 502–503f
 Receptor protein tyrosine phosphatases
 (RPTPs), structure, 504f
 Receptor tyrosine kinases (RTKs), molecular
 signaling mechanisms, cell surface
 receptors, 248
 Redox signaling, superoxide dismutase type
 1 mutations, 810
 Reelin signaling, neurogenic development, 539
 Refractory status epilepticus, GABA receptor
 endocytosis, 373
 Regeneration
 axonal growth and, 582–583, 583f
 central nervous system, 451f, 585–590
 axon growth, glial scar inhibition, 589–590
 knockout studies, *nogo* gene development,
 588
 myelin components, 588–589
 neurite growth inhibition, 589
 neurotrophic factors, 590
 Nogo-A inhibitor, 586, 587f, 588, 589
 reticulin superfamily, 587–588
 spinal cord injury, fiber growth and
 regeneration, 592
 cytoskeletal protein expression, 114
 peripheral nervous system, 583–585
 Regulated secretory pathway
 neuronal secretory cells, 133f, 134
 synaptic transmission, neuroendocrine
 definition, 245
 Remyelination, 579–580
 multiple sclerosis, 702
 therapeutic targeting of, 703
 Reperfusion damage
 free radicals, ischemia-reperfusion injury,
 629–631
 reactive oxygen species, 629
 ischemia, phospholipase A₂ signaling, 654,
 655f
 neuroinflammation, ischemia and, 616
 neuroprotectin D1 inhibition, 657
 Resolvin pathway
 docosanoids, 657
 lipoxygenases, 653
 neuroinflammation, 616
 Respiration
 ATP-adenosine signaling, glial cells, 385–386
 pH-dependent purine release, astrocyte
 control, 386
 Respiratory chain abnormalities, 776
 coenzyme Q1₀ deficiency, 777
 complex I, 776–777
 complex II, 777
 complex III, 777
 complex IV, 777–778
 complex V, 778
 Restless legs syndrome, 989
 Reticulon superfamily, axonal regeneration,
 nogo gene, 587–588
 Retina
 anatomy, 890f
 neurodegeneration, 899–900
 molecule-directed therapies, 900
 neuronal sublayers, 890, 891f
 Retinal phototransduction, G protein-
 activated phosphodiesterase,
 436–437
 Retinal pigmented epithelium (RPE), rhodopsin
 regeneration, 898–899, 898f
 Retinal tissue, docosahexaenoic acid (DHA)
 pathways, 656
 Retinoid recycling, rhodopsin regeneration,
 898–899, 898f
 Ret receptor tyrosine kinase, GFL receptors,
 554–555
 Retrograde amnesia, memory consolidation
 and, 971
 Retrograde axonal transport, fast transport,
 trophic factors, exogenous
 material and membrane
 constituents, 153–154
 Reverse genetics, prion protein analysis, 878
 Reward circuitry, opioid system, 1043
 RGD amino acid sequence, integrin receptors,
 cell adhesion, extracellular matrix
 proteins, 170–172
 RGS protein
 cognitive dysfunction and, 420
 heterotrimeric G protein modulation,
 416–417, 417f
 Rhabdomyolysis, phosphorylase deficiency, 763
 Rheb protein, tuberous sclerosis and, 421
 Rhodopsin
 calcium ion channel mediation, 894–895
 conformational activation, 894f
 docosahexaenoic acid (DHA) pathways
 and phospholipids, 656–657
 phototransduction, 898–899
 Ribonuclear inclusions, myotonic dystrophy,
 791–792
 RNA editing, glutamate receptor
 heterogeneity, 354–356
 RNA interference (RNAi), polyglutamine
 repeat diseases, 850–851
 RNA metabolism, amyotrophic lateral
 sclerosis, 804–805
 RNA polymerase II, transcription and, 516
 RNA toxicity, polyglutamine repeat diseases,
 850
 Rodent mutant studies, myelination and
 genetic disease, 576–577, 577t
 Rostrocaudal axis, central nervous system
 development, 535–538
 Rough endoplasmic reticulum (RER),
 biosynthetic secretory pathway,
 membrane-associated polysomes,
 126–127
 Ryanodine receptor, calcium release channels,
 malignant hyperthermia, 792–793
- ## S
- S-adenosylmethionine (SAM), methyl group
 transfer, neurodegenerative
 disease epigenetics, 731–733
 Saltatory conduction, myelin facilitation,
 180–181, 181f
 Sandhoff disease, 759–760
 Sarcoplasmic reticulum, smooth endoplasmic
 reticulum calcium pump, 48
 Sarcoplasmic reticulum calcium ATPase,
 Brody disease and, 793
 SCC8 gene family, anion antiporters, 56
 Schizophrenia
 atypical antipsychotic drugs, 1001–1002
 brain imaging, 1003–1004
 cellular and molecular studies, 1004–1009,
 1006f
 cholinergic agonists and antagonists, 1008
 clinical aspects, 1000–1003
 corticolimbic abnormalities, 1003–1004
 dopamine hypothesis, 1004–1005
 GABAergic neurons and, 1007–1008
 genetics, 1001, 1009–1010
 glial cells, 1008–1009
 intracellular signaling, 1008
 NMDA receptor hypofunction, 1005–1007
 symptom clusters, 1001
 Schmidt-Lanterman clefts, myelin
 ultrastructure, 183, 184f
 Schwann cell
 axonal regeneration, 584
 myelination and development of, 570, 571f
 myelin production, peripheral nervous
 system, 13–15, 14f
SCN1A gene mutations, epilepsy genetics,
 713
 Scrapie, prion protein dysfunction, 873–874
 Secondary active transport, 52–55
 carboxylic-acid transporters, 53
 choline transporter, 54
 glutamate symporters, SLC1 proteins, 53
 neurotransmitter sodium symporters, 52,
 53f

- Secondary active transport (*Continued*)
 proton-couple antiporters, 54
 SLC6 symporter subfamily, 52–53
 sodium-dependent D-glucose symporter,
 brain capillary endothelial cell
 and neuron expression, 52
- Second messenger system
 addiction, cyclic AMP upregulation and,
 1042–1043
 diacylglycerol, 449–451
 G protein regulation, intracellular
 signaling, 414–415
 inositol lipids, cell regulation, 451–453
 inositol phosphates, 448–449
 mechanisms, 423, 424f
 odorant recognition, 907–908, 908f
 protein Ser/Thr kinases, 472f, 473–476, 474t
- Secretory proteins
 axonal transport, fast transport 151–152,
 150f, 151f, 152f
 Golgi complex sorting and glycosylation,
 biosynthetic secretory pathway,
 129–130
- Secretory vesicles
 biogenesis, 134–135
 neurotransmitter release, eukaryotic cells,
 237–238, 237f
 synaptic vesicle trafficking, presynaptic
 terminal, 139
- Seizure disorders. *See also* Epilepsy
 hereditary folate malabsorption, 749
 lipid mediator pathways, platelet-
 activating factor, 651f, 652
 membrane lipid breakdown, 654–655
 nonketotic hyperglycinemia, 744–745
 phospholipases A₂, arachidonic/
 docosahexaenoic acid release, 647
 phospholipid targeting, synaptic
 membranes, 645
- Self-renewing stem cells, 558–559
- Semantic memory, 965
- Semilunar ganglion, pain management, 929
- Semiochemical detection, vomeronasal organ,
 910
- Serine
 AQP4 regulation, serine phosphorylation, 58
 glycine precursor, 250
 nonketotic hyperglycinemia and, 744
 phosphorylation
 cell regulation, 467–470, 468f
 G protein function and, 418
 human kinome, 471f
 myo-inositol in cells, 449
 neuronal phosphoproteins, 482–484, 483f
 phosphodiesterase regulation, 437
 protein kinases/phosphatases
 antagonistic actions, 468–470, 471f
 CREB transcription factor, 488f, 489
 extrasynaptic mechanisms, 489
 hereditary neuronal disorders, 474t,
 489–491
 neuronal functions, 481–482
 postsynaptic mechanism regulation,
 487–489
 presynaptic mechanism regulation,
 485–487, 485f
- synaptic plasticity and memory
 functions, 484–489, 484t
- protein Ser/Thr kinases, 470–479
 distribution, substrate specificity and
 regulation, 470–473, 472f
 MAPK cascade, 476–478, 476f
 second messenger-dependent proteins,
 473–476, 474t
 second messenger-independent proteins,
 476, 478–479
- protein Ser/Thr phosphatases, 479–482,
 479t
 dual-specificity phosphatases, 481
 protein phosphatase-1, 479–480
 protein phosphatase-2A, 480
 protein phosphatase-2B, 480–481
 protein phosphatase-2C, 481
- Serotonergic system
 anxiety disorders, 1031
 mood disorders, 1022–1023
- Serotonin
 amino acid L-tryptophan precursor, 304–
 306, 305f
 autism spectrum disorders, 1015–1016
 behavioral arousal/activity, 311–312
 chemical structure, 301f
 circadian rhythm modulation, 312
 feeding behavior and food intake, 312–313
 indolealkylamine 5-hydroxytryptamine
 identification, 301
 monoamine oxidase oxidative
 deamination, catabolic pathway
 regulation, 310–311
 neuroanatomical organization, 301–304,
 302f, 302t, 303f, 304f
 neuroendocrine function, 312
 receptors, 313–321
 5-HT_{1P} receptor, 320–321
 5-HT₁ subfamily, 314–317, 315t
 5-HT_{1A} receptor, 314
 5-HT_{1B} receptor, 316–317
 5-HT_{1D} receptor, 316–317
 5-HT_{1E} receptor, 317
 5-HT_{1F} receptor, 317
 5-HT₂ subfamily, 317–318
 5-HT_{2A} receptor, 317–318
 5-HT_{2B} receptor, 318
 5-HT_{2C} receptor, 318
 5-HT₃ receptor, as ligand-gated ion
 channel, 318–319
 5-HT₄ receptor, 319–320
 5-HT₅ receptor, 320–321
 5-HT₆ receptor, 320
 5-HT₇ receptor, 320
 mental illness and 5-HT_{1A}, 316
 subtype definition, 313–314
 subtype research, 314
 serotonin transporter, acute and chronic
 regulation, 309–310
 sleep regulation, 986–987
 synapse termination, 308–309, 310f
 synthesis conditions, 306
 vesicle storage and exocytotic release,
 306–308, 307f, 308f
 volume and paracrine neurotransmission,
 311
- Serotonin transporter (SERT)
 acute and chronic regulation, 309–310
 drug inhibition, 307, 308f
 psychomotor stimulant addiction,
 1043–1044
 synapse termination, 308–309
- 17kDA tetraspan protein, myelin sheath, 194
- Short-term memory, 965
- Signaling mechanisms
 energy requirements, 201–202
 histamine receptors, 334f
 neuropeptides, 403
 psychomotor stimulant addiction,
 dopamine receptors, 1045
 tau protein scaffolds, 840
- Signaling microdomains, sodium-potassium-
 adenosinetriphosphatase
 scaffolds, 48
- Signaling molecules
 pain management, 934
 receptor-mediated transcytosis, 22
- Signal recognition particle (SRP), biosynthetic
 secretory pathway, endoplasmic
 reticulum membrane, 122f, 126
- Signal transduction
 histamine H₄ receptor, 334–335
 myelin sheaths, 577–578
 protein phosphorylation cascades, 469f
 TrkB/BDNF-mediated neuronal survival
 and differentiation, 502–503f
- SLC1A1-4 gene, glutamate symporters, 53–54
- SLC1A6 gene, glutamate symporters, 53–54
- SLC1 proteins, glutamate symporters, 53
- SLC6 symporter subfamily, amino acid
 transmitters and biogenic amines,
 52–53
- SLC25A12 gene mutation, N-acetylaspartate
 formation, myelination and brain
 function, 212–213, 212f
- Sleep disorders
 depression and, 987
 GABAergic neurotransmission, 991
 hypocretins and, 990
 insomnia, 995–996
 medicine and neurobiology, 984–986
 pain and, opioid-induced sleep disruption,
 adenosine and, 993–994
 restless legs syndrome, 989
- Sleep regulation
 adenosine, 993–994
 amino acids, 990–993
 ATP-adenosine signaling, glial cells, 385–386
 brain energy metabolism, 983f
 dopamine and, 988–989
 functions, 983–984, 983f
 future research issues, 994, 994f
 glutamate neurotransmission and, 991–992
 histamine, 987
 hypocretins/orexins, 989–990
 monoamines, 986–987
 neurochemical substrates, 983–986
 neurotransmitters, 984, 985f
 norepinephrine, 986
 Parkinson's disease, 989
 serotonin, 986–987
 stress and

- Sleep-wake cycles, histamine and, 337, 338
- Slow channel syndrome, 790
- Slow component a (SCa), slow axonal transport, 155
- Slow component b (SCb), slow axonal transport, 155
- Slow potentials, excitable cell electrical signals, 65–66
- Small G proteins, 418–419, 418t
- Rab family, 419, 419f
- Ras proteins, 418–419
- Smell. *See* Olfaction
- Smooth endoplasmic reticulum (SER), biosynthetic secretory pathway
- membrane-associated polysomes, 126–127
- protein folding, covalent sugar addition, 126, 127t
- Smooth endoplasmic reticulum calcium (SERCA) pumps
- basic properties, 48–50
- sarcoplasmic reticulum, 48
- structural data, 48–50
- Smooth muscle, serotonin effects, 301
- Snake venom, muscle excitation alteration, 796–798
- SNARES. *See* Soluble N-ethyl-maleimide sulphydryl factor attachment protein receptors
- SNCA gene mutation, familial Parkinson's disease, 831
- Social communication, olfaction and, 909–910
- Sodium-calcium antiporters, 48
- sodium-potassium-adenosinetriphosphatase subunits, 55, 56f
- Sodium-dependent D-glucose symporter
- brain capillary endothelial cell and neuron expression, 52
- glutamate clearance, 361–362
- Sodium-dependent glutamine transporters, astrocyte to neuron glutamine transfer, 362
- Sodium-hydro-carbon symporter, intracellular pH in brain, 56
- Sodium-hydrogen antiporter, intracellular pH in brain, 56
- Sodium ion channel
- epileptic anti-seizure drugs, 711, 711f
- FMRF-amide-gated sodium ion channel, peptide expression, 402
- hyperkalemic periodic paralysis and congenital paramyotonia, 790–791
- neurotoxin labeling and cDNA cloning, 69–71, 70f
- at Nodes of Ranvier, 67
- pain management, 930
- single gene family, 75
- Sodium-potassium-adenosinetriphosphatase (Na,K-ATPase)
- cardiotonic steroid signal receptors, 46–48, 47f
- catalytic subunits, molecular structure, 43, 44f
- cerebral energy production, 45
- development, aging and dementia patterns in, 45
- heterodimer structure, 43
- mechanisms, 42–43, 42f
- plasmalemma regulation, 45, 46f
- signaling microdomain scaffolds, 48
- sodium-calcium antiporters and calcium pumps, 55, 56f
- trafficking regulatory factors, 46
- Sodium pump, catalytic gamma subunits, 44–45
- Soluble adenylyl cyclase, expression and regulation, 328
- Soluble guanylyl cyclases, 432–433
- Soluble N-ethyl-maleimide sulphydryl factor attachment protein receptors
- intracellular membrane trafficking, target membrane recognition, 125
- neurotransmission exocytosis, synaptic vesicle trafficking, 139–142
- Spastin, microtubule organization, 106
- Spatiotemporal integration, cyclic nucleotides, 438–439
- Spectrin
- neuronal and glial morphologies, 109
- protein-lipid binding, 29, 30f
- Spectrin-ankyrin network
- brain injury pathology and, 37
- membrane-organizing cytoskeleton and, 34–35, 35f
- Sphingolipids, long-chain aminodiol sphingosine backbone, 85–89, 89f
- Spinal cord, pain transmission, 930–931
- Spinal cord canal, ependymal cells in, 16, 16f
- Spinal cord imaging, glycine receptor distribution, 252
- Spinal cord injury, fiber growth and regeneration, 592
- Spinal interneurons, nociceptive pain, 930–931
- Spinal nerves, pain management, 929
- Spinocerebellar ataxias
- ataxin-1 protein association, 849
- ataxin-7 protein transcription, 849
- Splice variants, glutamate receptor heterogeneity, 354–356
- Spreading depression, brain injury, ischemic phase, 627
- Src family, tyrosine kinase structure, 499f
- Startle disease, molecular genetics and pathophysiology, 253
- Stathmin, microtubule organization, 106
- Status epilepticus model, temporal lobe epilepsy, 708
- Stem cell potential, transcription factor ectopic expression, 527–528, 527f
- Stem cells
- antigenic and functional identification, 561–563
- nervous system markers, 561, 562t
- neurosphere functional assay, 561–562, 562f
- brain neoplasms, 562
- cell replacement therapy, 564–565
- dysmyelinating diseases, 565
- embryonic stem cells, 559
- growth factors and guidance cues in, 565–566
- hematopoietic stem cells, 559f, 559
- induced pluripotent cell reprogramming and differentiation, 562–563
- leukodystrophies, enzyme/protein replacement, 564
- multiple sclerosis, immunomodulation, 566
- multipotent and self-renewing, 558–559
- in nervous system, 558
- nervous system repair, 563–567
- neural stem cells, 560, 560f, 561f
- neuron and glial development, 559–561
- Parkinson's disease, neurochemical replacement, 563–564
- peripheral nervous system, neural crest stem cells, 560–561
- radial glial stem cells, 560
- therapeutic applications, 566–567
- Stereocilia actin, hair cell molecules, 921–923
- Stereotyped action potentials, excitable cell electrical signals, 65–66
- Store-operated channels (SOC), calcium ions, 457f
- endoplasmic reticulum signaling, 460
- Stress
- anxiety disorders, 1032
- autism spectrum disorders, response systems, 1015
- brain function, 945–946, 947f
- allostasis and allostatic overload, 951
- behavioral effects, 950–951
- future research issues, 953–954
- hippocampus, 946–947
- modern life factors, 951–953
- neurogenesis and, 959–960
- prefrontal cortex and amygdala, 949–951
- research and definitions, 946–947
- sleep and circadian rhythms and stress axis, 946
- stress hormones, 946
- mood disorders and, 1026
- sleep regulation, norepinephrine, 986
- Stress hormones, brain function and, 946
- Stroke penumbra
- docosanoid protection, 635–638
- focal cerebral ischemia, 622–623, 622f, 623f, 624f, 625f, 626f
- microglial sensors, 618
- translational targeting, 639, 639f
- Structural compensatory plasticity, neonatal brain damage, 590
- [³H]Strychnine, glycine receptor distribution, 252
- Subacute sclerosing panencephalitis, immune functions and, 607
- Substance P
- anxiety disorders, 1033
- gene splicing, 399–400, 401f
- mood disorders, 1025
- neuropeptide receptors, 400–401
- Substantia nigra, Parkinson's disease, 831f
- Substrates
- brain energy metabolism, 203–204, 219–220
- mitochondrial disease, utilization defects, 775–776
- protein phosphorylation, kinase/phosphatase antagonism, 468–470

- Succinic semialdehyde dehydrogenase deficiency, 753
- Sulfur amino acid metabolism disorders, 745–749, 746f
- Sumoylation, polyglutamine repeat diseases, 850
- Superoxide dismutase, type 1 mutations
amyotrophic lateral sclerosis, 803, 807
molecular mechanisms, 808–809
redox signaling and, 810
transgenic mice studies, 809
wild-type SOD1 misfolding, familial
amyotrophic lateral sclerosis,
809–811
- Supply-demand relationships, brain energy metabolism, 205–207
- Synapses
cell adhesion molecules, cooperative regulation, 175–177, 176f, 177f
glutamate symporter failure, 54
nervous system development and formation of, 543, 544f
structure and function, 10–11, 10f
tyrosine phosphorylation, 509–511
- Synaptic clefts, neurotransmitter recovery, neurotransmitter sodium symporters, 52, 53f
- Synaptic membranes, phospholipid targeting, 645
- Synaptic plasticity
addiction and, 1051–1052
adenylyl cyclase molecular targeting, 330–331
apoptosis and caspase and, 675
cannabinoid addiction, 1046–1047
cGMP signaling, guanylyl cyclase receptors, 434
cyclooxygenase-2 participation, 652–653
learning mechanisms, Hebb's rule, 965–966
long-term depression and receptor-independent forms, 968
protein phosphorylation 484–489, 479t
- Synaptic transmission, 235–245
calcium ions, role in, 239–241, 243f
chemical transmission between nerve cells, 235–237, 236f
- epilepsy
antiseizure drugs, GABA-mediated inhibition, 711–712, 712f
axonal/dendritic sprouting, excitatory synaptic transmission, 709
inhibitory/excitatory synaptic input abnormalities, 709
exocytosis research, 237f, 238
quantal analysis, 239, 242f
glycinergic neurotransmission and neurologic disease, 250–255
glycine biochemistry and transport, 250
glycine receptor distribution, 252–253
glycine receptor structure and function, 251–252
H⁺-dependent vesicular transporter, 250
ligand-gated chloride channel, glycine inhibition, 250–251
postsynaptic effects and pharmacology, 250–251
- postsynaptic gene mutations, 253–254
presynaptic glycine transporter 2 mutation, 254
startle disease molecular genetics, 253
inhibitory/excitatory disruption, epilepsy, 706–708, 707f
- metabotropic glutamate, 358–359
neuroendocrine cells, regulated secretory pathway, 245
neuromuscular junction, 238–239, 240–241f
neurotransmitter release, eukaryotic cells, 237–238
neurotransmitter replenishment, vesicle recycling, 245
presynaptic events, 241–245, 243f, 244f
- Synaptic vesicles
acetylcholine packaging, 261–262
anterograde fast axonal transport, 153
axonal transport and neurodegeneration, 161
catecholamine release, 288
catecholamine storage, 288
glutamate accumulation, 346
intracellular membrane trafficking, 139–144
future research issues 143f, 142
life cycle, 141f
neurotransmission exocytosis, 139–142
neurotransmission release 143f, 142
presynaptic terminal organization, secretion/recycling optimization, 139, 140–141t
protein phosphorylation, 450f
- Synaptosomes, brain energy metabolism assays, 226
- Synucleinopathies
animal models, 833–834
diseases, 830t
future research issues, 834
research background, 829–830
- Synucleins
 α -synuclein
pathology, 832
synthetic filaments, 833, 833f
classification, 830, 831f
lipid-binding proteins, 830–831
multiple system atrophy, 833
Parkinson's and Lewy body diseases, 831–833, 831f, 832f, 833f
seeding and transmissibility, 883–884
- ## T
- Tachykinins, 391–392, 391f
- Tardive syndromes, drug therapies, basal ganglia disorders, 868
- Taste, olfaction mechanisms, 911–914, 912f
cranial nerves, 912
G-protein-coupled receptors, 912–913
G-protein-coupled signaling cascade, 913–914
ion channel interaction, salts and acids, 914
receptor cells, 912
- Tauopathies
animal models, 838–841, 838f
diseases, 830t
FTD mutations, 836, 837f
future research issues, 841
MAPT mutations, 836–837
- missense mutations, 837–838, 838f
progressive supranuclear palsy, corticobasal degeneration and Pick's disease, 836
research background, 829–830
transgenic mouse models, 820–821
- Tau protein
Alzheimer's disease, 835–836
neurofibrillary tangles, 818–819
transgenic mouse models, tauopathies, 820–821
axonal and dendritic cytoskeleton organization, 111
cytoskeleton alterations and, 114
frontotemporal dementia genetics
tau-negative FTLD, 726–727
tau-positive FTLD, 726
hyperphosphorylation, filamentous tau, 835–836
isoforms, in brain, 834–835, 835f
microtubule association, 834–835
paired helical filament, 835
pathological development, 836
phosphoprotein chemistry, 835
seeding and transmissibility, 883–884
signaling molecule scaffolds, 840
synthetic filaments, 838, 839f
- Tay-Sachs disease, 759–760
- T-cell activation
CNS immune activity, microglia ineffectivity, 606
major histocompatibility complex, neuroimmunology, 599–601, 600f
PAMP and DAMP signals, 602
- TDP-43 gene, amyotrophic lateral sclerosis, 804–805
- Temporal lobe epilepsy (TLE), kindling model, 708
- Temporal lobe system, memory function and, 964–965, 964f
- Temporal specificity, learning and synaptic plasticity, 966
- Tetraspan proteins, myelin sheath, 194–195
- Thalamus, pain management, 931–933
- Therapeutic targeting
myelin formation and stability, 701–702
nicotinic acetylcholine receptors, 273–274
- Threonine, phosphorylation
cell regulation, 467–470, 468f
G protein function and, 418
human kinome, 471f
myo-inositol in cells, 449
neuronal phosphoproteins, 482–484, 483f
phosphodiesterase regulation, 437
protein kinases/phosphatases
antagonistic actions, 468–470, 471f
CREB transcription factor, 488f, 489
extrasynaptic mechanisms, 489
hereditary neuronal disorders, 474t, 489–491
neuronal functions, 481–482
postsynaptic mechanism regulation, 487–489
presynaptic mechanism regulation, 485–487, 485f
synaptic plasticity and memory functions, 484–489, 484t
protein Ser/Thr kinases, 470–479

- distribution, substrate specificity and regulation, 470–473, 472f
- MAPK cascade, 476–478, 476f
- second messenger-dependent proteins, 473–476, 474t
- second messenger-independent proteins, 476, 478–479
- protein Ser/Thr phosphatases, 479–482, 479t
- dual-specificity phosphatases, 481
- protein phosphatase-1, 479–480
- protein phosphatase-2A, 480
- protein phosphatase-2B, 480–481
- protein phosphatase-2C, 481
- Thromboses, homocystinuria and risk of, 747
- Thyroid axis, mood disorders, 1024–1025
- Thyroid diseases, peripheral neuropathy, 684
- Tight junctions (TJ)
- central nervous system homeostasis, 16–17
 - cerebral capillaries, 18
 - spectrin-ankyrin network, cytoskeleton, 34–35
- Tissue injury, pain management, 934
- Toll-like receptors, neuroinflammation, 612–613
- Toxicology
- acetylcholinesterase inhibitors, 265–266, 266f
 - ADP-ribosylation, G protein modification, bacterial toxins, 419–420
 - calcium signaling and ischemia, 464
 - demyelination, animal studies, 697
 - motor neuron disease
 - copper oxidative toxicity, 809
 - SOD1 mutations, 808
 - myelin formation and stability, 701–702
 - peripheral neuropathies, 687
- Toxoplasmosis gondii*, neuroimmunology, 598–599
- Transcription
- chromatin immunoprecipitation assay, 518–520, 521f
 - co-regulators, chromatin modulation, 516
 - gene expression, 516f
 - histone acetylation, 516, 517f
 - histone and DNA methylation, 517–518
 - Huntington's disease and, 519
 - process, 514–518, 515f, 516f
 - transcription factor regulation, 518–521
- Transcription factors
- addiction and, 1051
 - cAMP regulation, 524–527, 524f, 525f, 526f
 - response element-binding protein, 525
 - transgenic organisms, 525–526
 - cellular phenotyping, 527–528, 527f
 - transcriptome regulation, 528
 - corticosteroid receptors, 522, 522f
 - drug development and targeting, 528–529
 - ectopic expression, 527–528
 - glucocorticoid/mineralocorticoid receptors, 521–524, 523f
 - NextGen sequencing, 520–521
 - oligodendrocyte specification and differentiation, 571–572
 - structure, 520f
 - transcription regulation, 518–521
- Transcriptome, cellular phenotype, 528
- Transducin
- conformational activation, 895f, 896f
 - identification of, 412
 - signal transduction mediation, 414
- Transforming growth factor- β 1, neuroinflammation and, 614
- Transgenic mice
- Alzheimer's disease models, 820–821
 - novel therapy development, 822–823
 - familial amyotrophic lateral sclerosis, dynactin p150^{Glued}, 808
 - learning research, 970f
 - motor neuron disease models, 807
 - NF gene mutations, 808
 - tubulin-specific chaperone mutations, 808
 - muscarinic cholinergic receptor, *in vivo* subtype assessment, 277–278
 - nicotinic acetylcholine receptor research, 271–272
 - tauopathy models, 838–841, 838f, 839f
- Transglutaminase inhibition, polyglutamine repeat disease therapy, 852–853
- Trans-Golgi network
- biosynthetic secretory pathway
 - lysosomal protein sorting, 132
 - organelle polarization, 129
 - plasma membrane protein sorting, 131–132
 - protein and lipid transport, 130–131, 131f
 - intracellular trafficking convergence, lysosomal convergence, 132
 - secretory vesicle biogenesis, 134–135
- Translation neuroscience, mediator lipidomics, 659, 659f
- Transmembrane domains (TMDs)
- cholesterol synthesis and, 32–33
 - intracellular signaling, 29, 30f
 - membrane proteins, 28–29, 29f
 - neuropeptide receptors, 400–401, 401f
 - receptor protein tyrosine kinase, 498–501
 - receptor protein tyrosine phosphatases, 505
- Transmembrane signaling, heterotrimeric G proteins, 411–412
- Transmembrane topology
- glutamate receptors, 354
 - guanylyl cyclases, 431–432, 431f
- Transmissible mink encephalopathy, 874
- Transport vesicles
- intracellular membrane trafficking, 120
 - budding process, 65
 - cargo unloading, membrane fusion, 125
 - dynamain protein targeting, 123–124
 - membrane potential production, 65
- Transsulfuration pathway, sulfur amino acid metabolism disorders, 745–746
- Trauma, necrosis and, 672
- Tricarboxylic acid (TCA) cycle
- brain energy metabolism, 215–219, 216f
 - acetyl coenzyme formation, 218–219
 - astrocytic pyruvate carboxylation, 218
 - ATP regulation, 217–218
 - citrate multifunctionality, astrocytic synthesis and release, 218
 - cycle rate, 217
 - electron transport chain, ATP production, 217
- glutamate-glutamine metabolism, 220
- malate dehydrogenase, in cytoplasm and mitochondria, 217
- mitochondrial heterogeneity, 219–220
- multifunctionality, 215–217
- phosphocreatine, ATP regulation, 218
- pyruvate dehydrogenase complex, glucose oxidation, 217
- glutamate derivation, 343–344, 344f, 345–346
- Trigeminal nerve, pain management, 929
- Tripartite synapse
- gliotransmitter and modulation, calcium signaling, 462–463, 463f
 - schizophrenia and, 1006f
- Triplet repeat neurodegenerative disorders, genetics, 729–730
- Trk receptors, 552, 552f
- Trophic factors
- acetylcholinesterase, 266
 - retrograde axonal transport, 153–154
- L-Tryptophan, serotonin precursor, 304–306
- TUBB3 syndromes
- congenital fibrosis of extraocular muscles 3, 115
 - microtubule organization, 104–105
- Tuberomammillary region, hypothalamus, histaminergic fibers, 324, 326f
- Tuberous sclerosis
- G proteins and, 421
 - nervous system development, 540
- β -III Tubulin mutations. *See also* TUBB3 syndromes
- congenital fibrosis of extraocular muscles 3, 115
- Tubulin mutations
- neurological disease, 115
 - tubulin-specific chaperone E mutations, 808
- Tubulin-specific chaperone E (TBCE), microtubule organization, 104–105
- Tyrosine, phosphorylation, 493, 494f
- acetylcholine receptors, 510, 510f
 - GABA receptors, 511
 - neuromuscular synapse, 509
 - neuronal development, 505–508, 508f
 - NMDA receptors, 510–511
 - protein tyrosine kinases, 494–501, 495f
 - enzyme domains, 494–498, 496f, 497t, 498f, 499f
 - pleiotropic receptor mutations, 507
 - receptor domains, 498–501, 500f
 - RPTK activation, 500, 500f
 - RPTK inactivation, 500–501, 501f
 - RPTK phosphorylation, 501, 502–503f
 - protein tyrosine phosphatases, 501–505, 504f
 - cysteine residue, 503–504
 - dual-specificity phosphatases, 505, 506f
 - RPTPs, 504f, 505
 - synapse formation, 509–511
 - voltage-gated ion channels, 511
- Tyrosine hydroxylase
- catecholamine regulation, 284–285, 285f
 - protein phosphoregulation, 483, 483f

U

- Ubiquitin-proteasome system, polyglutamine protein turnover, 846–847
- Urea cycle defects, 749–752, 749f cognition and, 752
- Uremia, peripheral neuropathy, 684

V

- V₀V₁ proton pumps, Golgi-derived organelles, 50, 50f
- Valosin-containing protein (VCP), amyotrophic lateral sclerosis, 806
- Varenicline, nicotine addiction, 273–274
- Vascular endothelial growth factor, blood vessel growth and permeability, 808
- Vascular permeability, A_{2B} receptor regulation, 384
- Vasculitic neuropathies, 684–687
- Vasopressin
 - diabetes insipidus and, 404
 - identification, 390–391
- Ventral tegmental area (VTA)
 - alcohol addiction and, 1049
 - nicotine addiction, 1048–1049
- Vesicle-associated protein-binding protein (VAPB), familial amyotrophic lateral sclerosis, 804
- Vesicle coating, intracellular membrane trafficking, transport vesicles, 65
- Vesicle recycling
 - catecholamine release, 288
 - synaptic transmission, neurotransmitter replenishment, 245
- Vesicle storage, serotonin, exocytotic release and, 306–308, 307f, 308f
- Vesicular acetylcholine transporter (VACHT), synaptic vesicles, 261

- Vesicular glutamate transporters (VGLUTs), glutamate accumulation, 346
- Vesicular monoamine transporters (VMATs), catecholamine storage, synaptic vesicles, 288, 289t
- Vestibular systems
 - balance, 923–926
 - hair cells, 918–923
- Video imaging, fast axonal transport, 151
- Visual system
 - brain development, 891–892
 - calcium ion channel regulation, light stimulation, 894–895
 - cone phototransduction, 895–897
 - optic nerve, ganglion cell axons, 890–891
 - photoreceptor downstream signaling, 897–898
 - photoreceptors and phototransduction, 892–897, 892f, 893f, 894f
 - phototransduction molecule recycling, 898–899, 898f
 - retinal neurodegeneration, 899–900
 - molecule-directed therapies, 900
 - retinal sublayers, 890
 - structure and development, 889–892, 890f
- Vitamin deficiency, peripheral neuropathies and, 687
- Voltage-gated ion channels
 - alcohol addiction and, 1049
 - antiseizure drugs, sodium channels, neuron firing regulation, 711, 711f
 - calcium channels, neurotransmitter receptors, G protein coupling, 413–414
 - gene family diversity, 76–77
 - macromolecular complexes, 67–68
 - mechanisms, 66, 67f
 - moving charges, 73f, 74

- protein component conformation, 68, 69f
- sodium channels, pain management, 930
- superfamily, 69–71, 76t
- calcium channels, 71, 72f
- potassium channels, 71
- sodium channels, 69–71, 70f
- tyrosine phosphorylation, 511
- Voltage-operated channels (VOC), calcium ions, 457f
- Volume transmission, serotonin, 311
- Vomeronasal organ
 - chemosensing system, 910, 911f
 - sensory neurons, 911
- Von Gierke disease, 771

W

- Wakefulness
 - acetylcholine and, 987–988
 - adenosine regulation, 993
 - GABA effects on, 991
 - glutamate neurotransmission and, 991–992
 - histamine, 987
 - hypocretins and, 990
 - neurochemical substrates, 983–984
 - neurotransmitters, 984, 985f
 - norepinephrine, 986
- Wallerian degeneration
 - peripheral nervous system 584f, 583
 - peripheral *vs.* central nervous system, 584t
- Water diffusion
 - aquaporins and, 56–58
 - neuronal extracellular clearance, 58
- White matter pathology, diffusion tensor imaging, 196–197

Z

- Zinc, in glutamatergic vesicles, 346
- Zonal expression, olfactory receptors, 907